Some,O
publications,O
have,O
reported,O
highest,O
risk,O
of,O
severe,O
complications,O
of,O
2019,O
novel,O
coronavirus,O
disease,O
(,O
COVID‐19,O
),O
in,O
cancer,O
patients,O
.,O
To,O
date,O
",",O
quarantine,O
is,O
the,O
only,O
recommended,O
preventive,O
attitude,O
against,O
COVID‐19,O
.,O
High,O
proportion,O
of,O
asymptomatic,O
patients,O
",",O
the,O
absence,O
of,O
validated,O
serological,O
testing,O
and,O
the,O
limitations,O
of,O
systematic,O
mass,O
testing,O
by,O
reverse,O
transcription‐polymerase,O
chain,O
reaction,O
(,O
RT‐PCR,O
),O
",",O
hamper,O
the,O
control,O
of,O
COVID‐19,O
outbreak,O
.,O
We,O
report,O
a,O
strategy,O
of,O
systematic,O
detection,O
of,O
COVID‐19,O
symptoms,O
with,O
patient‐reported,O
questionnaire,O
in,O
cancer,O
patients,O
.,O
We,O
estimated,O
the,O
incidence,O
rate,O
of,O
COVID‐19,O
among,O
cancer,O
patients,O
at,O
1.5,O
%,O
",",O
consistently,O
with,O
previous,O
results,O
.,O
This,O
might,O
be,O
underestimated,O
due,O
to,O
asymptomatic,O
forms,O
of,O
COVID‐19,O
",",O
low,O
specificity,O
of,O
COVID‐19,O
symptoms,O
in,O
context,O
of,O
malignancies,O
and,O
false‐negative,O
results,O
of,O
RT‐PCR,O
assay,O
.,O
One,O
of,O
limitation,O
in,O
our,O
study,O
is,O
the,O
lack,O
of,O
screening,O
of,O
digestive,O
symptoms,O
",",O
potentially,O
compatible,O
with,O
COVID‐19,O
.,O
Most,O
of,O
screened,O
patients,O
were,O
not,O
male,O
(,O
75.7,O
%,O
),O
and,O
had,O
no,O
comorbidity,O
(,O
55.6,O
%,O
),O
",",O
factors,O
predisposing,O
to,O
COVID‐19,O
and,O
severe,O
forms,O
.,O
Finally,O
",",O
we,O
excluded,O
patients,O
with,O
thoracic,O
and,O
hematological,O
malignancies,O
",",O
also,O
at,O
risk,O
of,O
COVID‐19,O
and,O
severe,O
events,O
.,O
Nine,O
patients,O
were,O
diagnosed,O
with,O
COVID‐19,O
and,O
none,O
developed,O
severe,O
form,O
",",O
contrary,O
to,O
other,O
studies,O
including,O
mostly,O
cancer,O
survivors,O
or,O
lung,O
cancer,O
patients,O
.,O
",",O
  ,O
Given,O
the,O
absence,O
of,O
severe,O
form,O
of,O
COVID‐19,O
",",O
we,O
did,O
not,O
study,O
biological,O
prognostic,O
factors,O
",",O
probably,O
poorly,O
specific,O
in,O
cancer,O
patients,O
.,O
Large‐scale,O
data,O
are,O
needed,O
to,O
further,O
explore,O
risk,O
factors,O
of,O
COVID‐19,O
severity,O
in,O
this,O
population,O
.,O
More,O
than,O
"10,000",O
globally,O
sourced,O
SARS,O
-,O
CoV-2,O
genomes,O
are,O
publicly,O
available,O
",",O
and,O
powerful,O
data,O
sharing,O
and,O
analysis,O
platforms,O
like,O
the,O
Global,B-Dataset
Initiative,I-Dataset
on,I-Dataset
Sharing,I-Dataset
All,I-Dataset
Influenza,I-Dataset
Data,I-Dataset
(GISAID),I-Dataset
EpiCoV,E-Dataset
 ,O
database,O
[,O
13,O
],O
and,O
Nextstrain,S-Repository
 ,O
[,O
14,O
],O
enable,O
the,O
collaborative,O
analysis,O
of,O
viral,O
population,O
structure,O
on,O
a,O
global,O
level,O
.,O
The,O
current,O
emergency,O
of,O
COVID‐19,O
arose,O
after,O
the,O
end,O
of,O
2019,O
in,O
Wuhan,O
(,O
China,O
),O
and,O
was,O
officially,O
declared,O
a,O
pandemic,O
by,O
the,O
World,O
Health,O
Organization,O
(,O
WHO,O
),O
on,O
11,O
March,O
2020,O
.,O
The,O
first,O
report,O
in,O
the,O
South,O
American,O
region,O
of,O
a,O
patient,O
with,O
COVID‐19,O
was,O
declared,O
by,O
Brazil,O
",",O
whereas,O
Venezuela,O
and,O
Uruguay,O
were,O
the,O
ultimate,O
nations,O
to,O
confirm,O
their,O
patient,O
zero,O
.,O
According,O
to,O
the,O
situation,O
report,O
(,O
No,O
.,O
102,O
),O
of,O
the,O
WHO,O
",",O
Brazil,O
has,O
the,O
highest,O
number,O
of,O
COVID‐19,O
confirmed,O
cases,O
(,O
78,O
 ,O
162,O
),O
and,O
deceases,O
(,O
5466,O
),O
due,O
to,O
this,O
disease,O
",",O
followed,O
by,O
Peru,O
with,O
33,O
 ,O
931,O
and,O
943,O
",",O
respectively,O
.,O
Analyses,O
were,O
performed,O
to,O
obtain,O
an,O
overview,O
of,O
genomic,O
SARS‐CoV‐2,O
mutations,O
of,O
circulating,O
strains,O
in,O
South,O
America,O
;,O
we,O
download,O
a,O
total,O
of,O
30,O
complete,O
genomes,O
of,O
South,O
American,O
countries,O
from,O
the,O
GISAID,S-Dataset
 ,O
(,O
https://www.gisaid.org/,S-URL
),O
database,O
.,O
Additionally,O
",",O
we,O
downloaded,O
688,O
genomes,O
from,O
the,O
GISAID,S-Dataset
 ,O
database,O
",",O
 ,O
the,O
genomes,O
were,O
complete,O
(,O
>,O
29,O
 ,O
000,O
 ,O
bp,O
),O
and,O
with,O
high,O
coverage,O
according,O
to,O
this,O
public,O
resource,O
.,O
Since,O
the,O
first,O
officially,O
reported,O
patient,O
in,O
South,O
America,O
in,O
Brazil,O
",",O
other,O
countries,O
have,O
been,O
informing,O
COVID‐19,O
cases,O
.,O
However,O
",",O
the,O
GISAID,B-Dataset
SARS‐CoV‐2,E-Dataset
 ,O
portal,O
(,O
URL,O
at,O
:,O
https://www.gisaid.org/epiflu-applications/next-hcov-19-app/,S-URL
),O
depicts,O
the,O
close,O
relationship,O
between,O
an,O
isolate,O
from,O
Oceania,O
(,O
EPI,B-AccessionNumber
ISL,I-AccessionNumber
417211,E-AccessionNumber
),O
and,O
the,O
strain,O
sequenced,O
in,O
Ecuador,O
.,O
After,O
more,O
than,O
4,O
months,O
of,O
the,O
COVID‐19,O
pandemics,O
with,O
genomic,O
information,O
of,O
SARS‐CoV‐2,O
around,O
the,O
globe,O
",",O
there,O
are,O
more,O
than,O
1000,O
complete,O
genomes,O
of,O
this,O
virus,O
.,O
We,O
used,O
691,O
genomes,O
from,O
the,O
GISAID,S-Dataset
 ,O
database,O
.,O
The,O
ongoing,O
COVID-19,O
pandemic,O
is,O
the,O
greatest,O
health,O
-,O
care,O
challenge,O
of,O
this,O
generation,O
.,O
To,O
facilitate,O
the,O
epidemiological,O
tracking,O
of,O
SARS,O
-,O
CoV-2,O
",",O
researchers,O
worldwide,O
have,O
created,O
various,O
web,O
-,O
portals,O
and,O
tools,O
",",O
such,O
as,O
the,O
Johns,O
Hopkins,O
University,O
COVID-19,O
dashboard,O
.,O
An,O
unprecedented,O
effort,O
to,O
make,O
COVID-19,O
-,O
related,O
data,O
accessible,O
in,O
near,O
real,O
-,O
time,O
has,O
resulted,O
in,O
more,O
than,O
25,O
 ,O
000,O
publicly,O
available,O
genome,O
sequences,O
of,O
SARS,O
-,O
CoV-2,O
on,O
Global,B-Dataset
Initiative,I-Dataset
on,I-Dataset
Sharing,I-Dataset
All,I-Dataset
Influenza,I-Dataset
Data,I-Dataset
(GISAID),E-Dataset
.,O
To,O
address,O
this,O
gap,O
",",O
we,O
have,O
developed,O
an,O
accessible,O
application,O
",",O
the,O
COVID-19,O
Genotyping,O
Tool,O
(,O
CGT,O
),O
.,O
A,O
video,O
demonstration,O
of,O
CGT,O
is,O
available,O
in,O
appendix,O
1,O
.,O
CGT,O
uses,O
publicly,O
deposited,O
SARS,O
-,O
CoV-2,O
consensus,O
genome,O
sequences,O
from,O
the,O
GISAID,B-Dataset
EpiCoV™,E-Dataset
 ,O
database,O
",",O
and,O
summarises,O
relevant,O
information,O
through,O
salient,O
visualisations,O
",",O
including,O
Uniform,O
Manifold,O
Approximation,O
and,O
Projection,O
(,O
UMAP,O
),O
",",O
Minimum,O
Spanning,O
Trees,O
(,O
MST,O
),O
of,O
sequence,O
networks,O
",",O
and,O
allele,O
frequencies,O
of,O
annotated,O
high,O
-,O
prevalence,O
non,O
-,O
synonymous,O
Single,O
-,O
Nucleotide,O
Polymorphisms,O
(,O
SNPs,O
),O
within,O
structural,O
protein,O
-,O
coding,O
genomic,O
regions,O
(,O
envelope,O
",",O
membrane,O
",",O
nucleocapsid,O
",",O
and,O
spike,O
proteins,O
;,O
figure,O
),O
.,O
New,O
sequencing,O
data,O
from,O
GISAID,S-Dataset
 ,O
are,O
added,O
to,O
CGT,O
once,O
a,O
week,O
.,O
We,O
use,O
UMAP,O
and,O
network,O
analysis,O
instead,O
of,O
phylogenetics,O
because,O
of,O
a,O
faster,O
computation,O
time,O
and,O
ease,O
of,O
interpretability,O
for,O
large,O
datasets,O
.,O
Our,O
results,O
indicate,O
that,O
there,O
are,O
distinct,O
viral,O
isolate,O
clusters,O
for,O
SARS,O
-,O
CoV-2,O
sequences,O
uploaded,O
to,O
GISAID,S-Dataset
.,O
Our,O
novel,O
tool,O
is,O
accessible,O
to,O
those,O
who,O
might,O
not,O
be,O
trained,O
in,O
bioinformatics,O
and,O
epidemiological,O
analysis,O
",",O
and,O
thus,O
it,O
serves,O
as,O
a,O
platform,O
for,O
aiding,O
in,O
a,O
pivotal,O
aspect,O
of,O
the,O
global,O
research,O
effort,O
against,O
the,O
COVID-19,O
pandemic,O
.,O
In,O
the,O
U.,O
S,O
and,O
UK,O
",",O
the,O
COVID,O
Symptom,O
tracker,O
app,O
developed,O
with,O
the,O
Coronavirus,B-Repository
Pandemic,I-Repository
Epidemiology,I-Repository
Consortium,I-Repository
(COPE),E-Repository
 ,O
is,O
being,O
widely,O
used,O
to,O
track,O
COVID,O
-,O
related,O
exposure,O
and,O
infections,O
.,O
[,O
12,O
],O
Our,O
current,O
project,O
aims,O
to,O
provide,O
a,O
systematic,O
review,O
of,O
the,O
literature,O
on,O
mobile,O
applications,O
with,O
multiple,O
function,O
including,O
:,O
information,O
dissemination,O
(,O
ID,O
),O
",",O
ID,O
with,O
symptom,O
checking,O
(,O
SSC,O
),O
",",O
contact,O
tracing,O
alone,O
",",O
SSC,O
",",O
training,O
health,O
care,O
workers,O
",",O
disinfection,O
checklist,O
",",O
and,O
service,O
Apps,O
around,O
COVID-19,O
.,O
Our,O
systematic,O
review,O
was,O
registered,O
with,O
PROSPERO,S-Repository
 ,O
(,O
CRD,O
42020180878,S-AccessionNumber
),O
",",O
consisted,O
of,O
a,O
mixed,O
methods,O
study,O
where,O
we,O
provide,O
an,O
overview,O
of,O
smartphone,O
applications,O
designed,O
for,O
COVID-19,O
through,O
both,O
a,O
literature,O
search,O
as,O
well,O
as,O
a,O
search,O
of,O
mobile,O
platforms,O
for,O
applications,O
.,O
We,O
limited,O
our,O
search,O
to,O
applications,O
released,O
or,O
updated,O
for,O
COVID-19,O
till,O
May,O
5th,O
",",O
2020,O
and,O
screened,O
these,O
applications,O
for,O
their,O
title,O
",",O
description,O
of,O
the,O
application,O
on,O
mobile,O
platforms,O
",",O
its,O
functions,O
around,O
COVID-19,O
and,O
then,O
completed,O
a,O
comprehensive,O
assessment,O
of,O
these,O
mobile,O
applications,O
(,O
Fig,O
.,O
 ,O
1a,O
),O
.,O
Due,O
to,O
rapidly,O
evolving,O
nature,O
of,O
the,O
COVID-19,O
pandemic,O
and,O
language,O
restrictions,O
",",O
we,O
limited,O
our,O
search,O
to,O
the,O
United,O
States,O
",",O
United,O
Kingdom,O
and,O
India,O
.,O
A,O
systematic,O
search,O
was,O
conducted,O
on,O
PubMed,S-Repository
 ,O
(,O
Medline,O
),O
",",O
Cochrane,B-Repository
central,I-Repository
register,I-Repository
for,I-Repository
controlled,I-Repository
trials,E-Repository
",",O
Google,B-Repository
Scholar,E-Repository
 ,O
and,O
Turning,B-Repository
Research,I-Repository
Into,I-Repository
Practice,E-Repository
 ,O
medical,O
database,O
from,O
9,O
-,O
10th,O
of,O
May,O
2020,O
to,O
identify,O
peer,O
-,O
reviewed,O
publications,O
and,O
grey,O
literature,O
on,O
the,O
utility,O
of,O
smartphone,O
applications,O
in,O
the,O
Covid-19,O
pandemic,O
and,O
help,O
aid,O
our,O
ongoing,O
assessment,O
of,O
mobile,O
platforms,O
.,O
[,O
16,O
],O
Apps,O
were,O
classified,O
based,O
on,O
their,O
key,O
functions-,O
ID,O
(,O
n,O
 ,O
=,O
 ,O
18,O
),O
",",O
ID,O
with,O
tracking,O
of,O
individuals,O
(,O
n,O
 ,O
=,O
 ,O
9,O
),O
",",O
or,O
ID,O
with,O
SSC,O
(,O
n,O
 ,O
=,O
 ,O
15,O
),O
",",O
contact,O
tracing,O
alone,O
(,O
n,O
 ,O
=,O
 ,O
8),O
",",O
SSC,O
(,O
n,O
 ,O
=,O
 ,O
7,O
),O
",",O
training,O
of,O
healthcare,O
workers,O
(,O
n,O
 ,O
=,O
 ,O
3,O
),O
",",O
disinfection,O
checklist,O
(,O
n,O
 ,O
=,O
 ,O
1,O
),O
",",O
and,O
service,O
apps,O
[,O
Delivery,O
or,O
fund,O
-,O
raising,O
],O
(,O
n,O
 ,O
=,O
 ,O
2,O
),O
.,O
The,O
most,O
downloaded,O
and,O
reviewed,O
app,O
on,O
the,O
Google,O
play,O
store,O
(,O
GPS,O
),O
was,O
Aarogya,O
Setu,O
developed,O
by,O
the,O
Government,O
of,O
India,O
(,O
"50,000,000",O
+,O
downloads,O
and,O
"343,842",O
reviews,O
),O
",",O
with,O
a,O
government,O
mandate,O
for,O
download,O
by,O
all,O
Indians,O
especially,O
those,O
who,O
travel,O
or,O
are,O
diagnosed,O
with,O
COVID-19,O
",",O
with,O
a,O
GPS,O
star,O
rating,O
of,O
4.6,O
out,O
of,O
5,O
(,O
Supplementary,O
Table,O
2,O
),O
.,O
In,O
addition,O
to,O
providing,O
self,O
-,O
screening,O
technology,O
",",O
it,O
displays,O
alerts,O
of,O
COVID-19,O
patients,O
diagnosed,O
within,O
a,O
500,O
 ,O
m,O
",",O
1,O
",",O
2,O
",",O
5,O
",",O
and,O
10,O
-,O
km,O
radius,O
of,O
the,O
user,O
which,O
is,O
a,O
useful,O
tool,O
to,O
understand,O
the,O
disease,O
load,O
in,O
the,O
proximity,O
of,O
an,O
individual,O
.,O
For,O
example,O
",",O
those,O
articles,O
which,O
focused,O
on,O
specialty,O
practice,O
during,O
COVID-19,O
and,O
telemedicine,O
",",O
smartphone,O
enabled,O
technology,O
that,O
did,O
not,O
involve,O
an,O
application,O
",",O
or,O
studies,O
that,O
utilized,O
apps,O
to,O
assess,O
for,O
mental,O
health,O
outcomes,O
among,O
COVID-19,O
patients,O
.,O
The,O
more,O
descriptive,O
studies,O
reviewed,O
the,O
evidence,O
of,O
the,O
utility,O
of,O
smartphone,O
apps,O
for,O
COVID-19,O
based,O
on,O
countries,O
’,O
experiences,O
(,O
Table,O
2,O
),O
.,O
Only,O
one,O
application,O
included,O
in,O
our,O
study,O
",",O
The,O
COVID-19,O
Symptom,O
Tracker,O
mobile,O
application,O
",",O
conducted,O
an,O
observational,O
study,O
to,O
provide,O
scientific,O
evidence,O
of,O
the,O
app,O
’s,O
utility,O
.,O
Important,O
results,O
in,O
their,O
study,O
demonstrated,O
that,O
the,O
app,O
could,O
predict,O
in,O
advance,O
the,O
COVID-19,O
incidence,O
of,O
a,O
region,O
.,O
[,O
17,O
],O
Further,O
",",O
our,O
study,O
provides,O
a,O
comprehensive,O
assessment,O
of,O
all,O
mobile,O
applications,O
across,O
three,O
regions,O
which,O
are,O
currently,O
experiencing,O
rapidly,O
rising,O
burden,O
of,O
COVID-19,O
related,O
cases,O
and,O
deaths,O
and,O
hence,O
",",O
identifying,O
the,O
key,O
scientific,O
features,O
of,O
mobile,O
applications,O
that,O
should,O
be,O
used,O
in,O
design,O
and,O
engagement,O
remains,O
very,O
crucial,O
to,O
sustained,O
public,O
health,O
efforts,O
aimed,O
at,O
mitigating,O
this,O
disaster,O
.,O
The,O
global,O
impact,O
of,O
COVID-19,O
pandemic,O
has,O
led,O
to,O
a,O
rapid,O
development,O
and,O
utilization,O
of,O
mobile,O
health,O
applications,O
.,O
Here,O
we,O
provide,O
an,O
overview,O
of,O
mobile,O
applications,O
being,O
currently,O
utilized,O
for,O
COVID-19,O
and,O
their,O
assessment,O
using,O
the,O
Mobile,O
Application,O
Rating,O
Scale,O
.,O
We,O
performed,O
a,O
systematic,O
review,O
of,O
the,O
literature,O
and,O
mobile,O
platforms,O
to,O
assess,O
mobile,O
applications,O
currently,O
utilized,O
for,O
COVID-19,O
",",O
and,O
a,O
quality,O
assessment,O
of,O
these,O
applications,O
using,O
the,O
Mobile,O
Application,O
Rating,O
Scale,O
(,O
MARS,O
),O
for,O
overall,O
quality,O
",",O
Engagement,O
",",O
Functionality,O
",",O
Aesthetics,O
",",O
and,O
Information,O
.,O
Our,O
search,O
identified,O
63,O
apps,O
that,O
are,O
currently,O
being,O
used,O
for,O
COVID-19,O
.,O
18,O
apps,O
were,O
developed,O
for,O
sharing,O
up,O
to,O
date,O
information,O
on,O
COVID-19,O
",",O
and,O
8,O
were,O
used,O
for,O
contact,O
tracing,O
while,O
9,O
apps,O
showed,O
features,O
of,O
both,O
.,O
As,O
of,O
May,O
23,O
",",O
2020,O
",",O
over,O
"5100,000",O
confirmed,O
cases,O
of,O
Coronavirus,O
Disease,O
2019,O
(,O
COVID-19,O
),O
and,O
"330,000",O
deaths,O
were,O
reported,O
globally,O
[,O
3,O
],O
",",O
with,O
over,O
200,O
countries,O
impacted,O
[,O
4,O
],O
",",O
[,O
5,O
],O
",",O
[,O
6,O
],O
",",O
[,O
7,O
],O
.,O
ACE2,O
has,O
also,O
been,O
shown,O
recently,O
as,O
the,O
cellular,O
receptor,O
for,O
SARS,O
-,O
CoV-2,O
in,O
virological,O
studies,O
or,O
bioinformatic,O
analyses,O
(,O
PMID,O
:,O
32015508,S-AccessionNumber
",",O
32142651,S-AccessionNumber
),O
[,O
9,O
],O
.,O
The,O
S,O
gene,O
sequence,O
of,O
SARS,O
-,O
CoV-2,O
(,O
GISAID,S-Dataset
",",O
No,O
.,O
EPI_ISL_402119,S-AccessionNumber
),O
and,O
SARS,O
-,O
CoV,O
(,O
GenBank,S-Repository
 ,O
No,O
.,O
AY278489.2,S-AccessionNumber
),O
were,O
codon,O
-,O
optimized,O
for,O
expression,O
in,O
human,O
cells,O
.,O
SARS,O
-,O
CoV-2,O
was,O
added,O
to,O
the,O
cells,O
(,O
200,O
50,O
%,O
tissue,O
culture,O
infective,O
dose,O
",",O
TCID50,O
),O
.,O
The,O
Ct,O
value,O
of,O
the,O
measured,O
sample,O
was,O
analyzed,O
with,O
the,O
standard,O
curve,O
to,O
calculate,O
the,O
corresponding,O
TCID50,O
value,O
of,O
the,O
sample,O
.,O
To,O
test,O
whether,O
hACE2,O
is,O
required,O
for,O
SARS,O
-,O
CoV-2,O
infection,O
",",O
we,O
infected,O
Vero,O
cells,O
with,O
50,O
TCID50,O
of,O
live,O
SARS,O
-,O
CoV-2,O
virus,O
in,O
the,O
presence,O
of,O
various,O
concentrations,O
of,O
recombinant,O
ACE2,O
",",O
as,O
a,O
soluble,O
form,O
of,O
ACE2,O
-,O
Fc,O
[,O
14,O
],O
.,O
Vaccines,O
inducing,O
broad,O
and,O
sustained,O
immunity,O
could,O
offer,O
effective,O
protection,O
against,O
infectious,O
diseases,O
such,O
as,O
COVID-19,O
[,O
"19,20",O
],O
.,O
Unfortunately,O
",",O
there,O
are,O
currently,O
no,O
approved,O
vaccines,O
available,O
against,O
any,O
human,O
coronavirus,O
",",O
despite,O
the,O
huge,O
medical,O
",",O
social,O
and,O
economic,O
impacts,O
imposed,O
by,O
the,O
SARS,O
",",O
MERS,O
",",O
and,O
the,O
COVID-19,O
pandemics,O
.,O
Developing,O
a,O
vaccine,O
",",O
ideally,O
a,O
universal,O
prophylactic,O
effective,O
against,O
coronaviruses,O
",",O
will,O
be,O
extremely,O
useful,O
for,O
combating,O
the,O
ongoing,O
COVID-19,O
pandemic,O
as,O
well,O
as,O
future,O
outbreaks,O
caused,O
by,O
SARS,O
-,O
CoV,O
variants,O
and,O
possibly,O
other,O
coronaviruses,O
.,O
Therefore,O
",",O
taking,O
into,O
account,O
all,O
available,O
data,O
in,O
SARS,O
-,O
CoV,O
infection,O
and,O
considering,O
SARS,O
-,O
CoV-2,O
as,O
a,O
virus,O
with,O
similar,O
characteristics,O
and,O
immunopathogenic,O
effects,O
to,O
SARS,O
-,O
Co,O
-,O
V,O
",",O
it,O
may,O
be,O
hypothesised,O
that,O
the,O
deleterious,O
events,O
in,O
patients,O
with,O
the,O
most,O
severe,O
forms,O
of,O
the,O
COVID-19,O
are,O
the,O
results,O
both,O
of,O
an,O
excessive,O
or,O
inadequate,O
immune,O
response,O
of,O
the,O
host,O
(,O
.,O
Currently,O
",",O
multiple,O
studies,O
have,O
identified,O
a,O
wide,O
range,O
of,O
neurological,O
deficits,O
associated,O
with,O
COVID-19,O
[,O
1,O
],O
",",O
reflecting,O
both,O
immune,O
-,O
mediated,O
process,O
involving,O
the,O
development,O
[,O
2,O
],O
and,O
parenchymal,O
injury,O
[,O
3,O
],O
.,O
Furthermore,O
",",O
a,O
recent,O
study,O
by,O
Lu,O
and,O
colleagues,O
demonstrated,O
that,O
microstructural,O
changes,O
in,O
the,O
cerebral,O
parenchyma,O
can,O
occur,O
during,O
the,O
recovery,O
phase,O
from,O
COVID-19,O
[,O
4,O
],O
",",O
indicating,O
that,O
the,O
onset,O
of,O
CNS,O
damage,O
can,O
be,O
asynchronous,O
with,O
systemic,O
manifestations,O
and,O
the,O
typically,O
salient,O
severe,O
respiratory,O
disease,O
.,O
To,O
evaluate,O
metagenomic,O
approaches,O
in,O
the,O
context,O
of,O
the,O
current,O
SARS,O
-,O
CoV-2,O
epidemic,O
",",O
laboratory,O
-,O
confirmed,O
positive,O
and,O
negative,O
samples,O
from,O
Seattle,O
",",O
Washington,O
were,O
evaluated,O
by,O
metagenomic,O
sequencing,O
",",O
with,O
comparison,O
to,O
a,O
2019,O
reference,O
genomic,O
database,O
created,O
before,O
the,O
emergence,O
of,O
SARS,O
-,O
CoV-2,O
.,O
The,O
amino,O
acid,O
sequences,O
of,O
SARS‐CoV‐2,O
genome,O
–,O
associated,O
proteins,O
",",O
that,O
is,O
",",O
ORF1ab,O
(,O
which,O
is,O
a,O
complex,O
of,O
the,O
following,O
proteins,O
:,O
5′‐untranslated,O
region,O
",",O
nsp‐2,O
",",O
nsp‐3,O
",",O
nsp‐4,O
",",O
3C‐like,O
protease,O
",",O
nsp‐6,O
",",O
nsp‐7,O
",",O
nsp‐8,O
",",O
nsp‐9,O
",",O
nsp‐10,O
",",O
RNA‐dependent,O
RNA,O
polymerase,O
[,O
nsp‐12,O
],O
",",O
helicase,O
[,O
nsp13,O
],O
",",O
3′‐5′,O
exonuclease,O
[,O
nsp‐14,O
],O
",",O
endoRNase,O
[,O
nsp‐15,O
],O
",",O
and,O
o‐ribose,O
methyltransferase,O
[,O
nsp‐16,O
],O
),O
",",O
surface,O
glycoprotein,O
“,O
S,O
",",O
”,O
ORF‐3a,O
",",O
Envelope,O
protein,O
“,O
E,O
",",O
”,O
Membrane,O
glycoprotein,O
“,O
M,O
",",O
”,O
ORF‐6,O
",",O
ORF‐7,O
",",O
ORF‐8,O
",",O
Nucleocapsid,O
phosphoprotein,O
“,O
N,O
”,O
and,O
ORF‐10,O
",",O
were,O
retrieved,O
from,O
the,O
National,B-Repository
Center,I-Repository
for,I-Repository
Biotechnology,I-Repository
Information,E-Repository
 ,O
database,O
.,O
Both,O
the,O
servers,O
are,O
recently,O
updated,O
versions,O
over,O
previously,O
used,O
CD4,O
epitope,O
prediction,O
servers,O
with,O
improved,O
accuracy,O
",",O
trained,O
on,O
extended,O
datasets,O
.,O
The,O
tertiary,O
structure,O
of,O
Toll‐like,O
receptor,O
3,O
(,O
TLR‐3,O
),O
was,O
retrieved,O
from,O
the,O
Protein,B-Repository
Data,I-Repository
Bank,E-Repository
 ,O
with,O
ID,O
:,O
2A0Z,S-AccessionNumber
.,O
For,O
diagnosis,O
of,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
",",O
a,O
SARS,O
-,O
CoV-2,O
virus,O
-,O
specific,O
reverse,O
transcriptase,O
polymerase,O
chain,O
reaction,O
(,O
RT,O
–,O
PCR,O
),O
test,O
is,O
routinely,O
used,O
.,O
However,O
",",O
this,O
test,O
can,O
take,O
up,O
to,O
2,O
d,O
to,O
complete,O
",",O
serial,O
testing,O
may,O
be,O
required,O
to,O
rule,O
out,O
the,O
possibility,O
of,O
false,O
negative,O
results,O
and,O
there,O
is,O
currently,O
a,O
shortage,O
of,O
RT,O
–,O
PCR,O
test,O
kits,O
",",O
underscoring,O
the,O
urgent,O
need,O
for,O
alternative,O
methods,O
for,O
rapid,O
and,O
accurate,O
diagnosis,O
of,O
patients,O
with,O
COVID-19,O
.,O
In,O
this,O
study,O
",",O
we,O
used,O
artificial,O
intelligence,O
(,O
AI,O
),O
algorithms,O
to,O
integrate,O
chest,O
CT,O
findings,O
with,O
clinical,O
symptoms,O
",",O
exposure,O
history,O
and,O
laboratory,O
testing,O
to,O
rapidly,O
diagnose,O
patients,O
who,O
are,O
positive,O
for,O
COVID-19,O
.,O
In,O
a,O
test,O
set,O
of,O
279,O
patients,O
",",O
the,O
AI,O
system,O
achieved,O
an,O
area,O
under,O
the,O
curve,O
of,O
0.92,O
and,O
had,O
equal,O
sensitivity,O
as,O
compared,O
to,O
a,O
senior,O
thoracic,O
radiologist,O
.,O
The,O
AI,O
system,O
also,O
improved,O
the,O
detection,O
of,O
patients,O
who,O
were,O
positive,O
for,O
COVID-19,O
via,O
RT,O
–,O
PCR,O
who,O
presented,O
with,O
normal,O
CT,O
scans,O
",",O
correctly,O
identifying,O
17,O
of,O
25,O
(,O
68,O
%,O
),O
patients,O
",",O
whereas,O
radiologists,O
classified,O
all,O
of,O
these,O
patients,O
as,O
COVID-19,O
negative,O
.,O
When,O
CT,O
scans,O
and,O
associated,O
clinical,O
history,O
are,O
available,O
",",O
the,O
proposed,O
AI,O
system,O
can,O
help,O
to,O
rapidly,O
diagnose,O
COVID-19,O
patients,O
.,O
Coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
is,O
a,O
newly,O
recognized,O
illness,O
caused,O
by,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
",",O
which,O
firstly,O
emerged,O
in,O
December,O
2019,O
in,O
the,O
city,O
of,O
Wuhan,O
in,O
Hubei,O
province,O
",",O
China,O
.,O
As,O
of,O
29,O
February,O
2020,O
",",O
a,O
cumulative,O
total,O
of,O
79,O
394,O
COVID-19,O
cases,O
were,O
reported,O
in,O
China,O
",",O
which,O
led,O
to,O
2838,O
deaths,O
",",O
according,O
to,O
the,O
report,O
of,O
the,O
World,O
Health,O
Organization,O
–,O
China,O
Joint,O
Mission,O
on,O
Coronavirus,O
Disease,O
2019,O
(,O
COVID-19,O
),O
[,O
1,O
],O
.,O
We,O
hypothesized,O
that,O
a,O
genetic,O
variant,O
of,O
the,O
interferon,O
-,O
induced,O
transmembrane,O
protein,O
3,O
(,O
IFITM3,O
),O
gene,O
(,O
IFITM3,O
),O
was,O
associated,O
with,O
the,O
severity,O
of,O
COVID-19,O
",",O
specifically,O
the,O
single,O
-,O
nucleotide,O
polymorphism,O
rs12252,O
.,O
It,O
is,O
currently,O
unknown,O
whether,O
IFITM3,O
shows,O
genetic,O
association,O
with,O
the,O
severity,O
of,O
COVID-19,O
.,O
To,O
investigate,O
whether,O
the,O
IFITM3,O
variant,O
was,O
associated,O
with,O
disease,O
severity,O
",",O
we,O
recruited,O
a,O
cohort,O
of,O
hospitalized,O
patients,O
with,O
laboratory,O
-,O
confirmed,O
COVID-19,O
.,O
COVID-19,O
was,O
diagnosed,O
according,O
to,O
the,O
diagnosis,O
and,O
treatment,O
of,O
COVID-19,O
recommended,O
by,O
the,O
National,O
Health,O
Commission,O
of,O
China,O
[,O
6,O
],O
.,O
Mild,O
disease,O
was,O
defined,O
as,O
COVID-19,O
with,O
the,O
presence,O
of,O
fever,O
",",O
respiratory,O
symptoms,O
",",O
and,O
pneumonia,O
at,O
imaging,O
.,O
Severe,O
disease,O
was,O
defined,O
as,O
COVID-19,O
with,O
the,O
additional,O
presence,O
of,O
significant,O
respiratory,O
distress,O
(,O
respirations,O
",",O
>,O
30,O
/,O
min,O
),O
",",O
blood,O
oxygen,O
saturation,O
<,O
93,O
%,O
",",O
ratio,O
of,O
arterial,O
oxygen,O
pressure,O
to,O
fraction,O
of,O
inspired,O
oxygen,O
<,O
300,O
mm,O
To,O
determine,O
whether,O
the,O
homozygous,O
C,O
-,O
allele,O
carriers,O
associate,O
with,O
the,O
severity,O
of,O
COVID-19,O
",",O
we,O
genotyped,O
the,O
cohort,O
by,O
sequencing,O
a,O
300,O
–,O
base,O
pair,O
locus,O
spanning,O
rs12252,O
.,O
These,O
findings,O
require,O
further,O
validation,O
but,O
represent,O
important,O
early,O
evidence,O
in,O
a,O
carefully,O
phenotyped,O
cohort,O
for,O
a,O
role,O
of,O
IFITM3,O
in,O
the,O
severity,O
of,O
COVID-19,O
.,O
Larger,O
cohort,O
studies,O
are,O
needed,O
to,O
confirm,O
this,O
genetic,O
association,O
with,O
severity,O
of,O
COVID-19,O
",",O
but,O
the,O
data,O
presented,O
here,O
support,O
the,O
need,O
for,O
such,O
genetic,O
analyses,O
in,O
different,O
global,O
populations,O
",",O
with,O
the,O
opportunity,O
for,O
early,O
targeted,O
intervention,O
in,O
persons,O
at,O
risk,O
if,O
robust,O
genetic,O
biomarkers,O
can,O
be,O
established,O
and,O
potential,O
therapeutic,O
targets,O
highlighted,O
.,O
Abstract,O
 ,O
A,O
major,O
unanswered,O
question,O
in,O
the,O
current,O
global,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
outbreak,O
is,O
why,O
severe,O
disease,O
develops,O
in,O
a,O
small,O
minority,O
of,O
infected,O
individuals,O
.,O
Here,O
we,O
link,O
replication,O
of,O
coronaviruses,O
",",O
including,O
SARS,O
-,O
CoV-2,O
",",O
the,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19)-causing,O
virus,O
",",O
with,O
cytoskeleton,O
-,O
dependent,O
signalling,O
and,O
3D,O
genome,O
organization,O
.,O
Three,O
-,O
week,O
-,O
old,O
male,O
BALB,O
/,O
c,O
mice,O
were,O
inoculated,O
with,O
100,O
μL,O
of,O
PHEV,O
(,O
104.45,O
TCID50/0.1,O
mL,O
),O
by,O
the,O
intranasal,O
route,O
",",O
and,O
their,O
brain,O
tissues,O
were,O
harvested,O
at,O
3,O
and,O
5,O
dpi,O
.,O
The,O
pandemic,O
of,O
COVID-19,O
",",O
caused,O
by,O
the,O
RNA,O
coronavirus,O
SARS,O
-,O
CoV2,O
has,O
spread,O
over,O
200,O
countries,O
and,O
infected,O
millions,O
of,O
people,O
worldwide,O
[,O
"1,2",O
],O
.,O
The,O
rapid,O
spread,O
of,O
COVID-19,O
across,O
various,O
countries,O
opens,O
an,O
intriguing,O
question,O
whether,O
the,O
variations,O
in,O
genome,O
sequences,O
of,O
the,O
novel,O
coronavirus,O
are,O
contributing,O
to,O
the,O
variation,O
of,O
infection,O
and,O
mortality,O
rate,O
[,O
"5,6",O
],O
.,O
Having,O
this,O
question,O
in,O
mind,O
",",O
with,O
the,O
reference,O
to,O
the,O
Wuhan,O
based,O
genome,O
NC_045512,S-AccessionNumber
",",O
missense,O
mutations,O
were,O
identified,O
in,O
the,O
SARS,O
-,O
CoV2,O
genomes,O
of,O
the,O
COVID-19,O
affected,O
Indian,O
patients,O
.,O
This,O
study,O
of,O
mutations,O
in,O
the,O
SARS,O
-,O
CoV2,O
genomes,O
of,O
128,O
COVID-19,O
affected,O
Indian,O
patients,O
has,O
been,O
carried,O
out,O
.,O
The,O
following,O
Table,O
2,O
",",O
Table,O
3,O
",",O
Table,O
4,O
",",O
Table,O
5,O
adumbrate,O
all,O
the,O
missense,O
mutations,O
along,O
with,O
silent,O
mutations,O
across,O
the,O
128,O
virus,O
genomes,O
from,O
Indian,O
COVID-19,O
affected,O
patients,O
.,O
This,O
may,O
suggest,O
that,O
designing,O
a,O
therapeutic,O
approach,O
against,O
ORF6,O
",",O
ORF10,O
and,O
E,O
genes,O
may,O
have,O
a,O
beneficial,O
effect,O
in,O
controlling,O
COVID-19,O
pandemic,O
especially,O
in,O
India,O
.,O
This,O
may,O
suggest,O
that,O
designing,O
a,O
therapeutic,O
approach,O
against,O
ORF6,O
",",O
ORF10,O
and,O
E,O
genes,O
may,O
have,O
a,O
beneficial,O
effect,O
in,O
controlling,O
COVID-19,O
pandemic,O
especially,O
in,O
India,O
.,O
Coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
",",O
caused,O
by,O
an,O
outbreak,O
of,O
the,O
severe,O
acute,O
respiratory,O
syndrome,O
-,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
in,O
Wuhan,O
",",O
China,O
",",O
has,O
led,O
to,O
an,O
unprecedented,O
health,O
and,O
economic,O
crisis,O
worldwide,O
[,O
1,O
],O
.,O
Initially,O
reported,O
in,O
December,O
2019,O
in,O
the,O
Chinese,O
city,O
of,O
Wuhan,O
",",O
and,O
potentially,O
linked,O
to,O
a,O
zoonosis,O
related,O
to,O
a,O
wild,O
animal,O
market,O
",",O
COVID-19,O
has,O
rapidly,O
spread,O
globally,O
",",O
and,O
the,O
World,O
Health,O
Organization,O
(,O
WHO,O
),O
declared,O
a,O
pandemic,O
on,O
March,O
11th,O
2020,O
.,O
These,O
figures,O
make,O
COVID-19,O
the,O
biggest,O
health,O
emergency,O
of,O
the,O
21st,O
century,O
.,O
COVID-19,O
typically,O
manifests,O
as,O
an,O
acute,O
respiratory,O
distress,O
syndrome,O
with,O
fever,O
",",O
dry,O
cough,O
and,O
breathing,O
difficulties,O
.,O
In,O
any,O
case,O
",",O
COVID-19,O
spreads,O
at,O
an,O
alarming,O
rate,O
",",O
and,O
both,O
mortality,O
rate,O
and,O
severity,O
increase,O
with,O
age,O
and,O
depend,O
on,O
pre,O
-,O
existing,O
comorbidity,O
",",O
such,O
as,O
hypertension,O
and,O
diabetes,O
",",O
which,O
are,O
age,O
-,O
related,O
diseases,O
.,O
This,O
defines,O
COVID-19,O
as,O
an,O
aging,O
-,O
dependent,O
disease,O
with,O
outcomes,O
determined,O
by,O
biological,O
age,O
.,O
The,O
input,O
dataset,O
for,O
the,O
analysis,O
",",O
formatted,O
from,O
Bojkova,O
et,O
al,O
.,O
[,O
10,O
],O
",",O
is,O
compiled,O
in,O
Supplementary,O
Table,O
1,O
.,O
The,O
linoleic,O
acid,O
metabolism,O
pathway,O
is,O
linked,O
to,O
arachidonic,O
acid,O
metabolism,O
and,O
eicosanoids,O
pathway,O
",",O
and,O
it,O
could,O
therefore,O
play,O
a,O
role,O
in,O
the,O
inflammatory,O
response,O
observed,O
in,O
disease,O
stages,O
II,O
and,O
III,O
in,O
COVID-19,O
patients,O
[,O
12,O
],O
.,O
This,O
observation,O
suggests,O
that,O
these,O
two,O
proteins,O
may,O
serve,O
as,O
early,O
systemic,O
biomarkers,O
for,O
COVID-19,O
infection,O
.,O
We,O
hypothesize,O
that,O
dysregulation,O
of,O
some,O
of,O
the,O
key,O
components,O
of,O
the,O
renin,O
-,O
angiotensin,O
system,O
could,O
be,O
related,O
to,O
the,O
lung,O
injury,O
and,O
worsening,O
observed,O
in,O
COVID-19,O
.,O
It,O
has,O
also,O
been,O
suggested,O
that,O
differential,O
levels,O
of,O
ACE2,O
in,O
the,O
cardiac,O
and,O
pulmonary,O
tissues,O
of,O
younger,O
versus,O
older,O
adults,O
may,O
be,O
at,O
least,O
partially,O
responsible,O
for,O
the,O
worse,O
outcomes,O
seen,O
in,O
elderly,O
COVID-19,O
patients,O
[,O
30,O
],O
.,O
The,O
impact,O
of,O
reduced,O
ACE2,O
expression,O
",",O
together,O
with,O
the,O
poorer,O
clinical,O
outcomes,O
observed,O
when,O
comorbidities,O
are,O
present,O
[,O
31,O
],O
",",O
which,O
is,O
also,O
generally,O
associated,O
to,O
age,O
",",O
makes,O
the,O
link,O
between,O
COVID-19,O
and,O
aging,O
strong,O
.,O
In,O
any,O
case,O
",",O
discontinuation,O
of,O
ACE,O
-,O
Is,O
/,O
ARBs,O
in,O
hypertension,O
patients,O
with,O
COVID-19,O
might,O
further,O
decrease,O
ACE2,O
levels,O
",",O
therefore,O
worsening,O
disease,O
prognosis,O
.,O
In,O
support,O
of,O
this,O
notion,O
",",O
a,O
recent,O
study,O
found,O
that,O
COVID-19,O
patients,O
with,O
untreated,O
hypertension,O
presented,O
higher,O
mortality,O
than,O
those,O
treated,O
with,O
ACE,O
-,O
Is,O
/,O
ARBs,O
[,O
33,O
],O
.,O
Coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
",",O
caused,O
by,O
an,O
outbreak,O
of,O
the,O
severe,O
acute,O
respiratory,O
syndrome,O
-,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
in,O
Wuhan,O
",",O
China,O
",",O
has,O
led,O
to,O
an,O
unprecedented,O
health,O
and,O
economic,O
crisis,O
worldwide,O
.,O
Upregulation,O
of,O
inflammatory,O
response,O
proteins,O
is,O
in,O
line,O
with,O
the,O
propagation,O
of,O
inflammatory,O
reaction,O
and,O
lung,O
injury,O
that,O
is,O
observed,O
in,O
advanced,O
stages,O
of,O
COVID-19,O
patients,O
and,O
which,O
worsens,O
with,O
age,O
.,O
The,O
present,O
coronavirus,O
disease,O
2019,O
(,O
COVID‐19,O
),O
is,O
a,O
pandemic,O
respiratory,O
disease,O
caused,O
by,O
the,O
novel,O
SARS,O
CoV‐2,O
.,O
Furthermore,O
",",O
in,O
order,O
to,O
estimate,O
the,O
evolutionary,O
progression,O
of,O
the,O
bat,O
SARS,O
CoV,O
genome,O
",",O
such,O
that,O
it,O
is,O
able,O
to,O
adapt,O
to,O
a,O
human,O
host,O
as,O
a,O
novel,O
coronavirus,O
causing,O
COVID‐19,O
",",O
we,O
have,O
analyzed,O
the,O
complete,O
genomes,O
of,O
the,O
bat,O
",",O
civet,O
",",O
human,O
SARS,O
CoV,O
",",O
and,O
human,O
SARS,O
CoV‐2,O
.,O
The,O
spike,O
proteins,O
were,O
retrieved,O
from,O
the,O
NCBI,S-Repository
 ,O
database,O
using,O
the,O
sequence,O
similarity,O
search,O
BLAST,O
program,O
",",O
 ,O
with,O
human,O
SARS,O
CoV‐2,O
spike,O
protein,O
as,O
the,O
query,O
sequence,O
(,O
NCBI,S-Repository
 ,O
code,O
:,O
QHD43416,S-AccessionNumber
),O
from,O
the,O
genome,O
(,O
GenBank,S-Repository
 ,O
code,O
:,O
MN908947.3,S-AccessionNumber
),O
.,O
The,O
complete,O
genome,O
nucleotide,O
sequences,O
of,O
SARS,O
CoV,O
from,O
bats,O
",",O
civets,O
",",O
and,O
SARS,O
CoV,O
and,O
CoV‐2,O
from,O
human,O
host,O
were,O
obtained,O
from,O
NCBI,S-Repository
 ,O
virus,O
database,O
(,O
https://www.ncbi.nlm.nih.gov/labs/virus/vssi/#/virus?SeqType_s=Nucleotide,S-URL
),O
in,O
FASTA,O
format,O
.,O
The,O
redundancy,O
in,O
each,O
data,O
 ,O
set,O
was,O
removed,O
using,O
the,O
CD‐HIT,O
program,O
.,O
In,O
the,O
NGPhylogeny,O
server,O
",",O
we,O
have,O
selected,O
FastME,O
2.0,O
program,O
that,O
infers,O
phylogenies,O
using,O
a,O
distance,O
approach,O
since,O
it,O
is,O
capable,O
of,O
handling,O
large,O
data,O
 ,O
sets,O
.,O
Abstract,O
 ,O
Coronavirus,O
disease,O
2019,O
(,O
COVID‐19,O
),O
is,O
a,O
pandemic,O
infectious,O
disease,O
caused,O
by,O
novel,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus‐2,O
(,O
SARS,O
CoV‐2,O
),O
.,O
2745,O
protein,O
and,O
1702,O
complete,O
genome,O
sequences,O
reported,O
sequences,O
available,O
on,O
May,O
18th,O
2020,O
were,O
downloaded,O
from,O
the,O
COVID,B-Dataset
19,I-Dataset
data,I-Dataset
hub,E-Dataset
.,O
Sequences,O
with,O
the,O
following,O
IDs,O
NC_045512,S-AccessionNumber
 ,O
and,O
YP_009724390.1,S-AccessionNumber
 ,O
were,O
considered,O
as,O
reference,O
sequences,O
(,O
refseq,O
),O
since,O
they,O
are,O
both,O
available,O
at,O
the,O
COVID,B-Dataset
19,I-Dataset
data,I-Dataset
hub,E-Dataset
.,O
From,O
the,O
NCBI,S-Repository
 ,O
database,O
",",O
the,O
primary,O
sequence,O
of,O
SARS,O
-,O
CoV-2,O
spike,O
glycoprotein,O
(,O
ID,O
Sequence,O
:,O
YP_009724390.1,S-AccessionNumber
),O
was,O
found,O
.,O
The,O
PDB,S-Repository
 ,O
ID,O
:,O
6VYB,S-AccessionNumber
 ,O
represents,O
the,O
up,O
conformation,O
",",O
whereas,O
PDB,S-Repository
 ,O
ID,O
:,O
6VXX,S-AccessionNumber
 ,O
constitutes,O
the,O
down,O
conformation,O
.,O
In,O
the,O
PDB,S-Repository
 ,O
database,O
we,O
searched,O
for,O
the,O
structures,O
of,O
the,O
MHC,O
-,O
I,O
-,O
II,O
proteins,O
;,O
for,O
the,O
HLA,O
-,O
DRB1,O
*,O
0401,O
molecule,O
",",O
the,O
crystal,O
with,O
the,O
PDB,S-Repository
 ,O
ID,O
:,O
6BIJ,S-AccessionNumber
",",O
for,O
HLA,O
-,O
A*2402,O
we,O
used,O
the,O
crystal,O
structure,O
PDB,S-Repository
 ,O
ID,O
:,O
3W0W,S-AccessionNumber
",",O
and,O
for,O
HLA,O
-,O
A*0301,O
we,O
used,O
the,O
structure,O
PDB,S-Repository
 ,O
ID,O
:,O
2XPG,S-AccessionNumber
 ,O
whereas,O
for,O
the,O
HLA,O
-,O
DRB1,O
*,O
0701,O
molecule,O
",",O
we,O
did,O
not,O
find,O
a,O
structure,O
in,O
the,O
PDB,S-Repository
",",O
so,O
we,O
modeled,O
the,O
structure,O
by,O
homology,O
modeling,O
using,O
Program,O
Modeller,O
9.23,O
(,O
Webb,O
&,O
Sali,O
",",O
2016,O
),O
.,O
We,O
employed,O
the,O
crystal,O
structure,O
PDB,S-Repository
 ,O
ID,O
:,O
3PDO,S-AccessionNumber
 ,O
as,O
a,O
template,O
",",O
with,O
an,O
identity,O
of,O
100,O
%,O
for,O
the,O
alpha,O
chain,O
and,O
an,O
identity,O
of,O
89.90,O
%,O
for,O
the,O
beta,O
chain,O
.,O
The,O
sequence,O
ID,O
YP_009724390.1,S-AccessionNumber
 ,O
was,O
analyzed,O
through,O
the,O
Servers,O
NetMHC,O
4.0,O
Server,O
and,O
NetMHCII,O
2.3,O
to,O
predict,O
immunogenic,O
regions,O
which,O
could,O
induce,O
antibodies,O
against,O
the,O
virus,O
SARS,O
-,O
CoV-2,O
.,O
In,O
addition,O
",",O
as,O
mentioned,O
in,O
the,O
databases,O
where,O
the,O
frequency,O
of,O
the,O
alleles,O
has,O
been,O
investigated,O
",",O
we,O
found,O
that,O
the,O
HLA,O
-,O
DRB1,O
*,O
0401,O
and,O
HLA,O
-,O
A*2401,O
alleles,O
are,O
distributed,O
in,O
different,O
ethnic,O
groups,O
",",O
therefore,O
these,O
peptides,O
could,O
be,O
used,O
as,O
a,O
base,O
to,O
design,O
new,O
vaccines,O
for,O
different,O
human,O
races,O
or,O
ethnic,O
groups,O
",",O
which,O
are,O
important,O
because,O
SARS,O
-,O
CoV-2,O
is,O
not,O
only,O
in,O
China,O
but,O
also,O
distributed,O
in,O
different,O
countries,O
.,O
Abstract,O
 ,O
The,O
Coronavirus,O
disease,O
named,O
COVID-19,O
is,O
caused,O
by,O
the,O
virus,O
reported,O
in,O
2019,O
first,O
identified,O
in,O
China,O
.,O
Then,O
incorporate,O
the,O
desired,O
mutation,O
at,O
the,O
end,O
of,O
section,O
B,O
(,O
40th,O
base,O
pair,O
",",O
or,O
the,O
39th,O
and,O
40th,O
base,O
pair,O
if,O
two,O
changes,O
are,O
required,O
),O
.,O
Is,O
airborne,O
transmission,O
of,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
a,O
potential,O
means,O
of,O
spreading,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
?,O
In,O
this,O
cohort,O
study,O
of,O
128,O
individuals,O
who,O
rode,O
1,O
of,O
2,O
buses,O
and,O
attended,O
a,O
worship,O
event,O
in,O
Eastern,O
China,O
",",O
those,O
who,O
rode,O
a,O
bus,O
with,O
air,O
recirculation,O
and,O
with,O
a,O
patient,O
with,O
COVID-19,O
had,O
an,O
increased,O
risk,O
of,O
SARS,O
-,O
CoV-2,O
infection,O
compared,O
with,O
those,O
who,O
rode,O
a,O
different,O
bus,O
.,O
Importance,O
 ,O
Evidence,O
of,O
whether,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
",",O
the,O
virus,O
that,O
causes,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
",",O
can,O
be,O
transmitted,O
as,O
an,O
aerosol,O
(,O
ie,O
",",O
airborne,O
),O
has,O
substantial,O
public,O
health,O
implications,O
.,O
To,O
investigate,O
potential,O
transmission,O
routes,O
of,O
SARS,O
-,O
CoV-2,O
infection,O
with,O
epidemiologic,O
evidence,O
from,O
a,O
COVID-19,O
outbreak,O
.,O
This,O
cohort,O
study,O
examined,O
a,O
community,O
COVID-19,O
outbreak,O
in,O
Zhejiang,O
province,O
.,O
We,O
also,O
divided,O
seats,O
on,O
the,O
exposed,O
bus,O
into,O
high,O
-,O
risk,O
and,O
low,O
-,O
risk,O
zones,O
according,O
to,O
the,O
distance,O
from,O
the,O
source,O
patient,O
and,O
compared,O
COVID-19,O
risks,O
in,O
each,O
zone,O
.,O
On,O
bus,O
2,O
",",O
24,O
of,O
the,O
68,O
individuals,O
(,O
35.3,O
%,O
[,O
including,O
the,O
index,O
patient,O
],O
),O
received,O
a,O
diagnosis,O
of,O
COVID-19,O
after,O
the,O
event,O
.,O
Among,O
the,O
other,O
172,O
individuals,O
at,O
the,O
worship,O
event,O
",",O
7,O
(,O
4.1,O
%,O
),O
subsequently,O
received,O
a,O
COVID-19,O
diagnosis,O
.,O
Individuals,O
in,O
bus,O
2,O
had,O
a,O
34.3,O
%,O
(,O
95,O
%,O
CI,O
",",O
24.1%-46.3,O
%,O
),O
higher,O
risk,O
of,O
getting,O
COVID-19,O
compared,O
with,O
those,O
in,O
bus,O
1,O
and,O
were,O
11.4,O
(,O
95,O
%,O
CI,O
",",O
5.1,O
-,O
25.4,O
),O
times,O
more,O
likely,O
to,O
have,O
COVID-19,O
compared,O
with,O
all,O
other,O
individuals,O
attending,O
the,O
worship,O
event,O
.,O
Within,O
bus,O
2,O
",",O
individuals,O
in,O
high,O
-,O
risk,O
zones,O
had,O
moderately,O
",",O
but,O
nonsignificantly,O
",",O
higher,O
risk,O
for,O
COVID-19,O
compared,O
with,O
those,O
in,O
the,O
low,O
-,O
risk,O
zones,O
.,O
In,O
this,O
cohort,O
study,O
and,O
case,O
investigation,O
of,O
a,O
community,O
outbreak,O
of,O
COVID-19,O
in,O
Zhejiang,O
province,O
",",O
individuals,O
who,O
rode,O
a,O
bus,O
to,O
a,O
worship,O
event,O
with,O
a,O
patient,O
with,O
COVID-19,O
had,O
a,O
higher,O
risk,O
of,O
SARS,O
-,O
CoV-2,O
infection,O
than,O
individuals,O
who,O
rode,O
another,O
bus,O
to,O
the,O
same,O
event,O
.,O
This,O
cohort,O
study,O
examines,O
the,O
potential,O
for,O
airborne,O
spread,O
of,O
COVID-19,O
through,O
investigation,O
of,O
an,O
outbreak,O
among,O
bus,O
riders,O
in,O
Eastern,O
China,O
.,O
Similar,O
to,O
its,O
predecessors,O
",",O
the,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
(,O
SARS,O
-,O
CoV,O
),O
and,O
the,O
Middle,O
East,O
respiratory,O
syndrome,O
coronavirus,O
(,O
MERS,O
-,O
CoV,O
),O
[,O
"2,3",O
],O
",",O
infection,O
with,O
SARS,O
-,O
CoV-2,O
(,O
officially,O
named,O
COVID-19,O
by,O
the,O
World,O
Health,O
Organization,O
on,O
February,O
11,O
",",O
2020,O
),O
can,O
manifest,O
as,O
bronchitis,O
",",O
pneumonia,O
",",O
or,O
a,O
severe,O
respiratory,O
illness,O
.,O
To,O
generate,O
a,O
composite,O
phylogenetic,O
tree,O
",",O
we,O
randomly,O
removed,O
sequences,O
to,O
create,O
a,O
dataset,O
proportional,O
to,O
these,O
newly,O
isolated,O
sequences,O
",",O
keeping,O
in,O
mind,O
that,O
the,O
homologous,O
sequences,O
remain,O
in,O
the,O
final,O
alignment,O
.,O
The,O
evolutionary,O
relationships,O
of,O
these,O
newly,O
sequenced,O
Saudi,O
MERS,O
-,O
CoV,O
isolates,O
were,O
assessed,O
in,O
combination,O
with,O
the,O
globally,O
isolated,O
sequences,O
available,O
in,O
the,O
GenBank,S-Repository
 ,O
database,O
(,O
Figs,O
.,O
"1,2",O
),O
.,O
The,O
end,O
of,O
2019,O
marked,O
the,O
beginning,O
of,O
the,O
COVID-19,O
(,O
Coronavirus,O
Disease,O
2019,O
),O
pandemic,O
[,O
1,O
],O
.,O
COVID-19,O
is,O
a,O
respiratory,O
disease,O
caused,O
by,O
a,O
novel,O
coronavirus,O
that,O
has,O
been,O
named,O
SARS,O
-,O
CoV-2,O
(,O
Severe,O
Acute,O
Respiratory,O
Syndrome,O
Coronavirus,O
2,O
),O
.,O
The,O
Global,B-Dataset
Initiative,I-Dataset
on,I-Dataset
Sharing,I-Dataset
All,I-Dataset
Influenza,I-Dataset
Data,I-Dataset
(GISAID),E-Dataset
 ,O
database,O
[,O
8,O
],O
has,O
provided,O
data,O
on,O
variations,O
in,O
the,O
WHO,O
-,O
recommended,O
primer,O
binding,O
regions,O
for,O
the,O
SARS,O
-,O
CoV-2,O
genomes,O
[,O
9,O
],O
with,O
the,O
so,O
-,O
called,O
Charité,O
primers,O
situated,O
in,O
the,O
most,O
conserved,O
regions,O
and,O
the,O
China,O
-,O
CDC,O
primers,O
in,O
variable,O
sites,O
.,O
Most,O
of,O
the,O
COVID-19,O
cases,O
reported,O
in,O
Nepal,O
have,O
been,O
traced,O
back,O
to,O
Nepalese,O
migrating,O
from,O
India,O
during,O
the,O
pandemic,O
(,O
Supplementary,O
Table,O
1,O
),O
.,O
We,O
analysed,O
primer,O
and,O
probe,O
binding,O
sites,O
in,O
the,O
genomes,O
of,O
SARS,O
-,O
CoV-2,O
deposited,O
in,O
the,O
GISAID,S-Dataset
 ,O
originating,O
from,O
Indian,O
labs,O
.,O
Genomic,O
sequence,O
data,O
for,O
all,O
Indian,O
SARS,O
-,O
CoV-2,O
samples,O
collected,O
on,O
or,O
before,O
29,O
March,O
2020,O
were,O
recovered,O
from,O
the,O
GISAID,S-Dataset
 ,O
database,O
on,O
7,O
May,O
2020,O
.,O
We,O
sincerely,O
want,O
to,O
avoid,O
any,O
misinterpretations,O
that,O
may,O
arise,O
based,O
on,O
the,O
content,O
of,O
this,O
letter,O
with,O
respect,O
to,O
the,O
Indian,O
origin,O
of,O
COVID-19,O
patients,O
in,O
Nepal,O
.,O
We,O
would,O
like,O
to,O
thank,O
Dr.,O
Shravan,O
Kumar,O
Mishra,O
",",O
NPHL,O
(,O
Nepal,O
),O
",",O
for,O
describing,O
the,O
more,O
recent,O
use,O
of,O
COVID-19,O
diagnostic,O
kits,O
in,O
NPHL,O
.,O
Our,O
sincere,O
gratitude,O
goes,O
to,O
all,O
the,O
scientists,O
and,O
submitting,O
laboratories,O
(,O
Supplementary,O
Acknowledgement,O
Table,O
2,O
),O
involved,O
in,O
collection,O
",",O
processing,O
and,O
deposition,O
of,O
SARS,O
-,O
CoV-2,O
sequences,O
as,O
well,O
as,O
the,O
meta,O
-,O
data,O
in,O
GISAID,S-Dataset
 ,O
without,O
which,O
this,O
work,O
could,O
not,O
have,O
been,O
done,O
.,O
Most,O
of,O
the,O
COVID-19,O
cases,O
in,O
Nepal,O
are,O
in,O
the,O
Southern,O
districts,O
of,O
Nepal,O
bordering,O
India,O
with,O
travel,O
histories,O
to,O
India,O
.,O
   ,O
•,O
Very,O
few,O
positive,O
cases,O
of,O
COVID-19,O
are,O
detected,O
in,O
Nepal,O
which,O
could,O
either,O
be,O
due,O
to,O
early,O
national,O
lockdown,O
.,O
Whole,O
genomes,O
of,O
93,O
clinical,O
samples,O
from,O
COVID-19,O
patients,O
were,O
analyzed,O
to,O
find,O
the,O
primer,O
and,O
probe,O
binding,O
sites,O
.,O
The,O
genome,O
(,O
accession,O
no,O
.,O
KP981644,S-AccessionNumber
),O
is,O
from,O
the,O
most,O
virulent,O
pantropic,O
CCoV,O
invading,O
multiple,O
canine,O
organs,O
(,O
Buonavoglia,O
et,O
 ,O
al,O
.,O
The,O
green,O
arrow,O
points,O
to,O
CCoV,O
(,O
accession,O
KC175339,S-AccessionNumber
 ,O
in,O
the,O
phylogeny,O
),O
that,O
had,O
been,O
propagated,O
extensively,O
in,O
cell,O
culture,O
before,O
sequencing,O
.,O
There,O
are,O
two,O
genomes,O
sequenced,O
for,O
CRCoV,O
(,O
accession,O
nos,O
.,O
JX860640,S-AccessionNumber
 ,O
and,O
KX432213,S-AccessionNumber
),O
.,O
3,O
",",O
genome,O
accession,O
KC175339,S-AccessionNumber
),O
.,O
The,O
interpretation,O
is,O
further,O
corroborated,O
by,O
a,O
recent,O
report,O
that,O
a,O
high,O
proportion,O
of,O
COVID-19,O
patients,O
also,O
suffer,O
from,O
digestive,O
discomfort,O
(,O
Pan,O
et,O
 ,O
al,O
.,O
2020,O
),O
.,O
In,O
a,O
comprehensive,O
study,O
of,O
the,O
first,O
12,O
COVID-19,O
patients,O
in,O
the,O
United,O
States,O
(,O
Midgley,O
and,O
The,O
COVID-19,O
Investigation,O
Team,O
",",O
2020,O
),O
",",O
one,O
patient,O
reported,O
diarrhea,O
as,O
the,O
initial,O
symptom,O
before,O
developing,O
fever,O
and,O
cough,O
(,O
Midgley,O
and,O
The,O
COVID-19,O
Investigation,O
Team,O
",",O
2020,O
),O
.,O
Stool,O
samples,O
from,O
7,O
out,O
of,O
10,O
patients,O
tested,O
positive,O
for,O
SARS,O
-,O
CoV-2,O
",",O
including,O
3,O
patients,O
with,O
diarrhea,O
(,O
Midgley,O
and,O
The,O
COVID-19,O
Investigation,O
Team,O
",",O
2020,O
),O
",",O
corroborating,O
a,O
previous,O
report,O
of,O
SARS,O
-,O
CoV-2,O
detection,O
in,O
stool,O
(,O
Holshue,O
et,O
 ,O
al,O
.,O
2020,O
),O
.,O
In,O
particular,O
",",O
live,O
SARS,O
-,O
CoV-2,O
virus,O
was,O
isolated,O
from,O
stool,O
of,O
a,O
COVID-19,O
patient,O
(,O
Zhang,O
et,O
 ,O
al,O
.,O
2020,O
),O
.,O
Nine,O
SARS,O
-,O
CoV-2,O
-,O
like,O
genomes,O
have,O
recently,O
been,O
isolated,O
and,O
sequenced,O
from,O
pangolin,O
and,O
deposited,O
in,O
GISAID,S-Dataset
 ,O
database,O
(,O
gisaid.org,S-URL
),O
.,O
The,O
one,O
with,O
the,O
highest,O
sequence,O
coverage,O
(,O
GISAID,S-Dataset
 ,O
ID,O
:,O
EPI_ISL_410721,S-AccessionNumber
),O
has,O
an,O
ICpG,O
value,O
of,O
0.3929,O
",",O
close,O
to,O
the,O
extreme,O
low,O
end,O
of,O
ICpG,O
values,O
observed,O
among,O
available,O
SARS,O
-,O
CoV-2,O
genomes,O
.,O
At,O
present,O
",",O
the,O
world,O
is,O
suffering,O
from,O
a,O
pandemic,O
of,O
SARS,O
-,O
CoV-2,O
",",O
which,O
causes,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
and,O
has,O
a,O
global,O
mortality,O
rate,O
that,O
remains,O
to,O
be,O
determined,O
(,O
Wu,O
et,O
 ,O
al,O
.,O
",",O
2020,O
",",O
Zhu,O
et,O
 ,O
al,O
.,O
",",O
2020,O
),O
.,O
More,O
severe,O
cases,O
of,O
COVID-19,O
develop,O
acute,O
respiratory,O
distress,O
syndrome,O
and,O
acute,O
lung,O
injury,O
",",O
leading,O
to,O
morbidity,O
and,O
mortality,O
caused,O
by,O
damage,O
to,O
the,O
alveolar,O
lumen,O
leading,O
to,O
inflammation,O
and,O
pneumonia,O
(,O
Wolfel,O
et,O
 ,O
al,O
.,O
",",O
2020,O
",",O
Xu,O
et,O
 ,O
al,O
.,O
",",O
2020,O
),O
.,O
The,O
current,O
pandemic,O
of,O
COVID-19,O
is,O
an,O
acute,O
and,O
rapidly,O
developing,O
global,O
health,O
crisis,O
.,O
To,O
better,O
understand,O
the,O
molecular,O
basis,O
of,O
the,O
disease,O
",",O
we,O
sought,O
to,O
characterize,O
the,O
transcriptional,O
response,O
to,O
infection,O
in,O
a,O
variety,O
of,O
model,O
systems,O
",",O
including,O
in,O
 ,O
vitro,O
tissue,O
culture,O
",",O
ex,O
 ,O
vivo,O
infection,O
of,O
primary,O
cells,O
",",O
and,O
in,O
 ,O
vivo,O
samples,O
derived,O
from,O
COVID-19,O
patients,O
and,O
animals,O
.,O
Additional,O
research,O
in,O
this,O
area,O
will,O
be,O
required,O
to,O
ascertain,O
whether,O
this,O
is,O
a,O
contributing,O
factor,O
toward,O
the,O
development,O
of,O
COVID-19,O
.,O
To,O
this,O
end,O
",",O
we,O
first,O
compared,O
post,O
-,O
mortem,O
lung,O
samples,O
from,O
COVID-19,O
-,O
positive,O
patients,O
with,O
biopsied,O
healthy,O
lung,O
tissue,O
from,O
uninfected,O
individuals,O
.,O
These,O
two,O
cohorts,O
tested,O
positive,O
for,O
SARS,O
-,O
CoV-2,O
by,O
nasopharyngeal,O
swabs,O
or,O
were,O
admitted,O
to,O
the,O
hospital,O
for,O
non,O
-,O
COVID-19,O
-,O
related,O
respiratory,O
issues,O
(,O
n,O
 ,O
=,O
24,O
for,O
each,O
group,O
),O
.,O
Moreover,O
",",O
analyses,O
of,O
cytokines,O
and,O
chemokines,O
quantified,O
in,O
individual,O
serum,O
samples,O
revealed,O
enhancement,O
of,O
generalized,O
inflammation,O
among,O
COVID-19,O
patients,O
",",O
marked,O
by,O
a,O
significant,O
increase,O
in,O
circulating,O
IL-6,O
",",O
IL1RA,O
",",O
CCL2,O
",",O
CCL8,O
CXCL2,O
",",O
CXCL8,O
",",O
CXCL9,O
",",O
and,O
CXCL16,O
levels,O
(,O
Figure,O
 ,O
4C,O
),O
.,O
Significant,O
elevation,O
of,O
CXCL9,O
and,O
CXCL16,O
(,O
chemoattractants,O
of,O
T,O
or,O
natural,O
killer,O
(,O
NK,O
),O
cells,O
",",O
respectively,O
),O
",",O
CCL8,O
and,O
CCL2,O
(,O
which,O
recruit,O
monocytes,O
and/or,O
macrophages,O
),O
",",O
and,O
CXCL8,O
(,O
a,O
classic,O
neutrophil,O
chemoattractant,O
),O
suggest,O
that,O
the,O
presence,O
of,O
these,O
cells,O
may,O
be,O
a,O
primary,O
driver,O
of,O
the,O
signature,O
pathology,O
observed,O
in,O
COVID-19,O
patients,O
(,O
Proudfoot,O
",",O
2002,O
),O
.,O
Although,O
this,O
sample,O
size,O
is,O
not,O
necessarily,O
representative,O
of,O
the,O
whole,O
population,O
of,O
infected,O
COVID-19,O
patients,O
",",O
our,O
data,O
are,O
consistent,O
with,O
what,O
we,O
observe,O
using,O
our,O
other,O
model,O
systems,O
.,O
In,O
the,O
present,O
study,O
",",O
we,O
focus,O
on,O
defining,O
the,O
host,O
response,O
to,O
SARS,O
-,O
CoV-2,O
and,O
other,O
human,O
respiratory,O
viruses,O
in,O
cell,O
lines,O
",",O
primary,O
cell,O
cultures,O
",",O
ferrets,O
",",O
and,O
COVID-19,O
patients,O
.,O
These,O
dynamics,O
are,O
also,O
likely,O
to,O
contribute,O
to,O
development,O
of,O
COVID-19,O
during,O
the,O
course,O
of,O
infection,O
(,O
Wolfel,O
et,O
 ,O
al,O
.,O
",",O
2020,O
),O
.,O
A,O
recent,O
study,O
analyzing,O
severe,O
versus,O
mild,O
cases,O
of,O
COVID-19,O
showed,O
that,O
peripherally,O
derived,O
macrophages,O
predominated,O
in,O
the,O
lungs,O
of,O
severe,O
cases,O
(,O
Liao,O
et,O
 ,O
al,O
.,O
",",O
2020,O
),O
.,O
In,O
addition,O
",",O
our,O
data,O
suggest,O
that,O
neutrophils,O
could,O
also,O
contribute,O
to,O
the,O
disease,O
observed,O
in,O
COVID-19,O
patients,O
",",O
as,O
demonstrated,O
by,O
CXCL2,O
and,O
CXCL8,O
induction,O
.,O
This,O
is,O
consistent,O
with,O
data,O
showing,O
elevated,O
circulating,O
neutrophil,O
levels,O
among,O
COVID-19,O
patients,O
(,O
Chen,O
et,O
 ,O
al,O
.,O
",",O
2020,O
",",O
Qin,O
et,O
 ,O
al,O
.,O
",",O
2020,O
),O
",",O
which,O
may,O
have,O
prognostic,O
value,O
for,O
identifying,O
individuals,O
at,O
risk,O
for,O
developing,O
severe,O
disease,O
.,O
It,O
is,O
also,O
noteworthy,O
that,O
two,O
of,O
the,O
cytokines,O
uniquely,O
elevated,O
in,O
response,O
to,O
SARS,O
-,O
CoV-2,O
are,O
IL-6,O
and,O
IL1RA,O
",",O
suggesting,O
that,O
there,O
might,O
be,O
a,O
parallel,O
between,O
COVID-19,O
and,O
cytokine,O
release,O
syndrome,O
(,O
CRS,O
),O
",",O
a,O
complication,O
commonly,O
seen,O
following,O
CAR,O
T,O
-,O
cell,O
treatment,O
(,O
Giavridis,O
et,O
 ,O
al,O
.,O
",",O
2018,O
),O
.,O
Should,O
this,O
be,O
true,O
",",O
drugs,O
such,O
as,O
tocilizumab,O
and,O
anakinra,O
may,O
prove,O
to,O
be,O
beneficial,O
for,O
treatment,O
of,O
COVID-19,O
(,O
Norelli,O
et,O
 ,O
al,O
.,O
",",O
2018,O
),O
.,O
SARS,O
-,O
related,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
",",O
Isolate,O
USA,O
-,O
WA1/2020,O
(,O
NR-52281,O
),O
was,O
deposited,O
by,O
the,O
Center,O
for,O
Disease,O
Control,O
and,O
Prevention,O
and,O
obtained,O
through,O
BEI,O
Resources,O
",",O
NIAID,O
",",O
NIH,O
.,O
All,O
RNA,O
-,O
Seq,O
data,O
performed,O
in,O
this,O
paper,O
can,O
be,O
found,O
on,O
the,O
NCBI,S-Repository
 ,O
Gene,B-Repository
Expression,I-Repository
Omnibus,I-Repository
(GEO),E-Repository
 ,O
under,O
accession,O
number,O
GSE147507,S-AccessionNumber
.,O
Cell,O
and,O
animal,O
models,O
of,O
SARS,O
-,O
CoV-2,O
infection,O
",",O
in,O
addition,O
to,O
transcriptional,O
and,O
serum,O
profiling,O
of,O
COVID-19,O
patients,O
",",O
consistently,O
revealed,O
a,O
unique,O
and,O
inappropriate,O
inflammatory,O
response,O
.,O
We,O
propose,O
that,O
reduced,O
innate,O
antiviral,O
defenses,O
coupled,O
with,O
exuberant,O
inflammatory,O
cytokine,O
production,O
are,O
the,O
defining,O
and,O
driving,O
features,O
of,O
COVID-19,O
.,O
Low,O
innate,O
antiviral,O
defenses,O
and,O
high,O
pro,O
-,O
inflammatory,O
cues,O
contribute,O
to,O
COVID-19,O
     ,O
In,O
comparison,O
to,O
other,O
respiratory,O
viruses,O
",",O
SARS,O
-,O
CoV-2,O
infection,O
drives,O
a,O
lower,O
antiviral,O
transcriptional,O
response,O
that,O
is,O
marked,O
by,O
low,O
IFN,O
-,O
I,O
and,O
IFN,O
-,O
III,O
levels,O
and,O
elevated,O
chemokine,O
expression,O
",",O
which,O
could,O
explain,O
the,O
pro,O
-,O
inflammatory,O
disease,O
state,O
associated,O
with,O
COVID-19,O
.,O
Early,O
reports,O
from,O
these,O
institutions,O
showed,O
that,O
severe,O
kidney,O
disease,O
is,O
a,O
hallmark,O
of,O
severe,O
COVID,O
disease,O
.,O
Their,O
finding,O
could,O
offer,O
confirmatory,O
evidence,O
that,O
direct,O
renal,O
infection,O
occurs,O
in,O
the,O
setting,O
of,O
AKI,O
in,O
COVID‐19,O
.,O
The,O
authors,O
found,O
that,O
collapsing,O
glomerulopathy,O
in,O
black,O
patients,O
with,O
COVID‐19,O
was,O
associated,O
with,O
high‐risk,O
APOL1,O
variants,O
.,O
Given,O
this,O
entity,O
's,O
resemblance,O
with,O
HIV‐associated,O
nephropathy,O
",",O
the,O
authors,O
proposed,O
the,O
term,O
COVID‐19‐associated,O
nephropathy,O
to,O
describe,O
the,O
condition,O
.,O
COVID‐19,O
is,O
recent,O
and,O
",",O
therefore,O
",",O
case,O
records,O
are,O
common,O
and,O
valuable,O
.,O
These,O
states‐of‐affairs,O
confront,O
nephrologists,O
and,O
intensivists,O
in,O
the,O
COVID‐19,O
pandemic,O
",",O
in,O
less,O
fortunate,O
clinical,O
settings,O
",",O
all,O
the,O
more,O
so,O
.,O
Since,O
COVID‐19,O
has,O
afflicted,O
many,O
patients,O
",",O
AKI,O
patient,O
series,O
have,O
been,O
collected,O
.,O
They,O
found,O
that,O
the,O
available,O
limited,O
published,O
data,O
to,O
indicate,O
that,O
severe,O
AKI,O
in,O
patients,O
with,O
COVID‐19,O
is,O
an,O
ominous,O
clinical,O
predictor,O
and,O
is,O
associated,O
with,O
high,O
mortality,O
(,O
no,O
surprise,O
here,O
),O
.,O
They,O
were,O
at,O
least,O
able,O
to,O
determine,O
an,O
incidence,O
AKI,O
rate,O
of,O
10,O
%,O
in,O
COVID‐19,O
patients,O
",",O
albeit,O
the,O
range,O
in,O
their,O
series,O
was,O
huge,O
(,O
so,O
as,O
not,O
to,O
be,O
helpful,O
),O
.,O
We,O
can,O
not,O
determine,O
a,O
specific,O
form,O
of,O
COVID‐19,O
AKI,O
or,O
chronic,O
nephropathy,O
.,O
Her,O
physicians,O
considered,O
the,O
diagnosis,O
of,O
COVID‐10,O
disease,O
that,O
was,O
confirmed,O
.,O
Cassol,O
et,O
al,O
have,O
recently,O
counselled,O
for,O
caution,O
in,O
interpreting,O
these,O
findings,O
(,O
Preprint,O
https://doi.org/10.34067/KID.0002692020,O
),O
.,O
In,O
contrast,O
to,O
the,O
AIDS,O
epidemic,O
(,O
largely,O
ignored,O
for,O
decades,O
),O
",",O
SARS‐Co‐V2,O
received,O
immediate,O
attention,O
",",O
in,O
terms,O
of,O
genomic,O
sequencing,O
",",O
assay,O
development,O
",",O
sharing,O
of,O
diagnostic,O
data,O
",",O
vaccine,O
development,O
and,O
other,O
international,O
cooperation,O
.,O
We,O
",",O
(,O
Covid‐19,O
Charité,O
investigators,O
),O
are,O
conducting,O
a,O
prospective,O
investigation,O
that,O
includes,O
incorporation,O
of,O
recent,O
“,O
biomarkers,O
”,O
for,O
AKI,O
in,O
a,O
patient,O
population,O
likely,O
to,O
need,O
them,O
.,O
Although,O
SARS,O
-,O
CoV-2,O
infection,O
of,O
lung,O
epithelium,O
is,O
a,O
critical,O
driver,O
of,O
disease,O
",",O
extrapulmonary,O
manifestations,O
of,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
infection,O
(,O
Gupta,O
et,O
 ,O
al,O
.,O
",",O
2020,O
),O
have,O
been,O
associated,O
with,O
direct,O
viral,O
damage,O
of,O
tissues,O
that,O
carry,O
the,O
ACE2,O
receptor,O
",",O
such,O
as,O
intestinal,O
enterocytes,O
and,O
renal,O
tissue,O
(,O
Monteil,O
et,O
 ,O
al,O
.,O
",",O
2020,O
),O
.,O
Deciphering,O
the,O
regulation,O
of,O
the,O
ACE2,O
gene,O
in,O
SARS,O
-,O
CoV-2,O
target,O
cells,O
is,O
a,O
step,O
forward,O
in,O
linking,O
ACE2,O
levels,O
with,O
viral,O
damage,O
and,O
COVID-19,O
pathology,O
.,O
Although,O
a,O
body,O
of,O
work,O
has,O
focused,O
on,O
the,O
pathology,O
of,O
COVID-19,O
during,O
pregnancy,O
(,O
Khalil,O
et,O
 ,O
al,O
.,O
",",O
2020,O
),O
",",O
the,O
extent,O
to,O
which,O
hormones,O
control,O
ACE2,O
expression,O
during,O
pregnancy,O
and,O
lactation,O
",",O
and,O
possibly,O
the,O
susceptibility,O
of,O
cells,O
to,O
SARS,O
-,O
CoV-2,O
infection,O
",",O
has,O
not,O
been,O
investigated,O
.,O
Expression,O
of,O
the,O
ACE2,O
gene,O
in,O
type,O
II,O
pneumocytes,O
is,O
activated,O
by,O
IFNs,O
(,O
Ziegler,O
et,O
 ,O
al,O
.,O
",",O
2020,O
),O
",",O
opening,O
the,O
possibility,O
that,O
the,O
cytokine,O
storm,O
in,O
COVID-19,O
patients,O
",",O
and,O
peptide,O
hormones,O
in,O
general,O
",",O
might,O
lead,O
to,O
increased,O
levels,O
of,O
ACE2,O
in,O
a,O
range,O
of,O
putative,O
SARS,O
-,O
CoV-2,O
target,O
tissues,O
.,O
To,O
directly,O
link,O
the,O
activation,O
of,O
the,O
intronic,O
enhancer,O
to,O
increased,O
Ace2,O
expression,O
",",O
we,O
analyzed,O
ChIP,O
-,O
seq,O
datasets,O
throughout,O
pregnancy,O
",",O
lactation,O
",",O
and,O
involution,O
(,O
Figure,O
 ,O
3,O
),O
.,O
Our,O
findings,O
built,O
a,O
framework,O
needed,O
to,O
assess,O
and,O
understand,O
the,O
contributions,O
of,O
a,O
range,O
of,O
cytokines,O
faced,O
under,O
various,O
physiological,O
conditions,O
in,O
extrapulmonary,O
manifestations,O
of,O
COVID-19,O
(,O
Gupta,O
et,O
 ,O
al,O
.,O
",",O
2020,O
),O
.,O
Although,O
SARS,O
-,O
CoV-2,O
has,O
been,O
detected,O
in,O
breast,O
milk,O
in,O
at,O
least,O
seven,O
studies,O
and,O
our,O
research,O
has,O
demonstrated,O
that,O
its,O
receptor,O
ACE2,O
is,O
present,O
in,O
mammary,O
tissue,O
and,O
highly,O
induced,O
during,O
lactation,O
",",O
the,O
impact,O
of,O
these,O
findings,O
on,O
COVID-19,O
requires,O
further,O
investigation,O
.,O
They,O
are,O
used,O
to,O
suppress,O
cytokine,O
storms,O
induced,O
by,O
the,O
pan,O
-,O
JAK,O
/,O
STAT,O
pathway,O
",",O
and,O
inflammation,O
in,O
COVID-19,O
patients,O
treated,O
with,O
the,O
JAK1/2,O
inhibitor,O
ruxolitinib,O
is,O
reduced,O
(,O
La,O
Rosée,O
et,O
 ,O
al,O
.,O
",",O
2020,O
),O
.,O
Similarly,O
",",O
baricitinib,O
",",O
which,O
inhibits,O
the,O
proinflammatory,O
signal,O
of,O
several,O
cytokines,O
by,O
suppressing,O
JAK1,O
/,O
JAK2,O
",",O
has,O
a,O
beneficial,O
impact,O
in,O
COVID-19,O
patients,O
(,O
Cantini,O
et,O
 ,O
al,O
.,O
",",O
2020,O
),O
.,O
By,O
including,O
steroid,O
hormones,O
and,O
males,O
and,O
females,O
of,O
different,O
ages,O
in,O
future,O
studies,O
",",O
insight,O
into,O
the,O
sex,O
differences,O
seen,O
in,O
COVID-19,O
morbidity,O
and,O
mortality,O
(,O
Galbadage,O
et,O
 ,O
al,O
.,O
",",O
2020,O
),O
might,O
emerge,O
.,O
The,O
world,O
is,O
currently,O
faced,O
with,O
a,O
pandemic,O
of,O
novel,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
",",O
which,O
is,O
caused,O
by,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
and,O
has,O
no,O
preventative,O
vaccine,O
or,O
proven,O
pharmacologic,O
treatment,O
.,O
It,O
is,O
predicted,O
that,O
the,O
development,O
of,O
a,O
safe,O
and,O
effective,O
vaccine,O
to,O
prevent,O
COVID-19,O
will,O
take,O
12,O
to,O
18,O
 ,O
months,O
",",O
by,O
which,O
time,O
many,O
millions,O
of,O
people,O
may,O
have,O
been,O
infected,O
.,O
Because,O
coronaviruses,O
causing,O
COVID-19,O
",",O
severe,O
acute,O
respiratory,O
syndrome,O
(,O
SARS,O
),O
",",O
and,O
Middle,O
East,O
respiratory,O
syndrome,O
(,O
MERS,O
),O
are,O
able,O
to,O
spontaneously,O
transfer,O
to,O
humans,O
from,O
diverse,O
animal,O
hosts,O
that,O
act,O
as,O
viral,O
reservoirs,O
",",O
there,O
is,O
a,O
pressing,O
need,O
to,O
develop,O
methods,O
to,O
broadly,O
combat,O
other,O
coronaviruses,O
that,O
may,O
emerge,O
in,O
the,O
future,O
(,O
Li,O
et,O
 ,O
al,O
.,O
",",O
2005,O
",",O
Mohd,O
et,O
 ,O
al,O
.,O
",",O
2016,O
",",O
Shi,O
and,O
Hu,O
",",O
2008,O
),O
.,O
The,O
novel,O
coronavirus,O
causing,O
COVID-19,O
belongs,O
to,O
a,O
family,O
of,O
positive,O
-,O
sense,O
RNA,O
viruses,O
",",O
which,O
typically,O
infect,O
the,O
upper,O
and,O
lower,O
respiratory,O
tracts,O
and,O
cause,O
disease,O
by,O
direct,O
cytotoxic,O
effects,O
and,O
the,O
induction,O
of,O
host,O
cytokine,O
-,O
mediated,O
inflammation,O
(,O
Liu,O
et,O
 ,O
al,O
.,O
",",O
2020,O
),O
.,O
We,O
argue,O
that,O
this,O
approach,O
",",O
in,O
which,O
the,O
lentivirus,O
-,O
derived,O
RNA,O
serves,O
as,O
a,O
PAC,O
-,O
MAN,O
target,O
prior,O
to,O
 ,O
lentivirus,O
integration,O
into,O
DNA,O
",",O
mimics,O
the,O
crRNA,O
targeting,O
conditions,O
that,O
would,O
apply,O
for,O
natural,O
COVID-19,O
infection,O
.,O
In,O
the,O
past,O
two,O
decades,O
",",O
multiple,O
variants,O
of,O
coronavirus,O
",",O
including,O
those,O
causing,O
COVID-19,O
",",O
SARS,O
",",O
and,O
MERS,O
",",O
emerged,O
from,O
animal,O
reservoirs,O
and,O
infected,O
humans,O
",",O
each,O
time,O
causing,O
a,O
significant,O
number,O
of,O
fatalities,O
(,O
Li,O
et,O
 ,O
al,O
.,O
",",O
2005,O
",",O
Mohd,O
et,O
 ,O
al,O
.,O
",",O
2016,O
",",O
Shi,O
and,O
Hu,O
",",O
2008,O
),O
.,O
We,O
found,O
that,O
just,O
two,O
crRNAs,O
could,O
target,O
∼50,O
%,O
of,O
coronavirus,O
genomes,O
",",O
including,O
those,O
causing,O
COVID-19,O
",",O
SARS,O
",",O
and,O
MERS,O
;,O
six,O
crRNAs,O
were,O
able,O
to,O
target,O
∼91,O
%,O
of,O
coronavirus,O
genomes,O
;,O
and,O
22,O
crRNAs,O
covered,O
all,O
sequenced,O
coronaviruses,O
with,O
no,O
mismatches,O
(,O
Figure,O
 ,O
5B,O
;,O
Table,O
S4,O
),O
.,O
Beta,O
coronaviruses,O
",",O
the,O
genus,O
of,O
viruses,O
causing,O
COVID-19,O
",",O
SARS,O
",",O
and,O
MERS,O
",",O
were,O
mainly,O
covered,O
by,O
three,O
crRNAs,O
(,O
crRNA,O
1–3,O
),O
",",O
while,O
the,O
other,O
genera,O
were,O
covered,O
by,O
crRNA,O
1–3,O
in,O
addition,O
to,O
three,O
other,O
crRNAs,O
.,O
To,O
verify,O
whether,O
crRNA,O
-,O
N18f,O
can,O
target,O
 ,O
all,O
L,O
and,O
S,O
strains,O
",",O
we,O
retrieved,O
a,O
set,O
of,O
"1,087",O
recently,O
sequenced,O
SARS,O
-,O
CoV-2,O
sequences,O
from,O
Global,B-Dataset
Initiative,I-Dataset
on,I-Dataset
Sharing,I-Dataset
All,I-Dataset
Influenza,I-Dataset
Data,I-Dataset
(GISAID),E-Dataset
.,O
It,O
is,O
important,O
to,O
note,O
that,O
PAC,O
-,O
MAN,O
is,O
currently,O
a,O
proof,O
-,O
of,O
-,O
concept,O
antiviral,O
strategy,O
for,O
robustly,O
and,O
broadly,O
targeting,O
conserved,O
viral,O
sequences,O
with,O
Cas13,O
",",O
and,O
multiple,O
important,O
steps,O
are,O
required,O
before,O
it,O
can,O
be,O
tested,O
in,O
clinical,O
trials,O
to,O
possibly,O
treat,O
COVID-19,O
.,O
These,O
steps,O
",",O
including,O
clinical,O
trials,O
",",O
will,O
likely,O
take,O
years,O
;,O
while,O
PAC,O
-,O
MAN,O
will,O
not,O
be,O
able,O
to,O
stem,O
the,O
current,O
rising,O
tide,O
of,O
 ,O
COVID-19,O
cases,O
and,O
related,O
deaths,O
",",O
there,O
is,O
potential,O
for,O
it,O
to,O
be,O
used,O
against,O
future,O
viral,O
threats,O
.,O
Forward,O
and,O
reverse,O
oligos,O
for,O
each,O
spacer,O
(,O
IDT,O
),O
were,O
 ,O
annealed,O
and,O
inserted,O
into,O
backbone,O
using,O
T4,O
DNA,O
Ligase,O
(,O
NEB,O
),O
.,O
The,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
pandemic,O
",",O
caused,O
by,O
the,O
SARS,O
-,O
CoV-2,O
virus,O
",",O
has,O
highlighted,O
the,O
need,O
for,O
antiviral,O
approaches,O
that,O
can,O
target,O
emerging,O
viruses,O
with,O
no,O
effective,O
vaccines,O
or,O
pharmaceuticals,O
.,O
Currently,O
",",O
nucleic,O
-,O
acid,O
based,O
tests,O
have,O
been,O
widely,O
used,O
as,O
the,O
reference,O
method,O
for,O
the,O
diagnosis,O
of,O
COVID-19.[7,O
],O
The,O
pandemic,O
of,O
COVID-19,O
was,O
first,O
discovered,O
by,O
metagenomic,O
next,O
-,O
generation,O
sequencing,O
(,O
mNGS,O
),O
in,O
which,O
the,O
novel,O
virus,O
was,O
found,O
to,O
be,O
a,O
new,O
pathogenic,O
member,O
of,O
the,O
betacoronavirus,O
genus,O
but,O
shared,O
only,O
about,O
79,O
%,O
in,O
genetic,O
similarity,O
with,O
SARS,O
-,O
CoV.[8,O
",",O
9,O
],O
A,O
tool,O
kit,O
of,O
rapid,O
diagnostics,O
faster,O
than,O
typical,O
RT,O
-,O
PCR,O
is,O
in,O
great,O
demand,O
to,O
circumvent,O
the,O
bottlenecks,O
in,O
assay,O
turnaround,O
time,O
and,O
reagent,O
supply,O
for,O
COVID-19,O
testing,O
.,O
Among,O
the,O
61,O
suspected,O
COVID-19,O
specimens,O
",",O
we,O
were,O
able,O
to,O
confirm,O
52,O
cases,O
with,O
read,O
numbers,O
mapping,O
to,O
the,O
novel,O
virus,O
across,O
6,O
orders,O
of,O
magnitudes,O
(,O
median,O
read,O
of,O
"1,484",O
",",O
from,O
2,O
to,O
"19,016,501",O
),O
.,O
Among,O
these,O
",",O
the,O
set,O
that,O
targeted,O
Orf1ab,O
showed,O
the,O
best,O
overall,O
performance,O
of,O
sensitivity,O
and,O
specificity,O
",",O
and,O
therefore,O
",",O
was,O
used,O
to,O
develop,O
CRISPR,O
-,O
COVID,O
in,O
this,O
study,O
for,O
further,O
evaluation,O
(,O
S2A,O
",",O
S2B,O
and,O
S2C,O
Fig,O
),O
.,O
As,O
shown,O
in,O
Fig,O
2B,O
",",O
CRISPR,O
-,O
COVID,O
consistently,O
detected,O
7.5,O
copies,O
/,O
reaction,O
of,O
SARS,O
-,O
CoV-2,O
in,O
all,O
10,O
replicates,O
",",O
2.5,O
copies,O
/,O
reaction,O
in,O
6,O
out,O
of,O
10,O
",",O
and,O
1.25,O
copies,O
/,O
reaction,O
in,O
2,O
out,O
of,O
10,O
runs,O
.,O
These,O
data,O
indicate,O
that,O
CRISPR,O
-,O
COVID,O
had,O
a,O
near,O
single,O
-,O
copy,O
sensitivity,O
.,O
To,O
confirm,O
its,O
specificity,O
",",O
we,O
tested,O
CRISPR,O
-,O
COVID,O
with,O
DNA,O
from,O
human,O
cells,O
as,O
well,O
as,O
a,O
panel,O
of,O
microbes,O
including,O
i,O
),O
bacteria,O
commonly,O
found,O
in,O
respiratory,O
infections,O
:,O
S.,O
pneumonia,O
",",O
H.,O
influenza,O
",",O
M.,O
pneumonia,O
",",O
C.,O
pneumonia,O
",",O
B.,O
pertusiss,O
;,O
ii,O
),O
human,O
Coronaviruses,O
:,O
HCoV,O
-,O
OC43,O
",",O
HCoV,O
-,O
NL63,O
",",O
HCoV,O
-,O
HKU1,O
",",O
HCoV-229E,O
;,O
iii,O
),O
other,O
viruses,O
commonly,O
found,O
in,O
respiratory,O
infections,O
:,O
Adenovirus,O
Type-3,O
",",O
H.,O
Influenza,O
B,O
(,O
Victoria,O
),O
",",O
H,O
influenza,O
A,O
(,O
H3N2,O
),O
",",O
HPIV-1,O
",",O
RSV,O
-,O
A,O
;,O
and,O
iii,O
),O
other,O
bacteria,O
:,O
S.,O
mitis,O
",",O
S.,O
pyogenes,O
",",O
S.,O
aureus,O
",",O
E.,O
coli,O
",",O
E.,O
facecaiis,O
.,O
Altogether,O
",",O
these,O
analytical,O
assessments,O
suggest,O
CRISPR,O
-,O
COVID,O
as,O
a,O
promising,O
molecular,O
assay,O
for,O
SARS,O
-,O
CoV-2,O
detection,O
with,O
great,O
sensitivity,O
and,O
specificity,O
.,O
Upon,O
completion,O
of,O
the,O
analytical,O
assessment,O
",",O
we,O
further,O
evaluated,O
the,O
diagnostic,O
potential,O
of,O
CRIPSR,O
-,O
COVID,O
in,O
clinical,O
specimens,O
.,O
A,O
total,O
of,O
114,O
RNA,O
samples,O
from,O
clinical,O
respiratory,O
samples,O
were,O
included,O
in,O
the,O
evaluation,O
",",O
which,O
consisted,O
of,O
61,O
suspected,O
COVID-19,O
cases,O
(,O
among,O
which,O
52,O
confirmed,O
and,O
9,O
ruled,O
-,O
out,O
by,O
mNGS,O
),O
",",O
17,O
SARS,O
-,O
CoV-2-/hCoV+,O
cases,O
and,O
36,O
samples,O
from,O
healthy,O
subjects,O
(,O
Fig,O
3A,O
),O
.,O
When,O
conducting,O
the,O
CRISPR,O
-,O
COVID,O
assay,O
",",O
a,O
positive,O
control,O
(,O
PC,O
),O
DNA,O
and,O
a,O
no,O
-,O
template,O
control,O
(,O
NC,O
),O
were,O
included,O
in,O
parallel,O
for,O
each,O
run,O
.,O
CRISPR,O
-,O
COVID,O
demonstrated,O
a,O
sensitivity,O
of,O
100,O
%,O
by,O
detecting,O
all,O
52,O
COVID-19,O
cases,O
.,O
No,O
false,O
positives,O
were,O
found,O
in,O
all,O
62,O
negative,O
cases,O
",",O
including,O
all,O
the,O
hCoV,O
-,O
infected,O
ones,O
(,O
Fig,O
3B,O
),O
",",O
suggesting,O
promising,O
clinical,O
sensitivity,O
and,O
specificity,O
of,O
CRISPR,O
-,O
COVID,O
.,O
To,O
further,O
evaluate,O
assay,O
compatibility,O
",",O
the,O
primer,O
and,O
gRNA,O
sequences,O
used,O
in,O
CRISPR,O
-,O
COVID,O
were,O
aligned,O
to,O
"2,439",O
SARS,O
-,O
CoV-2,O
genomes,O
obtained,O
from,O
public,O
databases,O
.,O
As,O
these,O
genomes,O
covered,O
wide,O
ranges,O
of,O
collection,O
times,O
(,O
from,O
2019/12/24,O
to,O
2020/05/06,O
),O
and,O
geographic,O
locations,O
(,O
over,O
20,O
countries,O
including,O
China,O
",",O
United,O
States,O
and,O
France,O
etc,O
.,O
),O
",",O
our,O
results,O
suggest,O
the,O
general,O
applicability,O
of,O
our,O
assay,O
for,O
COVID-19,O
diagnosis,O
.,O
Using,O
mNGS,O
and,O
the,O
PCR,O
as,O
the,O
reference,O
",",O
CRISPR,O
-,O
COVID,O
had,O
a,O
specificity,O
of,O
100,O
%,O
in,O
our,O
study,O
.,O
PCR,O
-,O
COVID,O
was,O
able,O
to,O
detect,O
the,O
virus,O
in,O
90.4,O
%,O
(,O
47/52,O
),O
of,O
the,O
positive,O
cases,O
",",O
with,O
Ct,O
’s,O
ranging,O
from,O
28.8,O
to,O
40.4,O
and,O
a,O
median,O
Ct,O
of,O
35.8,O
.,O
It,O
’s,O
worth,O
noting,O
that,O
the,O
5,O
false,O
negative,O
samples,O
by,O
PCR,O
-,O
COVID,O
had,O
a,O
median,O
mNGS,O
read,O
number,O
of,O
550,O
",",O
which,O
was,O
much,O
lower,O
than,O
that,O
of,O
the,O
other,O
positive,O
samples,O
at,O
"2,381",O
reads,O
",",O
suggesting,O
a,O
lower,O
titer,O
of,O
the,O
virus,O
in,O
these,O
samples,O
.,O
CRISPR,O
showed,O
a,O
greater,O
sensitivity,O
by,O
detecting,O
all,O
52,O
COVID-19,O
cases,O
(,O
100,O
%,O
),O
",",O
with,O
FC,O
values,O
ranging,O
from,O
5.0,O
to,O
66.3,O
and,O
a,O
median,O
FC,O
of,O
22.8,O
(,O
Fig,O
3C,O
),O
.,O
When,O
the,O
reaction,O
turn,O
-,O
around,O
time,O
(,O
TAT,O
),O
is,O
compared,O
",",O
the,O
CRISPR,O
-,O
COVID,O
reaction,O
requires,O
only,O
40,O
minutes,O
",",O
which,O
is,O
the,O
least,O
among,O
the,O
three,O
and,O
includes,O
30,O
minutes,O
of,O
DNA,O
amplification,O
and,O
10,O
minutes,O
of,O
Cas,O
reaction,O
.,O
PCR,O
-,O
COVID,O
requires,O
about,O
1.5,O
hours,O
for,O
a,O
completion,O
run,O
of,O
the,O
PCR,O
program,O
.,O
As,O
showed,O
in,O
Fig,O
4,O
",",O
CRISPR,O
-,O
COVID,O
presented,O
a,O
significant,O
advantage,O
in,O
effective,O
TAT,O
over,O
PCR,O
and,O
mNGS,O
.,O
Recent,O
progresses,O
in,O
molecular,O
diagnostic,O
technologies,O
",",O
especially,O
mNGS,O
",",O
allowed,O
rapid,O
",",O
initial,O
identification,O
of,O
this,O
novel,O
pathogenic,O
agent,O
at,O
the,O
beginning,O
of,O
the,O
current,O
COVID-19,O
pandemic.[8,O
],O
However,O
",",O
the,O
sudden,O
outbreak,O
of,O
COVID-19,O
created,O
a,O
dramatic,O
burden,O
not,O
only,O
on,O
the,O
society,O
",",O
but,O
also,O
on,O
public,O
health,O
.,O
The,O
surging,O
demand,O
for,O
rapid,O
screening,O
and,O
identification,O
of,O
COVID-19,O
posts,O
a,O
great,O
challenge,O
on,O
the,O
diagnostics.[21,O
],O
An,O
RT,O
-,O
PCR,O
assay,O
for,O
COVID-19,O
is,O
faster,O
and,O
more,O
affordable,O
.,O
As,O
we,O
demonstrated,O
in,O
this,O
study,O
",",O
CRISPR,O
-,O
COVID,O
was,O
able,O
to,O
deliver,O
comparable,O
sensitivity,O
and,O
specificity,O
as,O
mNGS,O
within,O
as,O
short,O
as,O
40,O
minutes,O
.,O
At,O
research,O
scale,O
",",O
the,O
material,O
costs,O
of,O
a,O
CRISPR,O
-,O
COVID,O
test,O
runs,O
at,O
less,O
than,O
$,O
3.5,O
",",O
which,O
could,O
be,O
dramatically,O
reduced,O
at,O
production,O
scale,O
to,O
below,O
$,O
0.7[23,O
],O
",",O
suggesting,O
CRISPR,O
-,O
COVID,O
as,O
a,O
competitive,O
alternative,O
not,O
only,O
technologically,O
but,O
also,O
financially,O
.,O
RT,O
-,O
PCR,O
assays,O
for,O
COVID-19,O
were,O
performed,O
using,O
a,O
clinically,O
validated,O
kit,O
approved,O
by,O
the,O
Chinese,O
National,O
Medical,O
Products,O
Administration,O
(,O
Liferiver,O
",",O
Shanghai,O
",",O
China,O
),O
on,O
a,O
ABI-7500,O
Real,O
-,O
Time,O
PCR,O
System,O
(,O
Thermo,O
Fisher,O
Scientific,O
",",O
Carlsbad,O
",",O
CA,O
),O
according,O
to,O
the,O
instructions,O
",",O
with,O
Ct,O
values,O
below,O
40,O
considered,O
positive,O
.,O
Clean,O
reads,O
were,O
aligned,O
against,O
the,O
reference,O
microbial,O
databases,O
including,O
archaea,O
",",O
bacteria,O
",",O
fungi,O
",",O
protozoa,O
",",O
and,O
viruses,O
.,O
The,O
CRISPR,O
-,O
COVID,O
test,O
combines,O
an,O
Reverse,O
-,O
transcription,O
Recombinase,O
Polymerase,O
Amplification,O
(,O
RT,O
-,O
RPA,O
),O
step,O
and,O
a,O
following,O
T7,O
transcription,O
and,O
Cas13,O
detection,O
step,O
as,O
described,O
previously,O
.,O
[,O
17,O
],O
In,O
this,O
study,O
",",O
we,O
developed,O
an,O
isothermal,O
",",O
CRISPR,O
-,O
based,O
diagnostic,O
for,O
COVID-19,O
with,O
near,O
single,O
-,O
copy,O
sensitivity,O
.,O
The,O
recently,O
discovered,O
betacoronavirus,O
severe,O
acute,O
respiratory,O
syndrome,O
(,O
SARS)-CoV-2,O
has,O
caused,O
an,O
outbreak,O
of,O
Coronavirus,O
Disease,O
2019,O
(,O
COVID-19,O
),O
that,O
rapidly,O
developed,O
into,O
a,O
global,O
pandemic,O
.,O
The,O
surging,O
demand,O
for,O
rapid,O
screening,O
and,O
identification,O
of,O
COVID-19,O
posts,O
great,O
diagnostic,O
challenges,O
.,O
Here,O
",",O
we,O
harnessed,O
the,O
unique,O
collateral,O
activity,O
of,O
programmable,O
CRISPR,O
/,O
Cas13a,O
to,O
develop,O
CRISPR,O
-,O
COVID,O
",",O
a,O
rapid,O
and,O
sensitive,O
diagnostic,O
for,O
SARS,O
-,O
CoV-2,O
infection,O
",",O
and,O
compared,O
it,O
to,O
sequencing,O
-,O
based,O
metagenomic,O
and,O
RT,O
-,O
PCR,O
-,O
based,O
assays,O
in,O
a,O
clinical,O
cohort,O
.,O
CRISPR,O
-,O
COVID,O
demonstrated,O
a,O
sensitivity,O
level,O
of,O
near,O
single,O
copy,O
and,O
was,O
highly,O
specific,O
without,O
cross,O
reacting,O
to,O
related,O
pathogens,O
.,O
CRISPR,O
-,O
COVID,O
takes,O
only,O
40,O
mins,O
and,O
requires,O
no,O
sophiscated,O
thermo,O
-,O
cyclers,O
",",O
providing,O
a,O
valuable,O
alternative,O
to,O
the,O
conventional,O
RT,O
–,O
PCR,O
assay,O
to,O
circumvent,O
the,O
bottlenecks,O
in,O
assay,O
turnaround,O
time,O
",",O
equipment,O
and,O
reagent,O
supplies,O
for,O
COVID-19,O
testing,O
.,O
Without,O
effective,O
management,O
",",O
COVID-19,O
could,O
be,O
catastrophic,O
in,O
Africa,O
",",O
exacerbated,O
by,O
high,O
infectious,O
and,O
non,O
-,O
infectious,O
disease,O
burdens,O
",",O
poor,O
healthcare,O
access,O
and,O
limited,O
health,O
resources,O
.,O
4,O
5,O
African,O
COVID-19,O
disease,O
profiles,O
may,O
also,O
differ,O
given,O
unique,O
regional,O
environmental,O
challenges,O
",",O
population,O
structure,O
and,O
genetic,O
make,O
-,O
up,O
",",O
and,O
potential,O
proliferation,O
of,O
specific,O
virus,O
strains,O
",",O
limiting,O
transferability,O
of,O
research,O
findings,O
from,O
other,O
continents,O
.,O
In,O
this,O
novel,O
COVID-19,O
pandemic,O
",",O
IRBs,O
have,O
no,O
recourse,O
to,O
historical,O
evidence,O
",",O
and,O
require,O
support,O
in,O
both,O
decision,O
-,O
making,O
challenges,O
and,O
a,O
greatly,O
increased,O
workload,O
.,O
Previous,O
pandemic,O
experience,O
has,O
informed,O
recommendations,O
for,O
strengthening,O
and,O
expediting,O
IRB,O
"processes,11",O
12,O
members,O
of,O
the,O
scientific,O
community,O
can,O
be,O
co,O
-,O
opted,O
to,O
assess,O
proposals,O
for,O
scientific,O
integrity,O
",",O
and,O
government,O
offices,O
and,O
scientific,O
organisations,O
can,O
provide,O
guidelines,O
for,O
acceptable,O
practices,O
(,O
eg,O
",",O
African,O
Academy,O
of,O
Sciences,O
COVID-19,O
research,O
ethics,O
",",O
https://www.aasciences.africa/,O
),O
.,O
Maximising,O
benefit,O
to,O
patient,O
populations,O
is,O
essential,O
for,O
ethical,O
COVID-19,O
research,O
in,O
Africa,O
",",O
given,O
limited,O
healthcare,O
capacity,O
.,O
Non,O
-,O
traditional,O
engagement,O
of,O
community,O
members,O
provided,O
in,O
local,O
languages,O
by,O
local,O
fieldworkers,O
must,O
accommodate,O
potentially,O
limited,O
resources,O
available,O
to,O
participants,O
and,O
researchers,O
",",O
for,O
example,O
",",O
using,O
call,O
-,O
back,O
short,O
message,O
services,O
(,O
SMS,O
),O
",",O
toll,O
-,O
free,O
numbers,O
for,O
information,O
",",O
printed,O
materials,O
and,O
free,O
-,O
data,O
websites,O
combining,O
information,O
about,O
COVID-19,O
public,O
health,O
measures,O
and,O
proposed,O
studies,O
.,O
Locally,O
relevant,O
COVID-19,O
health,O
promotion,O
information,O
and,O
links,O
to,O
local,O
psycho,O
-,O
social,O
support,O
should,O
also,O
be,O
provided,O
.,O
Existing,O
datasets,O
may,O
be,O
retrospectively,O
analysed,O
",",O
or,O
used,O
as,O
control,O
data,O
for,O
COVID-19,O
studies,O
where,O
ethics,O
approval,O
is,O
in,O
place,O
.,O
Such,O
data,O
can,O
be,O
anonymised,O
",",O
de,O
-,O
identified,O
",",O
perturbed,O
and,O
aggregated,O
to,O
be,O
useful,O
comparison,O
datasets,O
without,O
compromising,O
participants,O
;,O
or,O
new,O
consent,O
can,O
be,O
sought,O
for,O
repurposing,O
existing,O
data,O
.,O
The,O
sequences,O
used,O
for,O
analysis,O
were,O
downloaded,O
from,O
NCBI,S-Repository
 ,O
(,O
http://www.ncbi.nlm.nih.gov/,S-URL
),O
and,O
GISAID,S-Dataset
 ,O
(,O
http://www.gisaid.org,S-URL
),O
.,O
Next,O
-,O
generation,O
sequencing,O
of,O
BetaCoV,O
/,O
Korea,O
/,O
SNU01/2020,O
(,O
GenBank,S-Repository
 ,O
accession,O
no,O
.,O
MT039890,S-AccessionNumber
),O
revealed,O
9,O
mutations,O
compared,O
to,O
the,O
NC_045512,S-AccessionNumber
 ,O
reference,O
genome,O
isolated,O
from,O
Wuhan,O
(,O
Table,O
1,O
),O
.,O
The,O
emergence,O
of,O
SARS,O
-,O
coronavirus-2,O
(,O
SARS,O
-,O
CoV-2,O
),O
",",O
which,O
causes,O
coronavirus,O
-,O
mediated,O
disease,O
2019,O
",",O
or,O
COVID-19,O
",",O
has,O
now,O
spread,O
pandemically,O
",",O
resulting,O
in,O
a,O
serious,O
global,O
health,O
crisis,O
.,O
The,O
SARS,O
-,O
CoV-2,O
genome,O
sequences,O
from,O
England,O
(,O
hCoV-19,O
/,O
England/20136087804/2020|,O
EPI_ISL_420910,S-AccessionNumber
",",O
no,O
treatment,O
),O
and,O
Turkey,O
(,O
hCoV-19,O
/,O
Turkey,O
/,O
GLAB,O
-,O
CoV008/2020,O
),O
were,O
obtained,O
from,O
the,O
China,O
National,O
Bioinformatics,O
Center,O
",",O
GISAID,S-Dataset
 ,O
database,O
[,O
23,O
],O
(,O
https://www.gisaid.org,S-URL
),O
.,O
DianaTools,O
miRPath,O
V3,O
were,O
then,O
used,O
to,O
create,O
heat,O
maps,O
for,O
pathways,O
affected,O
by,O
selected,O
miRs,O
",",O
focusing,O
on,O
the,O
microT,O
-,O
CDS,O
version,O
5.0,O
database,O
.,O
The,O
data,O
have,O
been,O
deposited,O
with,O
links,O
to,O
BioProject,O
accession,O
number,O
PRJNA615032,S-AccessionNumber
 ,O
in,O
the,O
NCBI,S-Repository
 ,O
BioProject,O
database,O
(,O
https://www.ncbi.nlm.nih.gov/bioproject/,S-URL
),O
.,O
Several,O
database,O
sources,O
were,O
referenced,O
for,O
enrichment,O
analysis,O
",",O
including,O
Interpro,S-Repository
 ,O
[,O
32,O
],O
",",O
NCBI,S-Repository
 ,O
[,O
33,O
],O
",",O
MSigDB,S-Repository
 ,O
[,O
"34,35",O
],O
",",O
REACTOME,S-Repository
 ,O
[,O
36,O
],O
",",O
and,O
WikiPathways,S-Repository
 ,O
[,O
37,O
],O
.,O
The,O
miRBase,S-Repository
 ,O
online,O
database,O
holds,O
2565,O
miR,O
sequences,O
and,O
from,O
these,O
we,O
identified,O
regions,O
of,O
the,O
SARS,O
-,O
CoV-2,O
viral,O
genome,O
",",O
which,O
showed,O
high,O
similarity,O
to,O
human,O
miRs,O
.,O
The,O
selected,O
intersected,O
pathways,O
were,O
analyzed,O
as,O
significant,O
targets,O
as,O
p,O
value,O
0.05,O
with,O
threshold,O
value,O
0.8,O
and,O
Fisher,O
’s,O
Exact,O
Test,O
(,O
hypergeometric,O
distribution,O
),O
calculations,O
by,O
miRPath,O
version,O
3.0,O
in,O
the,O
microT,O
-,O
CDS,O
database,O
.,O
Using,O
the,O
GISAID,S-Dataset
 ,O
database,O
",",O
we,O
analysed,O
a,O
sample,O
of,O
viral,O
genomic,O
sequences,O
from,O
several,O
geographical,O
areas,O
for,O
mutations,O
in,O
the,O
potential,O
miR,O
sequences,O
(,O
n,O
=,O
28–133,O
),O
.,O
In,O
addition,O
",",O
miR-8066,O
is,O
found,O
to,O
be,O
associated,O
with,O
one,O
of,O
the,O
critical,O
clinical,O
problems,O
of,O
COVID-19,O
",",O
the,O
cytokine,O
storm,O
",",O
owing,O
to,O
its,O
potential,O
effect,O
on,O
the,O
cytokine,O
-,O
cytokine,O
receptor,O
pathway,O
.,O
Briefly,O
",",O
the,O
downregulation,O
of,O
host,O
cell,O
responses,O
’,O
related,O
pathway,O
members,O
such,O
as,O
SRP,O
-,O
dependent,O
co,O
-,O
translational,O
protein,O
targeting,O
to,O
membrane,O
",",O
L13a,O
-,O
mediated,O
translational,O
silencing,O
of,O
ceruloplasmin,O
expression,O
antigen,O
processing,O
",",O
ribosomal,O
organization,O
",",O
and,O
the,O
ERAD,O
pathway,O
",",O
were,O
observed,O
in,O
COVID-19,O
-,O
positive,O
lung,O
biopsy,O
specimens,O
.,O
miR-5197,O
-,O
3p,O
was,O
identified,O
as,O
the,O
most,O
effective,O
miR,O
to,O
interact,O
with,O
the,O
guide,O
RNA,O
of,O
SARS,O
-,O
CoV,O
",",O
MERS,O
-,O
CoV,O
and,O
COVID-19,O
[,O
49,O
],O
.,O
According,O
to,O
the,O
Harvard,O
and,O
MD,O
Anderson,O
databases,O
",",O
miR-5197,O
shows,O
significant,O
differences,O
between,O
Caucasians,O
and,O
Chinese,O
populations,O
(,O
data,O
gained,O
from,O
a,O
Han,O
Chinese,O
cohort,O
from,O
Nanjing,O
",",O
China,O
),O
[,O
50,O
],O
.,O
Because,O
of,O
its,O
potential,O
presence,O
in,O
SARS,O
-,O
CoV-2,O
-,O
mediated,O
cellular,O
responses,O
",",O
we,O
have,O
analysed,O
data,O
from,O
the,O
lung,O
tissue,O
biopsy,O
database,O
(,O
PRJNA615032,S-AccessionNumber
 ,O
Bioproject,O
),O
to,O
understand,O
its,O
function,O
.,O
Opioids,O
have,O
furthermore,O
been,O
shown,O
to,O
enhance,O
simian,O
acquired,O
immunodeficiency,O
syndrome,O
(,O
SAIDS,O
),O
in,O
rhesus,O
monkeys,O
[,O
68,O
],O
",",O
while,O
reduced,O
clearance,O
of,O
pulmonary,O
influenza,O
virus,O
infection,O
was,O
observed,O
in,O
morphine,O
-,O
treated,O
Lewis,O
rats,O
[,O
69,O
],O
.,O
In,O
AIDS,O
",",O
malabsorption,O
of,O
vitamin,O
12,O
has,O
been,O
related,O
to,O
gastric,O
secretory,O
failure,O
",",O
including,O
chronic,O
diarrhoea,O
",",O
due,O
to,O
advanced,O
HIV,O
infection,O
[,O
"87,88",O
],O
.,O
Also,O
",",O
vitamin,O
B3,O
was,O
found,O
to,O
be,O
highly,O
effective,O
to,O
help,O
lung,O
tissue,O
damage,O
repair,O
[,O
92,O
],O
and,O
it,O
was,O
suggested,O
to,O
be,O
given,O
to,O
COVID-19,O
patients,O
as,O
soon,O
as,O
the,O
CT,O
lung,O
abnormalities,O
were,O
detected,O
[,O
93,O
],O
.,O
Sudden,O
cardiac,O
death,O
is,O
a,O
major,O
problem,O
amongst,O
the,O
unexplained,O
deaths,O
in,O
COVID-19,O
",",O
and,O
it,O
has,O
been,O
identified,O
that,O
many,O
of,O
those,O
patients,O
suffered,O
from,O
primary,O
myocardial,O
fibrosis,O
(,O
PMF,O
),O
",",O
without,O
any,O
known,O
aetiology,O
.,O
Recently,O
",",O
higher,O
expression,O
of,O
miR-1468,O
-,O
3p,O
was,O
identified,O
as,O
a,O
disease,O
-,O
associated,O
and,O
age,O
-,O
dependent,O
cardiac,O
biomarker,O
",",O
as,O
it,O
promotes,O
cardiac,O
fibrosis,O
and,O
cell,O
senescence,O
",",O
although,O
no,O
difference,O
was,O
noted,O
in,O
the,O
mature,O
form,O
of,O
miR-1468,O
between,O
healthy,O
and,O
COVID-19,O
-,O
diseased,O
cardiac,O
tissue,O
[,O
101,O
],O
.,O
In,O
our,O
study,O
",",O
analysis,O
of,O
several,O
SARS,O
-,O
CoV-19,O
genomes,O
",",O
which,O
were,O
isolated,O
from,O
different,O
geographical,O
regions,O
",",O
shows,O
significant,O
similarity,O
scores,O
with,O
human,O
miRs,O
",",O
which,O
target,O
a,O
subset,O
of,O
genes,O
related,O
to,O
pathways,O
affecting,O
virus,O
pathogenicity,O
and,O
host,O
responses,O
observed,O
in,O
COVID-19,O
patients,O
.,O
In,O
our,O
current,O
study,O
we,O
identified,O
that,O
seven,O
completely,O
complementary,O
miRNAs,O
of,O
COVID-19,O
(,O
cc,O
-,O
miRc,O
),O
prevent,O
viral,O
replication,O
and,O
protein,O
translation,O
processes,O
.,O
Severe,O
acute,O
respiratory,O
syndrome,O
coronavirus-2,O
(,O
SARS,O
-,O
CoV-2,O
),O
is,O
a,O
member,O
of,O
the,O
betacoronavirus,O
family,O
",",O
which,O
causes,O
COVID-19,O
disease,O
.,O
Based,O
on,O
our,O
reported,O
findings,O
",",O
miRNAs,O
may,O
constitute,O
potential,O
and,O
effective,O
therapeutic,O
approaches,O
in,O
COVID-19,O
and,O
its,O
pathological,O
consequences,O
.,O
In,O
addition,O
to,O
the,O
need,O
for,O
virus,O
detection,O
",",O
evaluation,O
of,O
individual,O
serological,O
response,O
[,O
1,O
],O
",",O
and,O
biological,O
analytical,O
tools,O
to,O
manage,O
COVID-19,O
on,O
a,O
population,O
level,O
",",O
there,O
is,O
an,O
urgent,O
need,O
to,O
obtain,O
objective,O
information,O
to,O
identify,O
at,O
-,O
risk,O
individuals,O
and,O
to,O
understand,O
the,O
marked,O
variability,O
in,O
the,O
severity,O
of,O
the,O
disease,O
in,O
general,O
",",O
as,O
well,O
as,O
in,O
given,O
populations,O
.,O
Thus,O
",",O
in,O
this,O
context,O
",",O
here,O
we,O
develop,O
two,O
complementary,O
themes,O
:,O
(,O
i,O
),O
a,O
more,O
thorough,O
examination,O
of,O
the,O
membrane,O
shedding,O
of,O
angiotensin,O
-,O
converting,O
enzyme,O
2,O
(,O
ACE2,O
),O
",",O
the,O
SARS,O
-,O
CoV-2,O
cellular,O
target,O
",",O
and,O
its,O
potential,O
repercussion,O
on,O
virus,O
propagation,O
;,O
and,O
(,O
ii,O
),O
a,O
description,O
of,O
the,O
interindividual,O
variability,O
of,O
the,O
genes,O
(,O
SNPs,O
),O
involved,O
in,O
ACE2,O
processing,O
and,O
their,O
potential,O
impact,O
on,O
the,O
risk,O
of,O
contracting,O
COVID-19,O
.,O
Chen,O
et,O
al,O
.,O
recently,O
examined,O
a,O
large,O
Genotype–Tissue,B-Dataset
Expression,I-Dataset
(GTEx),E-Dataset
 ,O
database,O
and,O
investigated,O
the,O
expression,O
of,O
ACE2,O
in,O
different,O
human,O
tissues,O
[,O
3,O
],O
.,O
Globally,O
",",O
at,O
a,O
population,O
level,O
",",O
there,O
was,O
a,O
negative,O
correlation,O
between,O
ACE2,O
expression,O
and,O
COVID-19,O
severity,O
.,O
Cao,O
et,O
al,O
.,O
[,O
5,O
],O
compiled,O
a,O
database,O
analysis,O
of,O
all,O
1700,O
variants,O
in,O
the,O
region,O
of,O
the,O
ACE2,O
gene,O
located,O
on,O
the,O
X,O
chromosome,O
.,O
It,O
is,O
still,O
debatable,O
whether,O
these,O
differences,O
should,O
be,O
taken,O
into,O
consideration,O
in,O
epidemiological,O
studies,O
on,O
COVID-19,O
covering,O
ethnic,O
associations,O
with,O
disease,O
occurrence,O
[,O
6,O
],O
.,O
This,O
relationship,O
concurs,O
well,O
with,O
the,O
study,O
by,O
Chen,O
et,O
al,O
.,O
pointing,O
towards,O
a,O
negative,O
correlation,O
between,O
ACE2,O
expression,O
and,O
COVID-19,O
severity,O
[,O
3,O
],O
.,O
A,O
similar,O
supervised,O
genetic,O
approach,O
to,O
COVID-19,O
risk,O
assessment,O
could,O
complement,O
the,O
current,O
unsupervised,O
GWAS,O
investigations,O
",",O
which,O
require,O
large,O
population,O
studies,O
exploring,O
the,O
whole,O
patient,O
genome,O
for,O
DNA,O
variations,O
in,O
an,O
attempt,O
to,O
explain,O
interindividual,O
differences,O
in,O
COVID-19,O
severity,O
[,O
e.g.,O
",",O
the,O
Howard,O
Hughes,O
Medical,O
Institute,O
(,O
HHMI,O
),O
genetic,O
projecti,O
and,O
the,O
COVID-19,O
Human,O
Genetic,O
Effort,O
[,O
2,O
],O
),O
.,O
Ideally,O
",",O
in,O
a,O
final,O
step,O
",",O
a,O
multifactorial,O
predictive,O
index,O
could,O
be,O
established,O
incorporating,O
SNP,O
analysis,O
and,O
other,O
",",O
more,O
established,O
",",O
risk,O
factors,O
.,O
Based,O
on,O
a,O
broad,O
public,O
database,O
compilation,O
",",O
we,O
support,O
the,O
hypothesis,O
that,O
germinal,O
polymorphisms,O
may,O
regulate,O
the,O
expression,O
of,O
the,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
cellular,O
target,O
itself,O
and,O
proteases,O
controlling,O
the,O
process,O
of,O
its,O
shedding,O
or,O
",",O
conversely,O
",",O
its,O
internalization,O
.,O
Consequently,O
",",O
a,O
genetic,O
influence,O
on,O
individual,O
susceptibility,O
to,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
infection,O
is,O
strongly,O
suspected,O
.,O
In,O
late,O
December,O
2019,O
in,O
Wuhan,O
city,O
(,O
China,O
),O
",",O
a,O
new,O
coronavirus,O
called,O
SARS,O
-,O
CoV-2,O
(,O
initially,O
nCoV-2019,O
),O
caused,O
the,O
outbreak,O
of,O
a,O
respiratory,O
disease,O
known,O
as,O
the,O
infectious,O
disease,O
due,O
to,O
the,O
new,O
coronavirus,O
(,O
COVID-19,O
),O
(,O
Zhou,O
et,O
al,O
.,O
",",O
2020,O
;,O
Zhu,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
In,O
Colombia,O
",",O
the,O
first,O
case,O
of,O
COVID-19,O
was,O
identified,O
on,O
March,O
6,O
",",O
2020,O
",",O
shortly,O
before,O
the,O
World,O
Health,O
Organization,O
(,O
WHO,O
),O
declared,O
COVID-19,O
as,O
a,O
pandemic,O
after,O
it,O
had,O
spread,O
in,O
114,O
countries,O
in,O
all,O
continents,O
and,O
having,O
claimed,O
the,O
lives,O
of,O
4291,O
people,O
(,O
WHO,O
",",O
2020a,O
),O
.,O
The,O
first,O
case,O
of,O
COVID-19,O
in,O
Colombia,O
was,O
imported,O
from,O
Italy,O
",",O
a,O
country,O
that,O
had,O
the,O
most,O
alarming,O
epidemic,O
peak,O
in,O
Europe,O
at,O
that,O
time,O
.,O
Shortly,O
afterwards,O
",",O
cases,O
of,O
COVID-19,O
were,O
diagnosed,O
in,O
travelers,O
from,O
other,O
origins,O
",",O
as,O
well,O
as,O
in,O
multiple,O
of,O
their,O
contacts,O
.,O
After,O
the,O
publication,O
of,O
the,O
complete,O
SARS,O
-,O
CoV-2,O
genome,O
in,O
genomic,O
data,O
repositories,O
such,O
as,O
NCBI,S-Repository
 ,O
(,O
MN908947.3,S-AccessionNumber
),O
and,O
the,O
Global,B-Dataset
Initiative,I-Dataset
on,I-Dataset
Sharing,I-Dataset
All,I-Dataset
Influenza,I-Dataset
Data,I-Dataset
(GISAID),E-Dataset
 ,O
in,O
mid,O
-,O
January,O
2020,O
",",O
health,O
agencies,O
and,O
researchers,O
from,O
different,O
countries,O
quickly,O
developed,O
SARS,O
-,O
CoV-2,O
screening,O
tests,O
based,O
on,O
real,O
-,O
time,O
RT,O
-,O
PCR,O
(,O
rRT,O
-,O
PCR,O
),O
that,O
amplify,O
different,O
SARS,O
-,O
CoV-2,O
gene,O
regions,O
.,O
A,O
total,O
of,O
39,O
primer,O
and,O
probe,O
sequences,O
from,O
the,O
main,O
in,O
-,O
house,O
rRT,O
-,O
PCR,O
protocols,O
for,O
SARS,O
-,O
CoV-2,O
detection,O
published,O
at,O
WHO,O
website,O
were,O
aligned,O
to,O
the,O
reference,O
sequence,O
derived,O
from,O
the,O
first,O
confirmed,O
case,O
at,O
Wuhan,O
",",O
Hubei,O
province,O
",",O
China,O
",",O
and,O
named,O
Wuhan-1,O
strain,O
(,O
GenBank,S-Repository
 ,O
Accession,O
Number,O
:,O
NC_045512.2,S-AccessionNumber
),O
.,O
The,O
Corman,O
-,O
Berlin,O
(,O
2020,O
),O
RdRP,O
SARSr,O
-,O
F2,O
(,O
Corman,O
et,O
al,O
.,O
",",O
2020,O
),O
(,O
Fig,O
.,O
3,O
),O
region,O
was,O
variable,O
in,O
one,O
Colombian,O
SARS,O
-,O
CoV-2,O
sequence,O
from,O
the,O
department,O
of,O
Valle,O
del,O
Cauca,O
(,O
ID,O
:,O
79943,O
),O
",",O
involving,O
a,O
critical,O
site,O
at,O
the,O
3′,O
pentamer,O
.,O
The,O
Zhu,O
2020,O
CDC,O
-,O
China,O
Set,O
I,O
Probe(ORF1ab,O
),O
(,O
Zhu,O
et,O
al,O
.,O
",",O
2020,O
),O
(,O
Fig,O
.,O
4,O
),O
was,O
found,O
to,O
be,O
almost,O
completely,O
complementary,O
with,O
the,O
Colombian,O
SARS,O
-,O
CoV-2,O
sequences,O
",",O
except,O
for,O
a,O
viral,O
sequence,O
obtained,O
from,O
a,O
human,O
case,O
in,O
the,O
department,O
of,O
Antioquia,O
(,O
ID,O
:,O
79253,O
),O
",",O
bearing,O
a,O
single,O
substitution,O
at,O
the,O
seventh,O
probe,O
position,O
",",O
without,O
considerable,O
effect,O
on,O
the,O
thermodynamic,O
features,O
for,O
probe,O
-,O
target,O
hybridization,O
(,O
Table,O
S1,O
),O
.,O
The,O
primers,O
and,O
probes,O
sets,O
proposed,O
by,O
Pasteur,O
2020,O
(,O
France)nCoV,O
IP2,O
(,O
Fig,O
.,O
S1,O
),O
",",O
Hong,O
Kong,O
(,O
2020,O
),O
HKU,O
-,O
ORF1b,O
-,O
nsp14,O
(,O
Fig,O
.,O
S2,O
),O
",",O
Corman,O
Berlin(2020,O
),O
E,O
Sarbeco,O
(,O
Fig,O
.,O
S3,O
),O
",",O
CDC,O
2020(USA,O
),O
2019,O
-,O
nCoV,O
N1,O
(,O
Fig,O
.,O
S4,O
),O
",",O
DMC,O
-,O
MH,O
2020(Thailand)WH,O
-,O
NIC,O
N,O
(,O
Fig,O
.,O
S4,O
),O
",",O
CDC,O
2020(USA,O
),O
2019,O
-,O
nCoV,O
N3,O
(,O
Fig,O
.,O
S5,O
),O
",",O
Corman,O
Berlin(2020,O
),O
N,O
Sarbeco,O
(,O
Fig,O
.,O
S5,O
),O
",",O
Nao,O
2020(Japan)NIID,O
2019,O
-,O
nCOV,O
N,O
(,O
Fig,O
.,O
S6,O
),O
and,O
CDC,O
2020(USA,O
),O
2019,O
-,O
nCoV,O
N2,O
(,O
Fig,O
.,O
S6,O
),O
showed,O
correspondence,O
with,O
the,O
reference,O
sequence,O
and,O
with,O
all,O
the,O
accumulated,O
genetic,O
variability,O
in,O
available,O
sequences,O
of,O
Colombian,O
strains,O
of,O
SARS,O
-,O
CoV-2,O
.,O
One,O
of,O
the,O
primers,O
(,O
Nao,O
2020(Japan)NIID,O
2019,O
-,O
nCOV,O
N,O
F2,O
),O
had,O
the,O
3′,O
end,O
aligned,O
with,O
the,O
first,O
codon,O
position,O
of,O
the,O
codon,O
CUA,O
which,O
encodes,O
for,O
alanine,O
.,O
NGS,O
has,O
also,O
enabled,O
pathogen,O
discovery,O
in,O
a,O
timely,O
manner,O
compared,O
to,O
traditional,O
methods,O
",",O
being,O
essential,O
to,O
the,O
virus,O
taxonomic,O
classification,O
during,O
the,O
beginnings,O
of,O
COVID-19,O
pandemics,O
(,O
Zhou,O
et,O
al,O
.,O
",",O
2020,O
;,O
Zhu,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
By,O
the,O
time,O
of,O
this,O
report,O
",",O
more,O
than,O
31.000,O
sequences,O
have,O
been,O
made,O
available,O
on,O
GISAID,S-Dataset
 ,O
by,O
researchers,O
across,O
the,O
globe,O
;,O
in,O
line,O
with,O
the,O
“,O
Common,O
primer,O
check,O
for,O
high,O
-,O
quality,O
genomes,O
2020,O
-,O
05,O
-,O
22,O
”,O
analysis,O
from,O
this,O
database,O
(,O
BII,O
/,O
GIS,O
",",O
2020,O
),O
",",O
the,O
Zhu,O
2020,O
CDC,O
-,O
China,O
Set,O
II,O
(,O
N,O
),O
showed,O
the,O
higher,O
percent,O
of,O
genomes,O
with,O
mutation,O
in,O
both,O
",",O
the,O
entire,O
-and,O
the,O
3′,O
end,O
primer,O
region,O
",",O
which,O
can,O
affect,O
the,O
sensitivity,O
of,O
this,O
protocol,O
given,O
the,O
genetic,O
variability,O
present,O
in,O
the,O
country,O
.,O
Detection,O
of,O
SARS,O
-,O
CoV-2,O
viral,O
RNA,O
using,O
nucleic,O
acid,O
amplification,O
techniques,O
such,O
as,O
rRT,O
-,O
PCR,O
continues,O
to,O
be,O
the,O
gold,O
standard,O
for,O
the,O
diagnosis,O
of,O
COVID-19,O
(,O
WHO,O
",",O
2020d,O
),O
.,O
The,O
COVID-19,O
pandemic,O
caused,O
by,O
SARS,O
-,O
CoV-2,O
is,O
a,O
public,O
health,O
problem,O
unprecedented,O
in,O
the,O
recent,O
history,O
of,O
humanity,O
.,O
Complete,O
SARS,O
-,O
CoV-2,O
genomes,O
were,O
obtained,O
from,O
30,O
COVID-19,O
cases,O
",",O
representative,O
of,O
the,O
current,O
epidemiology,O
in,O
the,O
country,O
.,O
Genetic,O
variability,O
was,O
detected,O
in,O
Colombian,O
SARS,O
-,O
CoV-2,O
sequences,O
in,O
some,O
of,O
the,O
primer,O
/,O
probe,O
regions,O
for,O
in,O
-,O
house,O
rRT,O
-,O
PCR,O
diagnostic,O
tests,O
available,O
at,O
WHO,O
COVID-19,O
technical,O
guidelines,O
;,O
its,O
impact,O
on,O
the,O
performance,O
and,O
rates,O
of,O
false,O
-,O
negative,O
results,O
should,O
be,O
experimentally,O
evaluated,O
.,O
Highlights,O
    ,O
•,O
 ,O
Colombian,O
SARS,O
-,O
CoV-2,O
sequences,O
displayed,O
genetic,O
variability,O
in,O
some,O
target,O
regions,O
used,O
for,O
COVID-19,O
diagnosis,O
.,O
•,O
 ,O
Genomic,O
data,O
of,O
circulating,O
SARS,O
-,O
CoV-2,O
allow,O
the,O
refinement,O
of,O
molecular,O
protocols,O
for,O
COVID-19,O
diagnosis,O
Since,O
its,O
first,O
identification,O
as,O
a,O
human,O
pathogen,O
in,O
the,O
Wuhan,O
province,O
of,O
China,O
in,O
December,O
2019,O
",",O
the,O
SARS‐CoV‐2,O
virus,O
",",O
which,O
causes,O
COVID‐19,O
",",O
has,O
become,O
a,O
global,O
pandemic,O
with,O
immense,O
medical,O
and,O
socio‐economic,O
costs,O
.,O
It,O
is,O
comforting,O
",",O
however,O
",",O
that,O
previous,O
data,O
from,O
several,O
randomised,O
",",O
double‐blind,O
",",O
placebo‐controlled,O
trials,O
indicate,O
that,O
ALN‐RSV01,O
(,O
a,O
siRNA‐based,O
drug,O
),O
is,O
safe,O
to,O
use,O
and,O
effective,O
against,O
respiratory,O
syncytial,O
virus,O
infection,O
.,O
",",O
  ,O
Taken,O
together,O
",",O
siRNA‐based,O
therapeutics,O
might,O
be,O
considered,O
as,O
an,O
effective,O
strategy,O
to,O
treat,O
of,O
COVID‐19,O
.,O
Potential,O
effects,O
of,O
siRNAs,O
on,O
silencing,O
viral,O
genes,O
at,O
the,O
post‐transcriptional,O
level,O
in,O
COVID‐19,O
.,O
As,O
of,O
July,O
7,O
",",O
2020,O
",",O
more,O
than,O
11.5,O
million,O
cases,O
of,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
had,O
been,O
confirmed,O
",",O
with,O
0.53,O
million,O
deaths,O
globally,O
(,O
WHO,O
Situation,O
Report,O
),O
.,O
An,O
early,O
viral,O
genome,O
sequence,O
was,O
published,O
to,O
inform,O
and,O
assist,O
public,O
health,O
control,O
",",O
followed,O
by,O
the,O
genome,O
sequencing,O
data,O
of,O
"60,000",O
samples,O
deposited,O
in,O
the,O
database,O
curated,O
by,O
the,O
Global,B-Dataset
Initiative,I-Dataset
on,I-Dataset
Sharing,I-Dataset
All,I-Dataset
Influenza,I-Dataset
Data,I-Dataset
(GISAID),E-Dataset
 ,O
(,O
Elbe,B-Creator
and,I-Creator
"Buckland-Merrett,",I-Creator
2017,E-Creator
),O
.,O
The,O
diagnosis,O
of,O
COVID-19,O
is,O
of,O
high,O
priority,O
for,O
patient,O
and,O
public,O
health,O
management,O
to,O
minimize,O
spread,O
of,O
the,O
infection,O
.,O
Chest,O
computed,O
tomography,O
(,O
CT,O
),O
imaging,O
can,O
be,O
used,O
to,O
diagnose,O
patients,O
with,O
COVID-19,O
(,O
Zu,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
Even,O
though,O
the,O
initial,O
RT,O
-,O
PCR,O
test,O
was,O
negative,O
",",O
repeated,O
RT,O
-,O
PCR,O
tests,O
have,O
increased,O
the,O
cumulative,O
positive,O
rate,O
for,O
COVID-19,O
(,O
Al,O
-,O
Tawfiq,O
and,O
Memish,O
",",O
2020,O
),O
.,O
WHO,O
documented,O
the,O
interim,O
guidance,O
of,O
laboratory,O
testing,O
",",O
which,O
denotes,O
nucleic,O
acid,O
amplification,O
test,O
(,O
i.e.,O
RT,O
-,O
PCR,O
),O
should,O
be,O
conducted,O
to,O
COVID-19,O
suspected,O
cases,O
(,O
World,O
Health,O
Organization,O
",",O
2020a,O
),O
.,O
To,O
date,O
",",O
protocols,O
of,O
RT,O
-,O
PCR,O
assay,O
to,O
detect,O
SARS,O
-,O
CoV-2,O
are,O
designed,O
in,O
several,O
countries,O
including,O
USA,O
(,O
Centers,O
for,O
Disease,O
Control,O
and,O
Prevention,O
[,O
CDC,O
],O
),O
",",O
China,O
(,O
China,O
CDC,O
),O
",",O
Japan,O
(,O
National,O
Institute,O
of,O
Infectious,O
Diseases,O
[,O
NIID,O
],O
),O
",",O
Germany,O
(,O
Charité,O
),O
",",O
France,O
(,O
Institut,O
Pasteur,O
),O
",",O
Hong,O
Kong,O
(,O
The,O
University,O
of,O
Hong,O
Kong,O
),O
and,O
Thailand,O
(,O
National,O
Institute,O
of,O
Health,O
),O
(,O
World,O
Health,O
Organization,O
",",O
2020b,O
),O
.,O
The,O
NIID,O
assay,O
also,O
shows,O
positive,O
percent,O
agreement,O
(,O
100,O
%,O
",",O
10/10,O
),O
and,O
negative,O
percent,O
agreement,O
(,O
100,O
%,O
",",O
15/15,O
),O
compared,O
to,O
the,O
result,O
of,O
LightMix,O
Modular,O
SARS,O
and,O
Wuhan,O
CoV,O
E,O
-,O
gene,O
assay,O
(,O
Okamaoto,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
We,O
purchased,O
the,O
2019,O
-,O
nCoV,O
CDC,O
qPCR,O
Probe,O
Assays,O
(,O
renamed,O
the,O
2019,O
-,O
nCoV,O
RUO,O
Kit,O
),O
from,O
Integrated,O
DNA,O
Technologies,O
(,O
IDT,O
",",O
Coralville,O
",",O
IA,O
",",O
USA,O
),O
",",O
which,O
contains,O
research,O
-,O
use,O
-,O
only,O
primer,O
and,O
probe,O
sets,O
based,O
on,O
the,O
protocol,O
announced,O
by,O
the,O
CDC,O
(,O
hereafter,O
called,O
the,O
CDC,O
assay,O
),O
.,O
The,O
NIID,O
has,O
also,O
designed,O
an,O
RT,O
-,O
PCR,O
assay,O
and,O
published,O
associated,O
data,O
(,O
Shirato,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
We,O
obtained,O
these,O
primer,O
and,O
probe,O
sets,O
from,O
the,O
NIID,O
(,O
hereafter,O
called,O
the,O
NIID,O
assay,O
),O
.,O
The,O
NIID,O
assay,O
includes,O
two,O
sets,O
of,O
primers,O
",",O
as,O
well,O
as,O
probes,O
containing,O
a,O
5′-FAM,O
dye,O
and,O
a,O
3’-TAMRA,O
dye,O
(,O
Table,O
1,O
),O
.,O
We,O
further,O
designed,O
double,O
-,O
quencher,O
probes,O
(,O
purchased,O
from,O
IDT,O
),O
based,O
on,O
the,O
same,O
primers,O
/,O
probe,O
sequence,O
reported,O
in,O
the,O
NIID,O
protocol,O
(,O
hereafter,O
called,O
the,O
YCH,O
assay,O
),O
.,O
These,O
probes,O
each,O
incorporate,O
a,O
5′-FAM,O
dye,O
",",O
an,O
internal,O
ZEN,O
quencher,O
",",O
and,O
a,O
3′-Iowa,O
Black,O
Fluorescent,O
Quencher,O
(,O
IBFQ,O
),O
(,O
Table,O
1,O
),O
.,O
The,O
internal,O
ZEN,O
quencher,O
was,O
incorporated,O
between,O
bases,O
9,O
and,O
10,O
from,O
the,O
5′,O
end,O
of,O
the,O
probe,O
.,O
All,O
of,O
the,O
primer,O
/,O
probe,O
sets,O
in,O
the,O
CDC,O
",",O
NIID,O
",",O
and,O
YCH,O
assays,O
target,O
the,O
N,O
gene,O
of,O
SARS,O
-,O
CoV-2,O
.,O
The,O
CDC,O
assay,O
targets,O
three,O
sites,O
along,O
the,O
N,O
gene,O
",",O
and,O
both,O
of,O
the,O
NIID,O
and,O
YCH,O
assays,O
target,O
two,O
sites,O
along,O
this,O
gene,O
.,O
All,O
three,O
of,O
the,O
CDC,O
",",O
NIID,O
",",O
and,O
YCH,O
assays,O
amplified,O
the,O
N,O
gene,O
of,O
SARS,O
-,O
CoV-2,O
(,O
Fig,O
.,O
1,O
),O
.,O
The,O
CDC,O
assay,O
targets,O
three,O
sites,O
along,O
this,O
gene,O
(,O
N1,O
",",O
N2,O
",",O
and,O
N3,O
),O
",",O
and,O
the,O
NIID,O
and,O
YCH,O
assays,O
target,O
two,O
sites,O
(,O
N1,O
and,O
N2,O
),O
(,O
Fig,O
.,O
1,O
),O
.,O
A,O
previous,O
study,O
showed,O
that,O
the,O
reverse,O
primer,O
for,O
N1,O
detection,O
in,O
the,O
NIID,O
assay,O
has,O
one,O
mismatch,O
with,O
the,O
sequence,O
in,O
the,O
current,O
database,O
because,O
it,O
was,O
constructed,O
based,O
on,O
another,O
reported,O
sequence,O
(,O
GenBank,O
:,O
MN908947.1,O
),O
(,O
Shirato,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
With,O
10,O
copies,O
",",O
we,O
could,O
detect,O
amplification,O
signals,O
for,O
CDC,O
-,O
N2,O
",",O
YCH,O
-,O
N1,O
",",O
YCH,O
-,O
N2,O
",",O
and,O
NIID,O
-,O
N2,O
.,O
We,O
observed,O
that,O
the,O
Ct,O
values,O
obtained,O
for,O
both,O
the,O
N1,O
and,O
N2,O
sites,O
with,O
the,O
NIID,O
assay,O
were,O
relatively,O
high,O
compared,O
with,O
those,O
obtained,O
with,O
the,O
YCH,O
assay,O
(,O
Fig,O
.,O
2,O
),O
",",O
despite,O
the,O
primer,O
and,O
probe,O
sequences,O
being,O
equivalent,O
.,O
The,O
baseline,O
fluorescence,O
signal,O
obtained,O
for,O
the,O
N1,O
site,O
with,O
the,O
NIID,O
assay,O
ranged,O
from,O
150,O
 ,O
×,O
 ,O
104,O
to,O
200,O
 ,O
×,O
 ,O
104,O
relative,O
fluorescence,O
units,O
(,O
RFU,O
),O
",",O
whereas,O
that,O
obtained,O
with,O
the,O
YCH,O
assay,O
was,O
≤50,O
 ,O
×,O
 ,O
104,O
RFU,O
.,O
Similarly,O
",",O
the,O
signal,O
obtained,O
for,O
the,O
N2,O
site,O
with,O
the,O
NIID,O
assay,O
ranged,O
from,O
125,O
 ,O
×,O
 ,O
104,O
to,O
200,O
 ,O
×,O
 ,O
104,O
RFU,O
",",O
while,O
that,O
obtained,O
with,O
the,O
YCH,O
assay,O
was,O
75,O
 ,O
×,O
 ,O
104,O
to,O
100,O
 ,O
×,O
 ,O
104,O
RFU,O
.,O
To,O
compare,O
the,O
assay,O
performances,O
of,O
single-,O
and,O
double,O
-,O
quencher,O
probes,O
",",O
we,O
tested,O
nasopharyngeal,O
swabs,O
from,O
66,O
patients,O
using,O
NIID,O
and,O
YCH,O
assays,O
.,O
Of,O
the,O
66,O
samples,O
",",O
positive,O
signals,O
were,O
detected,O
in,O
10,O
",",O
11,O
",",O
17,O
and,O
18,O
samples,O
by,O
NIID,O
-,O
N1,O
",",O
YCH,O
-,O
N1,O
",",O
NIID,O
-,O
N2,O
and,O
YCH,O
-,O
N2,O
",",O
respectively,O
(,O
Table,O
2,O
),O
.,O
Several,O
companies,O
have,O
developed,O
commercially,O
available,O
kits,O
for,O
the,O
RT,O
-,O
PCR,O
detection,O
of,O
SARS,O
-,O
CoV-2,O
.,O
IDT,O
launched,O
an,O
assay,O
kit,O
targeting,O
three,O
sites,O
along,O
the,O
N,O
gene,O
and,O
the,O
human,O
RPP30,O
gene,O
according,O
to,O
the,O
CDC,O
protocol,O
in,O
USA,O
",",O
and,O
this,O
kit,O
was,O
used,O
in,O
this,O
study,O
.,O
They,O
showed,O
that,O
the,O
CDC,O
-,O
N2,O
(,O
USA,O
),O
",",O
CDC,O
-,O
N3,O
(,O
USA,O
),O
",",O
and,O
NIID,O
-,O
N2,O
(,O
Japan,O
),O
sets,O
were,O
the,O
most,O
sensitive,O
and,O
reliable,O
laboratory,O
tests,O
for,O
SARS,O
-,O
CoV-2,O
.,O
We,O
also,O
observed,O
that,O
the,O
CDC,O
-,O
N2,O
(,O
USA,O
),O
and,O
NIID,O
-,O
N2,O
(,O
Japan,O
),O
assays,O
could,O
detect,O
a,O
low,O
copy,O
number,O
of,O
the,O
DNA,O
positive,O
control,O
.,O
Previous,O
studies,O
showed,O
that,O
the,O
N1,O
site,O
of,O
the,O
NIID,O
assay,O
is,O
less,O
sensitive,O
when,O
using,O
the,O
RNA,O
positive,O
control,O
(,O
Shirato,O
et,O
al,O
.,O
",",O
2020,O
;,O
Ishige,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
In,O
this,O
study,O
",",O
we,O
also,O
confirmed,O
that,O
the,O
N1,O
site,O
of,O
the,O
NIID,O
assay,O
has,O
a,O
limit,O
of,O
detection,O
of,O
10,O
copies,O
of,O
the,O
DNA,O
positive,O
control,O
.,O
In,O
addition,O
",",O
we,O
observed,O
that,O
the,O
Ct,O
value,O
was,O
high,O
for,O
the,O
N1,O
site,O
with,O
the,O
NIID,O
assay,O
.,O
The,O
amplification,O
region,O
of,O
CDC,O
-,O
N3,O
partially,O
overlapped,O
with,O
that,O
of,O
NIID,O
-,O
N1,O
and,O
YCH,O
-,O
N1,O
.,O
When,O
the,O
amplification,O
signal,O
was,O
detected,O
in,O
only,O
NIID,O
-,O
N1,O
but,O
not,O
in,O
NIID,O
-,O
N2,O
",",O
we,O
think,O
it,O
is,O
better,O
to,O
repeat,O
test,O
and,O
confirm,O
the,O
reproducibility,O
.,O
We,O
used,O
the,O
primers,O
and,O
single,O
-,O
quencher,O
probes,O
recommended,O
by,O
the,O
CDC,O
(,O
N1,O
",",O
N2,O
and,O
N3,O
),O
in,O
the,O
USA,O
and,O
the,O
NIID,O
(,O
N1,O
and,O
N2,O
),O
in,O
Japan,O
.,O
In,O
addition,O
",",O
we,O
designed,O
double,O
-,O
quencher,O
probes,O
according,O
to,O
the,O
virus,O
sequence,O
provided,O
by,O
the,O
NIID,O
to,O
develop,O
a,O
further,O
assay,O
(,O
termed,O
the,O
YCH,O
assay,O
[,O
N1,O
and,O
N2,O
],O
),O
.,O
The,O
threshold,O
cycle,O
(,O
Ct,O
),O
value,O
of,O
the,O
RT,O
-,O
PCR,O
was,O
relatively,O
low,O
for,O
the,O
CDC,O
and,O
YCH,O
assays,O
compared,O
with,O
the,O
NIID,O
assay,O
.,O
The,O
background,O
fluorescence,O
signal,O
at,O
the,O
baseline,O
was,O
lower,O
for,O
the,O
YCH,O
assay,O
compared,O
with,O
the,O
NIID,O
assay,O
.,O
We,O
assessed,O
the,O
diagnostic,O
performance,O
between,O
single-,O
(,O
NIID,O
),O
and,O
double,O
-,O
quencher,O
(,O
YCH,O
),O
probes,O
using,O
66,O
nasopharyngeal,O
swabs,O
.,O
When,O
the,O
results,O
of,O
YCH,O
-,O
N2,O
assay,O
were,O
used,O
as,O
a,O
reference,O
",",O
each,O
assay,O
detected,O
SARS,O
-,O
CoV-2,O
with,O
positive,O
percent,O
agreements,O
of,O
56,O
%,O
for,O
NIID,O
-,O
N1,O
",",O
61,O
%,O
for,O
YCH,O
-,O
N1,O
",",O
and,O
94,O
%,O
for,O
NIID,O
-,O
N2,O
",",O
and,O
100,O
%,O
negative,O
percent,O
agreements,O
for,O
NIID,O
-,O
N1,O
",",O
YCH,O
-,O
N1,O
and,O
NIID,O
-,O
N2,O
.,O
Coronavirus,O
disease,O
2019,O
(,O
COVID‐19,O
),O
",",O
caused,O
by,O
the,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS‐CoV‐2,O
),O
",",O
was,O
declared,O
a,O
pandemic,O
by,O
the,O
World,O
Health,O
Organisation,O
(,O
WHO,O
),O
on,O
12,O
March,O
2020,O
after,O
rapid,O
global,O
spread,O
.,O
COVID‐19,O
has,O
a,O
varied,O
clinical,O
presentation,O
ranging,O
from,O
asymptomatic,O
/,O
mild,O
infection,O
to,O
life‐threatening,O
illness,O
requiring,O
multi‐organ,O
support,O
.,O
Data,O
from,O
other,O
cohorts,O
worldwide,O
suggest,O
mortality,O
from,O
COVID‐19,O
is,O
higher,O
in,O
haematology,O
patients,O
compared,O
to,O
the,O
general,O
population,O
",",O
",",O
 ,O
",",O
  ,O
with,O
reported,O
mortality,O
rates,O
between,O
39,O
%,O
and,O
50,O
%,O
in,O
other,O
British,O
haematology,O
patient,O
cohorts,O
.,O
",",O
 ,O
",",O
In,O
particular,O
",",O
a,O
recent,O
UK,O
case,O
series,O
reported,O
significantly,O
higher,O
case,O
fatality,O
rates,O
in,O
haematology,O
patients,O
receiving,O
immunosuppressive,O
or,O
cytotoxic,O
therapy,O
within,O
three,O
months,O
of,O
COVID‐19,O
diagnosis,O
",",O
raising,O
concerns,O
about,O
the,O
delivery,O
of,O
systemic,O
anti‐cancer,O
therapy,O
(,O
SACT,O
),O
during,O
the,O
pandemic,O
.,O
We,O
studied,O
55,O
patients,O
 ,O
≥,O
 ,O
18,O
 ,O
years,O
old,O
with,O
a,O
haematological,O
disorder,O
who,O
tested,O
positive,O
for,O
SARS‐CoV‐2,O
or,O
were,O
diagnosed,O
with,O
COVID‐19,O
based,O
on,O
radiological,O
or,O
clinical,O
criteria,O
",",O
between,O
20,O
March,O
and,O
20,O
April,O
2020,O
.,O
Cases,O
were,O
identified,O
through,O
departmental,O
surveillance,O
which,O
identified,O
haematology,O
patients,O
testing,O
positive,O
for,O
SARS‐CoV‐2,O
or,O
with,O
suspected,O
or,O
confirmed,O
COVID‐19,O
in,O
outpatient,O
and,O
inpatient,O
departments,O
.,O
This,O
cohort,O
included,O
52,O
patients,O
with,O
an,O
underlying,O
haematological,O
malignancy,O
",",O
two,O
with,O
bone,O
marrow,O
failure,O
syndromes,O
and,O
one,O
with,O
immune‐mediated,O
thrombotic,O
thrombocytopenic,O
purpura,O
(,O
TTP,O
),O
receiving,O
elective,O
immunosuppressive,O
therapy,O
Table,O
 ,O
I.,O
Patients,O
had,O
laboratory‐confirmed,O
SARS‐CoV‐2,O
[,O
defined,O
as,O
a,O
positive,O
result,O
on,O
reverse‐transcriptase‐polymerase‐chain‐reaction,O
(,O
RT‐PCR,O
),O
assay,O
on,O
a,O
combined,O
nose,O
and,O
throat,O
swab,O
specimen,O
],O
or,O
a,O
high,O
clinical,O
suspicion,O
of,O
COVID‐19,O
(,O
defined,O
as,O
SARS‐CoV‐2,O
RT‐PCR‐negative,O
patients,O
who,O
had,O
radiological,O
evidence,O
of,O
pneumonia,O
or,O
an,O
influenza‐like,O
illness,O
in,O
the,O
absence,O
of,O
another,O
identifiable,O
cause,O
),O
.,O
Among,O
patients,O
requiring,O
hospital,O
admission,O
86,O
%,O
(,O
44/51,O
),O
were,O
on,O
SACT,O
at,O
the,O
time,O
of,O
COVID‐19,O
diagnosis,O
",",O
87,O
%,O
(,O
48/55,O
),O
had,O
a,O
laboratory‐confirmed,O
diagnosis,O
of,O
COVID‐19,O
",",O
9,O
%,O
(,O
5/55,O
),O
were,O
diagnosed,O
based,O
on,O
radiological,O
appearances,O
on,O
a,O
plain,O
chest,O
radiograph,O
(,O
CXR,O
),O
or,O
computed,O
tomography,O
(,O
CT,O
),O
",",O
while,O
4,O
%,O
(,O
2/55,O
),O
had,O
indeterminate,O
radiology,O
but,O
a,O
highly,O
suggestive,O
clinical,O
picture,O
of,O
COVID‐19,O
.,O
Median,O
age,O
at,O
time,O
of,O
COVID‐19,O
diagnosis,O
was,O
63,O
(,O
range,O
23–88,O
),O
years,O
",",O
and,O
67,O
%,O
(,O
37/55,O
),O
were,O
male,O
.,O
Four,O
patients,O
were,O
admitted,O
with,O
symptoms,O
including,O
cough,O
and,O
fever,O
but,O
were,O
found,O
to,O
be,O
pancytopenic,O
and,O
a,O
new,O
diagnosis,O
of,O
acute,O
leukaemia,O
/,O
myelodysplastic,O
syndrome,O
(,O
MDS,O
),O
was,O
made,O
[,O
two,O
acute,O
myeloid,O
leukaemia,O
(,O
AML,O
),O
",",O
one,O
B‐cell,O
acute,O
lymphoblastic,O
leukaemia,O
(,O
B‐ALL,O
),O
",",O
one,O
high‐risk,O
MDS,O
],O
with,O
concomitant,O
COVID‐19,O
.,O
Two,O
patients,O
were,O
admitted,O
to,O
hospital,O
for,O
management,O
of,O
their,O
haematological,O
malignancy,O
and,O
were,O
asymptomatic,O
or,O
had,O
mild,O
symptoms,O
of,O
COVID‐19,O
.,O
Four,O
patients,O
had,O
been,O
in,O
hospital,O
for,O
greater,O
than,O
seven,O
 ,O
days,O
before,O
they,O
developed,O
symptoms,O
and,O
thus,O
likely,O
acquired,O
COVID‐19,O
in,O
hospital,O
.,O
Four,O
patients,O
were,O
neutropenic,O
(,O
neuts,O
 ,O
<,O
 ,O
1,O
 ,O
×,O
 ,O
109,O
/,O
l,O
),O
at,O
time,O
of,O
COVID‐19,O
diagnosis,O
.,O
Thirteen,O
percent,O
(,O
7/55,O
),O
developed,O
neutropenia,O
(,O
<,O
1,O
 ,O
×,O
 ,O
109,O
/,O
l,O
),O
in,O
the,O
seven,O
 ,O
days,O
following,O
COVID‐19,O
diagnosis,O
.,O
Of,O
those,O
who,O
were,O
currently,O
on,O
or,O
had,O
recently,O
received,O
SACT,O
",",O
65,O
%,O
(,O
34/52,O
),O
had,O
their,O
therapy,O
modified,O
by,O
dose,O
change,O
(,O
n,O
 ,O
=,O
 ,O
1,O
),O
",",O
treatment,O
delay,O
(,O
n,O
 ,O
=,O
 ,O
28,O
),O
and/or,O
a,O
change,O
in,O
treatment,O
regimen,O
(,O
n,O
 ,O
=,O
 ,O
5,O
),O
due,O
to,O
concerns,O
regarding,O
the,O
administration,O
of,O
standard,O
chemotherapy,O
during,O
the,O
COVID‐19,O
pandemic,O
and,O
in,O
line,O
with,O
national,O
guidance,O
.,O
These,O
regimens,O
were,O
felt,O
to,O
be,O
less,O
myelosuppressive,O
compared,O
to,O
standard,O
therapy,O
.,O
",",O
  ,O
A,O
patient,O
with,O
a,O
new,O
diagnosis,O
of,O
Philadelphia‐positive,O
B‐ALL,O
and,O
a,O
mild,O
clinical,O
presentation,O
of,O
COVID‐19,O
underwent,O
reduced‐intensity,O
imatinib‐based,O
induction,O
therapy,O
on,O
the,O
UKALL60,O
+,O
 ,O
protocol,O
.,O
All,O
four,O
patients,O
recovered,O
from,O
COVID‐19,O
despite,O
undergoing,O
induction,O
therapy,O
during,O
their,O
illness,O
.,O
In,O
all,O
",",O
86,O
%,O
(,O
43/50,O
),O
of,O
patients,O
received,O
systemic,O
antibiotics,O
",",O
and,O
6,O
%,O
(,O
3/50,O
),O
antifungal,O
therapy,O
during,O
their,O
COVID‐19,O
illness,O
.,O
A,O
number,O
of,O
patients,O
had,O
other,O
concomitant,O
infections,O
diagnosed,O
during,O
their,O
COVID‐19,O
admission,O
(,O
Table,O
 ,O
SIII,O
),O
.,O
We,O
report,O
the,O
outcomes,O
of,O
a,O
large,O
cohort,O
of,O
haematology,O
patients,O
with,O
COVID‐19,O
",",O
the,O
majority,O
of,O
whom,O
were,O
receiving,O
SACT,O
.,O
Despite,O
valid,O
concerns,O
regarding,O
the,O
vulnerability,O
of,O
haematology,O
patients,O
to,O
COVID‐19,O
",",O
our,O
observed,O
mortality,O
of,O
37,O
%,O
in,O
hospitalised,O
patients,O
indicates,O
that,O
a,O
significant,O
proportion,O
of,O
haematology,O
patients,O
recover,O
from,O
COVID‐19,O
",",O
despite,O
recent,O
or,O
concurrent,O
SACT,O
.,O
Despite,O
heterogeneity,O
in,O
our,O
patient,O
cohort,O
and,O
methodology,O
",",O
the,O
mortality,O
rate,O
described,O
here,O
is,O
consistent,O
with,O
those,O
from,O
other,O
UK,O
cohorts,O
of,O
patients,O
with,O
haematological,O
malignancy,O
and,O
COVID‐19,O
(,O
39–52,O
%,O
),O
.,O
",",O
 ,O
",",O
While,O
a,O
direct,O
comparison,O
with,O
a,O
non‐haematology,O
cohort,O
has,O
not,O
been,O
performed,O
",",O
our,O
data,O
corroborate,O
existing,O
studies,O
that,O
haematology,O
patients,O
are,O
at,O
increased,O
risk,O
of,O
severe,O
disease,O
and,O
mortality,O
from,O
COVID‐19,O
",",O
with,O
a,O
large,O
UK,O
population,O
study,O
reporting,O
lower,O
mortality,O
of,O
33,O
%,O
of,O
all,O
hospitalised,O
cases,O
",",O
despite,O
an,O
older,O
median,O
study,O
age,O
of,O
72,O
 ,O
years,O
.,O
Several,O
risk,O
factors,O
for,O
severe,O
COVID‐19,O
in,O
the,O
general,O
population,O
are,O
relevant,O
to,O
patients,O
with,O
haematological,O
disorders,O
.,O
In,O
this,O
patient,O
cohort,O
",",O
81,O
%,O
had,O
SACT,O
modifications,O
(,O
delay,O
or,O
de‐intensification,O
),O
in,O
light,O
of,O
their,O
COVID‐19,O
diagnosis,O
",",O
including,O
when,O
receiving,O
induction,O
treatment,O
for,O
new,O
diagnoses,O
of,O
haematological,O
malignancies,O
",",O
in,O
line,O
with,O
emerging,O
evidence,O
and,O
guidance,O
.,O
While,O
patients,O
who,O
received,O
SACT,O
within,O
28,O
 ,O
days,O
of,O
COVID‐19,O
diagnosis,O
had,O
higher,O
rates,O
of,O
severe,O
disease,O
and,O
mortality,O
",",O
this,O
was,O
not,O
statistically,O
significant,O
",",O
although,O
analysis,O
is,O
limited,O
by,O
the,O
size,O
and,O
heterogeneity,O
of,O
the,O
cohort,O
.,O
While,O
a,O
recent,O
UK,O
series,O
has,O
suggested,O
that,O
recent,O
SACT,O
confers,O
a,O
higher,O
risk,O
of,O
death,O
from,O
COVID‐19,O
in,O
haemato‐oncology,O
patients,O
",",O
 ,O
two,O
recent,O
multicentre,O
cohort,O
studies,O
including,O
haematology,O
patients,O
have,O
found,O
no,O
impact,O
of,O
SACT,O
timing,O
on,O
COVID‐19,O
outcome,O
",",O
",",O
  ,O
highlighting,O
the,O
need,O
for,O
further,O
data,O
regarding,O
the,O
implications,O
for,O
different,O
disease,O
subtypes,O
and,O
treatment,O
modalities,O
.,O
While,O
caution,O
in,O
instituting,O
SACT,O
is,O
clearly,O
warranted,O
",",O
our,O
data,O
suggest,O
that,O
modification,O
of,O
therapy,O
including,O
the,O
use,O
of,O
non‐standard,O
treatment,O
regimens,O
can,O
be,O
considered,O
in,O
haematology,O
patients,O
with,O
COVID‐19,O
to,O
allow,O
treatment,O
of,O
the,O
haematological,O
diagnosis,O
while,O
accepting,O
risks,O
of,O
COVID‐19,O
infection,O
.,O
Where,O
the,O
COVID‐19,O
pandemic,O
has,O
forced,O
a,O
paradigm,O
shift,O
in,O
therapy,O
",",O
the,O
long‐term,O
follow‐up,O
of,O
these,O
patients,O
will,O
be,O
crucial,O
to,O
assess,O
efficacy,O
in,O
comparison,O
to,O
more,O
intensive,O
chemotherapy‐based,O
regimens,O
.,O
Furthermore,O
",",O
the,O
cases,O
of,O
newly,O
diagnosed,O
leukaemia,O
highlight,O
the,O
importance,O
of,O
COVID‐19,O
testing,O
as,O
part,O
of,O
routine,O
investigation,O
of,O
patients,O
with,O
haematological,O
malignancies,O
in,O
the,O
current,O
climate,O
.,O
Recent,O
data,O
from,O
patients,O
in,O
the,O
general,O
population,O
with,O
COVID‐19,O
have,O
identified,O
that,O
haematological,O
parameters,O
including,O
anaemia,O
or,O
thrombocytopenia,O
are,O
risk,O
factors,O
for,O
severe,O
disease,O
.,O
",",O
Coagulopathy,O
in,O
COVID‐19,O
pathophysiology,O
is,O
an,O
ongoing,O
area,O
of,O
research,O
",",O
with,O
early,O
observations,O
highlighting,O
high,O
rates,O
of,O
VTE,O
occurrence,O
",",O
particularly,O
in,O
those,O
with,O
severe,O
COVID‐19,O
.,O
",",O
 ,O
",",O
 ,O
",",O
  ,O
Prophylactic,O
LMWH,O
",",O
unless,O
contraindicated,O
",",O
is,O
",",O
therefore,O
",",O
advised,O
for,O
all,O
COVID‐19,O
patients,O
.,O
Summary,O
 ,O
Haematology,O
patients,O
receiving,O
chemo‐,O
or,O
immunotherapy,O
are,O
considered,O
to,O
be,O
at,O
greater,O
risk,O
of,O
COVID‐19‐related,O
morbidity,O
and,O
mortality,O
.,O
We,O
aimed,O
to,O
identify,O
risk,O
factors,O
for,O
COVID‐19,O
severity,O
and,O
assess,O
outcomes,O
in,O
patients,O
where,O
COVID‐19,O
complicated,O
the,O
treatment,O
of,O
their,O
haematological,O
disorder,O
.,O
A,O
retrospective,O
cohort,O
study,O
was,O
conducted,O
in,O
55,O
patients,O
with,O
haematological,O
disorders,O
and,O
COVID‐19,O
",",O
including,O
52,O
with,O
malignancy,O
",",O
two,O
with,O
bone,O
marrow,O
failure,O
and,O
one,O
immune‐mediated,O
thrombotic,O
thrombocytopenic,O
purpura,O
(,O
TTP,O
),O
.,O
COVID‐19,O
diagnosis,O
coincided,O
with,O
a,O
new,O
diagnosis,O
of,O
a,O
haematological,O
malignancy,O
in,O
four,O
patients,O
.,O
Among,O
patients,O
",",O
82,O
%,O
were,O
on,O
systemic,O
anti‐cancer,O
therapy,O
(,O
SACT,O
),O
at,O
the,O
time,O
of,O
COVID‐19,O
diagnosis,O
.,O
The,O
majority,O
of,O
patients,O
recovered,O
from,O
COVID‐19,O
",",O
despite,O
receiving,O
recent,O
SACT,O
.,O
This,O
suggests,O
that,O
SACT,O
",",O
where,O
urgent,O
",",O
should,O
be,O
administered,O
despite,O
intercurrent,O
COVID‐19,O
infection,O
",",O
which,O
should,O
be,O
managed,O
according,O
to,O
standard,O
pathways,O
.,O
A,O
promising,O
approach,O
to,O
combat,O
the,O
COVID19,O
pandemic,O
involves,O
development,O
of,O
antiviral,O
antibodies,O
targeting,O
the,O
spike,O
protein,O
of,O
SARS,O
-,O
CoV-2,O
.,O
Antibodies,O
targeting,O
the,O
spike,O
protein,O
of,O
SARS,O
-,O
CoV-2,O
present,O
a,O
promising,O
approach,O
to,O
combat,O
the,O
COVID19,O
pandemic,O
;,O
however,O
",",O
concerns,O
remain,O
that,O
mutations,O
can,O
yield,O
antibody,O
resistance,O
.,O
To,O
seek,O
potential,O
Chinese,O
herbal,O
medicine,O
(,O
CHM,O
),O
for,O
the,O
treatment,O
of,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
through,O
the,O
molecular,O
docking,O
of,O
the,O
medicine,O
with,O
SARS,O
-,O
CoV-2,O
3CL,O
hydrolytic,O
enzyme,O
and,O
the,O
angiotensin,O
converting,O
enzyme,O
II(ACE2,O
),O
as,O
receptors,O
",",O
using,O
computer,O
virtual,O
screening,O
technique,O
",",O
so,O
as,O
to,O
provide,O
a,O
basis,O
for,O
combination,O
forecasting,O
.,O
Based,O
on,O
the,O
perspective,O
of,O
network,O
pharmacology,O
",",O
the,O
chemical,O
-,O
target,O
network,O
was,O
constructed,O
",",O
and,O
the,O
functional,O
enrichment,O
analysis,O
of,O
gene,O
ontology,O
and,O
the,O
pathway,O
enrichment,O
analysis,O
of,O
Kyoto,O
encyclopedia,O
of,O
genes,O
and,O
genomes,O
were,O
carried,O
out,O
by,O
DAVID,O
to,O
speculate,O
about,O
the,O
mechanism,O
of,O
action,O
of,O
the,O
core,O
drug,O
pairs,O
.,O
Among,O
238,O
potential,O
anti,O
-,O
COVID-19,O
herbs,O
screened,O
in,O
total,O
",",O
16,O
kinds,O
of,O
CHM,O
containing,O
the,O
most,O
active,O
ingredients,O
",",O
and,O
5,O
candidate,O
anti,O
-,O
COVID-19,O
herbs,O
that,O
had,O
been,O
used,O
in,O
high,O
frequency,O
",",O
as,O
well,O
as,O
a,O
core,O
drug,O
pair,O
",",O
namely,O
",",O
Forsythiae,O
Fructus,O
-,O
Lonicerae,O
Japonicae,O
The,O
core,O
drug,O
pair,O
of,O
Forsythiae,O
Fructus,O
-,O
Lonicerae,O
Japonicae,O
Flos,O
containing,O
multiple,O
components,O
and,O
targets,O
is,O
easy,O
to,O
combine,O
with,O
3CLpro,O
and,O
ACE2,O
",",O
and,O
exerts,O
an,O
anti,O
-,O
COVID-19,O
pneumonia,O
effect,O
through,O
multi,O
-,O
component,O
and,O
multi,O
-,O
target,O
",",O
and,O
plays,O
the,O
role,O
of,O
anti,O
-,O
COVID-19,O
pneumonia,O
in,O
multi,O
-,O
pathway,O
.,O
National,O
guidelines,O
are,O
being,O
issued,O
to,O
provide,O
continuous,O
adult,O
cancer,O
care,O
without,O
increasing,O
the,O
risk,O
of,O
COVID,O
infection,O
[,O
9,O
],O
",",O
[,O
10,O
],O
.,O
Gy,O
;,O
SIB,O
schedules,O
are,O
incorporated,O
into,O
the,O
FaR,O
-,O
RMS,O
radiotherapy,O
guidelines,O
.,O
The,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
",",O
is,O
caused,O
by,O
severe,O
acute,O
respiratory,O
syndrome,O
corona,O
virus-2,O
(,O
SARS,O
-,O
CoV-2,O
),O
",",O
has,O
emerged,O
from,O
Wuhan,O
",",O
China,O
",",O
in,O
December,O
2019,O
[,O
1,O
],O
and,O
spread,O
rapidly,O
across,O
worldwide,O
.,O
On,O
11th,O
March,O
2020,O
",",O
the,O
World,O
Health,O
Organization,O
(,O
WHO,O
),O
declared,O
COVID-19,O
as,O
a,O
pandemic,O
(,O
https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020,O
),O
.,O
ACE2,O
receptor,O
plays,O
a,O
crucial,O
role,O
in,O
cellular,O
invading,O
of,O
SARS,O
-,O
CoV-2,O
as,O
well,O
as,O
various,O
pathophysiological,O
conditions,O
of,O
the,O
COVID-19,O
[,O
16,O
],O
.,O
However,O
",",O
in,O
the,O
present,O
report,O
",",O
we,O
observed,O
a,O
positive,O
correlation,O
of,O
allele,O
D,O
with,O
infection,O
an,O
mortality,O
rate,O
of,O
COVID-19,O
.,O
The,O
minor,O
allele,O
of,O
ACE,O
I,O
/,O
D,O
was,O
linked,O
with,O
COVID-19,O
mortality,O
in,O
the,O
Asian,O
population,O
.,O
Several,O
reports,O
have,O
been,O
highlighted,O
the,O
importance,O
of,O
ACE-2,O
on,O
the,O
pathogenesis,O
of,O
COVID-19,O
.,O
Data,O
on,O
COVID-19,O
infection,O
rate,O
(,O
per,O
million,O
),O
",",O
mortality,O
/,O
million,O
",",O
and,O
percentage,O
of,O
recovery,O
were,O
acquired,O
form,O
worldometer,S-Dataset
 ,O
website,O
.,O
The,O
COVID-19,O
pandemic,O
poses,O
unprecedented,O
challenges,O
to,O
the,O
field,O
of,O
oncology,O
.,O
I,O
read,O
with,O
great,O
interest,O
the,O
recent,O
recommendations,O
outlined,O
by,O
Deitz,O
et,O
al,O
.,O
for,O
patients,O
with,O
breast,O
cancer,O
during,O
the,O
COVID-19,O
pandemic,O
[,O
1,O
],O
.,O
COVID‐19,O
is,O
a,O
severe,O
acute,O
respiratory,O
syndrome,O
caused,O
by,O
SARS‐CoV‐2,O
that,O
affected,O
in,O
the,O
last,O
few,O
months,O
more,O
than,O
12,O
million,O
individuals,O
around,O
the,O
world,O
(,O
https://covid19.who.int/,O
),O
.,O
A,O
recent,O
study,O
by,O
Ellinghaus,O
et,O
al,O
",",O
investigating,O
a,O
large,O
cohort,O
of,O
COVID‐19,O
patients,O
from,O
Italy,O
and,O
Spain,O
",",O
using,O
a,O
genome‐wide,O
association,O
study,O
approach,O
",",O
did,O
not,O
find,O
any,O
significant,O
evidence,O
of,O
HLA,O
involvement,O
.,O
Reads,O
were,O
analyzed,O
using,O
the,O
HLA,O
TypeStream,O
Visual,O
Software,O
(,O
One,O
Lambda,O
),O
",",O
ver,O
.,O
1.3,O
",",O
updated,O
to,O
the,O
IPD‐IMGT/HLA,S-Repository
 ,O
last,O
database,O
release,O
",",O
3.40.0,O
.,O
In,O
Table,O
2,O
",",O
we,O
also,O
show,O
the,O
HLA,O
alleles,O
distribution,O
of,O
the,O
99,O
COVID‐19,O
patients,O
.,O
The,O
increased,O
frequencies,O
that,O
we,O
observed,O
for,O
DRB1,O
*,O
15:01,O
and,O
DQB1,O
*,O
06:02,O
",",O
in,O
strong,O
linkage,O
disequilibrium,O
with,O
each,O
other,O
",",O
in,O
the,O
99,O
severe,O
affected,O
COVID‐19,O
Italian,O
patients,O
were,O
not,O
in,O
line,O
with,O
the,O
results,O
obtained,O
on,O
a,O
larger,O
survey,O
studied,O
by,O
Ellinghaus,O
et,O
al,O
 ,O
that,O
did,O
not,O
show,O
any,O
association,O
between,O
HLA,O
and,O
COVID‐19,O
",",O
but,O
confirmed,O
those,O
published,O
by,O
Kachuri,O
et,O
al,O
 ,O
identifying,O
these,O
two,O
alleles,O
among,O
seven,O
HLA,O
susceptibility,O
alleles,O
.,O
With,O
the,O
aim,O
to,O
individuate,O
alleles,O
that,O
may,O
reflect,O
a,O
higher,O
susceptibility,O
to,O
the,O
disease,O
",",O
in,O
the,O
present,O
study,O
we,O
analyzed,O
the,O
HLA,O
allele,O
frequency,O
distribution,O
in,O
a,O
group,O
of,O
99,O
Italian,O
patients,O
affected,O
by,O
a,O
severe,O
or,O
extremely,O
severe,O
form,O
of,O
COVID‐19,O
.,O
The,O
increased,O
frequencies,O
observed,O
may,O
contribute,O
to,O
identify,O
potential,O
markers,O
of,O
susceptibility,O
to,O
the,O
disease,O
",",O
although,O
controversial,O
results,O
on,O
the,O
role,O
of,O
single,O
HLA,O
alleles,O
in,O
COVID‐19,O
patients,O
have,O
been,O
recently,O
reported,O
.,O
Variables,O
from,O
the,O
EHR,O
were,O
chosen,O
for,O
this,O
analysis,O
based,O
on,O
a,O
combination,O
of,O
their,O
prevalence,O
per,O
patient,O
across,O
the,O
dataset,O
",",O
relevance,O
to,O
COVID-19,O
based,O
on,O
previous,O
literature,O
and,O
empirical,O
evidence,O
",",O
and,O
the,O
goals,O
of,O
this,O
study,O
.,O
Based,O
on,O
the,O
utility,O
of,O
these,O
lab,O
values,O
in,O
clinical,O
practice,O
and,O
the,O
similarity,O
between,O
their,O
statistical,O
distributions,O
",",O
labs,O
derived,O
from,O
a,O
VBG,O
or,O
BMP,O
were,O
collapsed,O
into,O
a,O
single,O
category,O
(,O
i.e.,O
",",O
“,O
SODIUM,O
”,O
),O
",",O
and,O
arterial,O
labs,O
were,O
not,O
incorporated,O
as,O
features,O
in,O
these,O
analyses,O
.,O
Of,O
2864,O
patients,O
discharged,O
alive,O
following,O
hospitalization,O
for,O
COVID-19,O
",",O
103,O
(,O
3.6,O
%,O
),O
returned,O
to,O
one,O
of,O
five,O
hospitals,O
within,O
14,O
days,O
",",O
with,O
56,O
(,O
54.4,O
%,O
),O
readmitted,O
and,O
the,O
remaining,O
47,O
(,O
45.6,O
%,O
),O
discharged,O
or,O
left,O
from,O
the,O
emergency,O
department,O
(,O
ED,O
),O
(,O
Table,O
1,O
),O
.,O
Though,O
lower,O
BMI,O
could,O
serve,O
as,O
a,O
marker,O
for,O
and,O
has,O
been,O
associated,O
with,O
worse,O
health,O
outcomes,O
in,O
other,O
disease,O
states,O
",",O
the,O
distributions,O
of,O
BMI,O
between,O
those,O
returning,O
to,O
the,O
hospital,O
and,O
those,O
who,O
did,O
not,O
were,O
relatively,O
similar,O
(,O
Supplementary,O
Figure,O
1,O
),O
with,O
a,O
low,O
difference,O
in,O
means,O
;,O
therefore,O
",",O
further,O
work,O
is,O
needed,O
to,O
unravel,O
the,O
association,O
between,O
BMI,O
and,O
outcomes,O
in,O
COVID-19,O
.,O
Background,O
 ,O
Data,O
on,O
patients,O
with,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
who,O
return,O
to,O
hospital,O
after,O
discharge,O
are,O
scarce,O
.,O
To,O
describe,O
clinical,O
characteristics,O
of,O
patients,O
with,O
COVID-19,O
who,O
returned,O
to,O
the,O
emergency,O
department,O
(,O
ED,O
),O
or,O
required,O
readmission,O
within,O
14,O
days,O
of,O
discharge,O
.,O
Conclusions,O
 ,O
Return,O
to,O
hospital,O
after,O
admission,O
for,O
COVID-19,O
was,O
infrequent,O
within,O
14,O
days,O
of,O
discharge,O
.,O
With,O
COVID-19,O
",",O
the,O
time,O
and,O
place,O
a,O
biosample,O
was,O
collected,O
has,O
suddenly,O
become,O
a,O
life,O
and,O
death,O
issue,O
.,O
SARS,O
CoV‐2,O
",",O
the,O
virus,O
which,O
causes,O
COVID19,O
",",O
is,O
similar,O
to,O
",",O
but,O
not,O
identical,O
with,O
the,O
SARS‐CoV‐1,O
virus,O
",",O
which,O
caused,O
the,O
SARS,O
epidemic,O
originating,O
in,O
China,O
in,O
2002,O
to,O
2003,O
.,O
For,O
example,O
",",O
analyses,O
of,O
different,O
strains,O
showed,O
that,O
predominance,O
of,O
COVID‐19,O
cases,O
in,O
the,O
New,O
York,O
City,O
area,O
resulted,O
largely,O
from,O
infected,O
patients,O
who,O
flew,O
in,O
from,O
Europe,O
",",O
rather,O
than,O
Asia,O
.,O
Consequently,O
",",O
barring,O
US,O
entry,O
to,O
recent,O
visitors,O
to,O
China,O
on,O
January,O
31st,O
",",O
and,O
from,O
European,O
countries,O
on,O
March,O
11th,O
was,O
largely,O
ineffective,O
in,O
preventing,O
the,O
COVID,O
outbreak,O
in,O
the,O
United,O
States,O
.,O
The,O
impact,O
of,O
the,O
COVID‐19,O
epidemic,O
suggests,O
that,O
interest,O
in,O
the,O
development,O
of,O
a,O
vaccine,O
will,O
be,O
more,O
enduring,O
.,O
The,O
COVID‐19,O
epidemic,O
was,O
not,O
the,O
first,O
coronavirus,O
epidemic,O
of,O
this,O
century,O
and,O
represents,O
one,O
of,O
the,O
increasing,O
number,O
of,O
zoonoses,O
from,O
wildlife,O
to,O
impact,O
global,O
health,O
.,O
SARS,O
CoV‐2,O
",",O
the,O
virus,O
causing,O
the,O
COVID‐19,O
epidemic,O
is,O
distinct,O
from,O
",",O
but,O
closely,O
resembles,O
SARS,O
CoV‐1,O
",",O
which,O
was,O
responsible,O
for,O
the,O
severe,O
acute,O
respiratory,O
syndrome,O
(,O
SARS,O
),O
outbreak,O
in,O
2002,O
.,O
We,O
review,O
recent,O
coronavirus‐related,O
epidemics,O
and,O
distinguish,O
clinical,O
and,O
molecular,O
features,O
of,O
CoV‐2,O
",",O
the,O
causative,O
agent,O
for,O
COVID‐19,O
",",O
and,O
review,O
the,O
current,O
status,O
of,O
vaccine,O
trials,O
.,O
One,O
set,O
of,O
questions,O
involves,O
susceptibility,O
and,O
outcomes,O
related,O
to,O
SARS,O
-,O
CoV-2,O
infection,O
(,O
COVID-19,O
),O
.,O
Large,O
",",O
international,O
studies,O
and,O
collaborations,O
have,O
formed,O
to,O
investigate,O
host,O
genetic,O
factors,O
related,O
to,O
COVID-19,O
.,O
These,O
investigations,O
include,O
analyses,O
of,O
existing,O
public,O
and,O
private,O
datasets,O
",",O
as,O
well,O
as,O
the,O
establishment,O
of,O
new,O
cohorts,O
(,O
e.g.,O
",",O
see,O
“,O
The,B-Repository
COVID-19,I-Repository
Host,I-Repository
Genetics,I-Repository
Initiative,E-Repository
”,O
and,O
“,O
23andMe/23andMe,O
Research,O
Blog,O
”,O
entries,O
in,O
the,O
Web,O
Resources,O
),O
.,O
We,O
use,O
themes,O
identified,O
in,O
our,O
review,O
of,O
these,O
articles,O
to,O
highlight,O
areas,O
that,O
are,O
particularly,O
relevant,O
to,O
human,O
studies,O
of,O
COVID-19,O
;,O
in,O
addition,O
to,O
the,O
limited,O
references,O
cited,O
here,O
",",O
please,O
refer,O
to,O
Table,O
S1,O
for,O
the,O
additional,O
literature,O
identified,O
through,O
this,O
search,O
",",O
as,O
well,O
as,O
section,O
-,O
specific,O
 ,O
references,O
not,O
included,O
in,O
the,O
main,O
manuscript,O
.,O
In,O
the,O
burgeoning,O
studies,O
of,O
COVID-19,O
host,O
genetic,O
factors,O
",",O
controlling,O
for,O
these,O
types,O
of,O
other,O
variables,O
will,O
be,O
challenging,O
and,O
important,O
.,O
Similar,O
approaches,O
have,O
achieved,O
significant,O
results,O
for,O
other,O
etiologically,O
and,O
medically,O
complex,O
diseases,O
(,O
such,O
as,O
preterm,O
birth,O
),O
",",O
including,O
using,O
some,O
of,O
the,O
same,O
datasets,O
and,O
approaches,O
being,O
proposed,O
for,O
COVID-19,O
studies,O
.,O
This,O
aspect,O
bears,O
further,O
scrutiny,O
in,O
COVID-19,O
studies,O
",",O
especially,O
given,O
recent,O
data,O
regarding,O
SARS,O
-,O
CoV-2,O
genetic,O
changes,O
detected,O
in,O
different,O
areas,O
of,O
the,O
world,O
(,O
e.g.,O
",",O
see,O
data,O
from,O
Nextstrain,S-Repository
 ,O
under,O
Web,O
Resources,O
),O
.,O
Related,O
to,O
the,O
human,O
implications,O
of,O
this,O
type,O
of,O
work,O
",",O
newer,O
gene,O
editing,O
techniques,O
may,O
be,O
an,O
efficient,O
way,O
to,O
provide,O
experimental,O
validation,O
of,O
specific,O
variants,O
that,O
have,O
been,O
implicated,O
in,O
COVID-19,O
.,O
This,O
line,O
of,O
reasoning,O
may,O
also,O
be,O
relevant,O
to,O
age,O
-,O
specific,O
differences,O
observed,O
with,O
COVID-19,O
in,O
humans,O
.,O
That,O
is,O
",",O
one,O
of,O
several,O
potential,O
factors,O
that,O
may,O
explain,O
why,O
most,O
children,O
are,O
more,O
mildly,O
affected,O
by,O
COVID-19,O
is,O
age,O
-,O
related,O
differences,O
in,O
ACE2,O
receptor,O
expression,O
.,O
Several,O
studies,O
have,O
used,O
(,O
and,O
are,O
using,O
),O
existing,O
datasets,O
to,O
explore,O
allele,O
frequencies,O
(,O
such,O
as,O
in,O
ACE2,O
),O
in,O
various,O
geographic,O
/,O
ancestral,O
populations,O
:,O
the,O
hypothesis,O
is,O
that,O
differences,O
in,O
allele,O
frequencies,O
—,O
as,O
well,O
as,O
observed,O
differences,O
in,O
gene,O
expression,O
—,O
may,O
be,O
one,O
reason,O
for,O
differential,O
impacts,O
of,O
COVID-19,O
in,O
different,O
parts,O
of,O
the,O
world,O
.,O
",",O
Only,O
studies,O
reporting,O
ORs,O
and,O
CIs,O
are,O
shown,O
(,O
PMID,O
:,O
32348495,S-AccessionNumber
 ,O
did,O
not,O
include,O
CI,O
),O
.,O
Validating,O
findings,O
with,O
biological,O
data,O
will,O
also,O
be,O
helpful,O
—,O
for,O
example,O
",",O
a,O
recent,O
study,O
on,O
COVID-19,O
showed,O
that,O
certain,O
immune,O
mediators,O
",",O
cytokines,O
",",O
and,O
chemokines,O
correlate,O
with,O
aspects,O
of,O
disease,O
.,O
Because,O
of,O
today,O
’s,O
availability,O
of,O
genomic,O
approaches,O
",",O
and,O
in,O
contrast,O
to,O
the,O
previously,O
published,O
studies,O
(,O
described,O
in,O
Tables,O
1,O
and,O
S2,O
),O
",",O
emerging,O
studies,O
on,O
COVID-19,O
will,O
most,O
likely,O
have,O
to,O
consider,O
both,O
rare,O
and,O
common,O
variants,O
in,O
these,O
and,O
other,O
genes,O
",",O
as,O
well,O
as,O
combinatorial,O
models,O
explaining,O
susceptibility,O
and,O
outcomes,O
.,O
SARS,O
-,O
CoV-2,O
studies,O
have,O
suggested,O
that,O
truncated,O
ACE2,O
could,O
act,O
as,O
a,O
COVID-19,O
therapeutic,O
through,O
inhibition,O
of,O
SARS,O
-,O
CoV-2,O
spike,O
protein,O
activity,O
.,O
Modern,O
gene,O
editing,O
techniques,O
have,O
been,O
studied,O
in,O
this,O
context,O
;,O
these,O
have,O
also,O
garnered,O
recent,O
interest,O
in,O
COVID-19,O
.,O
In,O
COVID-19,O
",",O
the,O
use,O
of,O
splice,O
-,O
switching,O
antisense,O
oligonucleotides,O
has,O
been,O
proposed,O
to,O
affect,O
ACE2,O
in,O
order,O
to,O
limit,O
SARS,O
-,O
CoV-2,O
entry,O
.,O
As,O
with,O
other,O
questions,O
in,O
COVID-19,O
(,O
e.g.,O
",",O
ethical,O
questions,O
pertaining,O
to,O
human,O
challenge,O
studies,O
in,O
vaccine,O
trials,O
),O
",",O
balancing,O
risks,O
and,O
benefits,O
will,O
be,O
critical,O
.,O
Studies,O
of,O
cheetahs,O
present,O
an,O
interesting,O
example,O
related,O
to,O
MHC,O
genes,O
",",O
which,O
may,O
have,O
connections,O
to,O
human,O
COVID-19,O
studies,O
.,O
In,O
humans,O
",",O
severe,O
COVID-19,O
outcomes,O
have,O
already,O
been,O
reported,O
in,O
peer,O
-,O
reviewed,O
literature,O
(,O
as,O
well,O
as,O
many,O
lay,O
articles,O
),O
",",O
but,O
specific,O
suggestions,O
of,O
associations,O
with,O
consanguinity,O
have,O
not,O
been,O
identified,O
.,O
The,O
HLA,O
genes,O
remain,O
a,O
logical,O
target,O
of,O
interest,O
in,O
relation,O
to,O
COVID-19,O
.,O
An,O
in,O
silico,O
analysis,O
of,O
viral,O
peptide,O
-,O
MHC,O
class,O
I,O
binding,O
affinity,O
in,O
relation,O
to,O
HLA,O
genotypes,O
for,O
SARS,O
-,O
CoV-2,O
peptides,O
",",O
as,O
well,O
as,O
potential,O
cross,O
-,O
protective,O
immunity,O
related,O
to,O
four,O
common,O
human,O
coronaviruses,O
",",O
provides,O
evidence,O
that,O
HLA,O
-,O
B∗46:01,O
may,O
be,O
associated,O
with,O
COVID-19,O
vulnerability,O
",",O
whereas,O
HLA,O
-,O
B∗15:03,O
may,O
enable,O
cross,O
-,O
protective,O
T,O
-,O
cell,O
-,O
based,O
immunity,O
.,O
Work,O
in,O
humans,O
so,O
far,O
has,O
also,O
concentrated,O
on,O
key,O
immune,O
genes,O
(,O
see,O
Tables,O
1,O
and,O
S2,O
),O
;,O
similar,O
work,O
in,O
relation,O
to,O
COVID-19,O
has,O
been,O
proposed,O
.,O
An,O
example,O
of,O
a,O
population,O
-,O
specific,O
consideration,O
has,O
already,O
been,O
mentioned,O
in,O
relation,O
to,O
COVID-19,O
is,O
that,O
a,O
variant,O
in,O
SCN5A,O
(,O
MIM,O
:,O
600163,S-AccessionNumber
),O
that,O
is,O
common,O
in,O
individuals,O
of,O
recent,O
African,O
descent,O
may,O
increase,O
the,O
risk,O
of,O
cardiovascular,O
morbidity,O
and,O
mortality,O
",",O
including,O
upon,O
exposure,O
to,O
hydroxychloroquine,O
and,O
azithromycin,O
.,O
Specific,O
examples,O
have,O
already,O
been,O
reported,O
in,O
the,O
literature,O
on,O
COVID-19,O
.,O
Another,O
area,O
of,O
interest,O
may,O
involve,O
studying,O
individuals,O
with,O
identified,O
pathogenic,O
or,O
severe,O
variants,O
(,O
e.g.,O
",",O
“,O
human,O
knockouts,O
”,O
),O
to,O
determine,O
correlations,O
with,O
COVID-19,O
.,O
Currently,O
",",O
age,O
appears,O
to,O
be,O
strongly,O
correlated,O
with,O
COVID-19,O
outcomes,O
.,O
Human,O
host,O
genetic,O
studies,O
on,O
coronavirus,O
have,O
been,O
largely,O
candidate,O
driven,O
to,O
date,O
(,O
see,O
Tables,O
1,O
and,O
S2,O
and,O
Figures,O
3,O
and,O
4,O
for,O
details,O
on,O
human,O
studies,O
",",O
including,O
specific,O
references,O
),O
",",O
though,O
many,O
hypothesis,O
-,O
free,O
studies,O
on,O
COVID-19,O
are,O
in,O
various,O
phases,O
of,O
completion,O
.,O
Previously,O
",",O
lists,O
of,O
recommended,O
secondary,O
genes,O
have,O
been,O
compiled,O
in,O
general,O
contexts,O
",",O
and,O
recommendations,O
have,O
been,O
made,O
about,O
informing,O
individuals,O
about,O
these,O
findings,O
(,O
prior,O
to,O
the,O
COVID-19,O
pandemic,O
),O
.,O
With,O
COVID-19,O
",",O
genomic,O
investigators,O
have,O
newly,O
assembled,O
lists,O
of,O
secondary,O
genetic,O
information,O
that,O
may,O
be,O
relevant,O
to,O
the,O
pandemic,O
.,O
Beyond,O
this,O
overarching,O
framework,O
",",O
specific,O
papers,O
have,O
already,O
been,O
published,O
about,O
pharmacogenomic,O
considerations,O
for,O
medications,O
",",O
such,O
as,O
anti,O
-,O
IL-6,O
agents,O
for,O
the,O
treatment,O
of,O
COVID-19,O
(,O
as,O
well,O
as,O
hydroxychloroquine,O
and,O
azithromycin,O
),O
.,O
",",O
Details,O
of,O
the,O
human,O
studies,O
are,O
presented,O
in,O
the,O
section,O
on,O
Literature,O
Search,O
and,O
Sources,O
",",O
and,O
in,O
Table,O
1,O
",",O
S2,O
",",O
and,O
Figures,O
3,O
",",O
4,O
",",O
and,O
5,O
.,O
In,O
addition,O
to,O
the,O
germline,O
variants,O
described,O
in,O
these,O
previous,O
studies,O
",",O
non,O
-,O
germline,O
changes,O
are,O
discussed,O
as,O
possibly,O
pertinent,O
to,O
COVID-19,O
.,O
Correlations,O
between,O
clonal,O
hematopoiesis,O
and,O
COVID-19,O
mortality,O
have,O
been,O
suggested,O
",",O
as,O
have,O
the,O
potential,O
importance,O
of,O
tumor,O
-,O
based,O
ACE2,O
genetics,O
and,O
epigenetics,O
.,O
MERS,O
and,O
SARS,O
-,O
CoV-1,O
are,O
severe,O
",",O
but,O
the,O
fact,O
that,O
these,O
epidemics,O
were,O
limited,O
more,O
than,O
the,O
COVID-19,O
pandemic,O
may,O
have,O
fortunately,O
led,O
to,O
a,O
lack,O
of,O
cases,O
to,O
conduct,O
traditional,O
association,O
studies,O
(,O
unlike,O
some,O
other,O
respiratory,O
infections,O
leading,O
to,O
more,O
widespread,O
disease,O
),O
.,O
The,O
literature,O
already,O
reflects,O
specific,O
guidance,O
and,O
lessons,O
learned,O
for,O
many,O
genetic,O
conditions,O
",",O
such,O
as,O
Charcot,O
-,O
Marie,O
-,O
Tooth,O
",",O
G6PD,O
deficiency,O
",",O
Gaucher,O
disease,O
",",O
inherited,O
arrhthymias,O
",",O
and,O
inborn,O
errors,O
of,O
metabolism,O
(,O
see,O
Table,O
S3,O
for,O
references,O
for,O
COVID-19,O
guidance,O
related,O
to,O
these,O
conditions,O
),O
.,O
In,O
addition,O
to,O
these,O
pragmatic,O
guidelines,O
",",O
understanding,O
gained,O
from,O
studying,O
the,O
impact,O
of,O
COVID-19,O
on,O
people,O
with,O
these,O
rare,O
diseases,O
may,O
yield,O
insights,O
that,O
can,O
be,O
applied,O
to,O
the,O
population,O
at,O
large,O
",",O
much,O
like,O
how,O
unraveling,O
the,O
causes,O
of,O
primary,O
immunodeficiencies,O
can,O
lead,O
to,O
generalizable,O
knowledge,O
about,O
the,O
immune,O
system,O
.,O
We,O
outline,O
key,O
genes,O
and,O
loci,O
from,O
animal,O
and,O
human,O
host,O
genetic,O
studies,O
that,O
may,O
bear,O
investigation,O
in,O
the,O
study,O
of,O
COVID-19,O
.,O
We,O
outline,O
key,O
genes,O
and,O
loci,O
from,O
animal,O
and,O
human,O
host,O
genetic,O
studies,O
that,O
may,O
bear,O
investigation,O
in,O
the,O
study,O
of,O
COVID-19,O
.,O
Travel,O
-,O
associated,O
cases,O
of,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
were,O
reported,O
outside,O
of,O
China,O
as,O
early,O
as,O
January,O
13,O
",",O
2020,O
",",O
and,O
the,O
virus,O
has,O
subsequently,O
spread,O
to,O
nearly,O
all,O
nations,O
(,O
World,O
Health,O
Organization,O
",",O
2020a,O
",",O
World,O
Health,O
Organization,O
",",O
2020b,O
),O
.,O
The,O
majority,O
of,O
early,O
COVID-19,O
cases,O
in,O
the,O
United,O
States,O
were,O
(,O
1,O
),O
associated,O
with,O
travel,O
to,O
a,O
“,O
high,O
-,O
risk,O
”,O
country,O
or,O
(,O
2,O
),O
close,O
contacts,O
of,O
previously,O
identified,O
cases,O
according,O
to,O
the,O
testing,O
criteria,O
adopted,O
by,O
the,O
Centers,O
for,O
Disease,O
Control,O
and,O
Prevention,O
(,O
CDC,O
),O
(,O
Centers,O
for,O
Disease,O
Control,O
and,O
Prevention,O
",",O
2020b,O
),O
.,O
From,O
March,O
1–19,O
",",O
2020,O
",",O
the,O
number,O
of,O
reported,O
COVID-19,O
cases,O
in,O
the,O
United,O
States,O
rapidly,O
increased,O
from,O
74,O
to,O
"13,677",O
",",O
and,O
the,O
virus,O
was,O
detected,O
in,O
all,O
50,O
states,O
(,O
Dong,O
et,O
 ,O
al,O
.,O
",",O
2020,O
),O
.,O
It,O
was,O
recently,O
estimated,O
that,O
the,O
true,O
number,O
of,O
COVID-19,O
cases,O
in,O
the,O
United,O
States,O
is,O
likely,O
in,O
the,O
tens,O
of,O
thousands,O
(,O
Perkins,O
et,O
 ,O
al,O
.,O
",",O
2020,O
),O
",",O
suggesting,O
substantial,O
undetected,O
infections,O
and,O
spread,O
within,O
the,O
country,O
.,O
We,O
hypothesized,O
that,O
",",O
with,O
the,O
growing,O
number,O
of,O
COVID-19,O
cases,O
in,O
the,O
United,O
States,O
and,O
the,O
large,O
volume,O
of,O
domestic,O
travel,O
",",O
new,O
United,O
States,O
outbreaks,O
are,O
now,O
more,O
likely,O
to,O
result,O
from,O
interstate,O
rather,O
than,O
international,O
spread,O
.,O
To,O
delineate,O
the,O
roles,O
of,O
domestic,O
and,O
international,O
virus,O
spread,O
in,O
the,O
emergence,O
of,O
new,O
United,O
States,O
COVID-19,O
outbreaks,O
",",O
we,O
sequenced,O
SARS,O
-,O
CoV-2,O
viruses,O
collected,O
from,O
cases,O
identified,O
in,O
Connecticut,O
.,O
We,O
sequenced,O
SARS,O
-,O
CoV-2,O
genomes,O
from,O
nine,O
of,O
the,O
first,O
COVID-19,O
cases,O
reported,O
in,O
Connecticut,O
",",O
with,O
sample,O
collection,O
dating,O
from,O
March,O
6–14,O
",",O
2020,O
(,O
Data,O
S1,O
),O
.,O
We,O
shared,O
the,O
genomes,O
of,O
these,O
viruses,O
publicly,O
as,O
we,O
generated,O
them,O
(,O
GISAID,S-Dataset
 ,O
EPI_ISL_416416-416424,S-AccessionNumber
),O
.,O
We,O
combined,O
our,O
genomes,O
with,O
other,O
publicly,O
available,O
sequences,O
for,O
a,O
final,O
dataset,O
of,O
168,O
SARS,O
-,O
CoV-2,O
genomes,O
(,O
Figure,O
 ,O
1,O
;,O
Data,O
S2,O
),O
.,O
The,O
dataset,O
can,O
be,O
visualized,O
on,O
our,O
“,O
community,O
”,O
Nextstrain,S-Repository
 ,O
page,O
(,O
https://nextstrain.org/community/grubaughlab/CT-SARS-CoV-2/paper1,S-URL
),O
.,O
Regardless,O
",",O
neither,O
the,O
CT,O
-,O
Yale-001,O
nor,O
the,O
CT,O
-,O
Yale-006,O
COVID-19,O
cases,O
were,O
travel,O
-,O
associated,O
",",O
which,O
indicates,O
that,O
these,O
patients,O
were,O
part,O
of,O
domestic,O
transmission,O
chains,O
that,O
stemmed,O
from,O
undetected,O
introductions,O
.,O
Importantly,O
",",O
our,O
data,O
indicate,O
that,O
",",O
by,O
early,O
to,O
mid,O
-,O
March,O
",",O
there,O
had,O
already,O
been,O
interstate,O
spread,O
during,O
the,O
early,O
COVID-19,O
epidemic,O
in,O
the,O
United,O
States,O
.,O
Our,O
phylogenetic,O
analysis,O
shows,O
that,O
the,O
COVID-19,O
outbreak,O
in,O
Connecticut,O
was,O
driven,O
",",O
in,O
part,O
",",O
by,O
domestic,O
virus,O
introductions,O
.,O
(,O
E,O
),O
We,O
calculated,O
importation,O
risk,O
by,O
modeling,O
the,O
number,O
of,O
daily,O
prevalent,O
COVID-19,O
cases,O
in,O
each,O
potential,O
importation,O
source,O
and,O
then,O
estimating,O
the,O
number,O
of,O
infected,O
travelers,O
using,O
the,O
daily,O
air,O
travel,O
volume,O
from,O
each,O
location,O
.,O
We,O
first,O
estimated,O
daily,O
passenger,O
volumes,O
arriving,O
in,O
the,O
region,O
from,O
the,O
five,O
countries,O
(,O
China,O
",",O
Italy,O
",",O
Iran,O
",",O
Spain,O
",",O
and,O
Germany,O
),O
and,O
out,O
-,O
of,O
-,O
region,O
states,O
(,O
Washington,O
",",O
California,O
",",O
Florida,O
",",O
Illinois,O
",",O
and,O
Louisiana,O
),O
that,O
have,O
reported,O
the,O
most,O
COVID-19,O
cases,O
to,O
date,O
(,O
Figures,O
2A–2D,O
),O
.,O
We,O
found,O
that,O
the,O
daily,O
domestic,O
passenger,O
volumes,O
were,O
∼100,O
times,O
greater,O
than,O
international,O
in,O
Hartford,O
",",O
∼10,O
times,O
greater,O
in,O
Boston,O
",",O
and,O
∼4,O
times,O
greater,O
in,O
New,O
York,O
in,O
our,O
dataset,O
(,O
Figure,O
 ,O
2B,O
),O
.,O
By,O
combining,O
daily,O
passenger,O
volumes,O
(,O
Figure,O
 ,O
2B,O
),O
with,O
COVID-19,O
prevalence,O
at,O
the,O
travel,O
route,O
origin,O
(,O
Figures,O
2C,O
and,O
2D,O
),O
and,O
accounting,O
for,O
differences,O
in,O
reporting,O
rates,O
",",O
we,O
found,O
that,O
the,O
domestic,O
and,O
international,O
SARS,O
-,O
CoV-2,O
importation,O
risk,O
started,O
to,O
increase,O
dramatically,O
at,O
the,O
beginning,O
of,O
March,O
2020,O
(,O
Figure,O
 ,O
2E,O
),O
.,O
Because,O
of,O
the,O
overall,O
low,O
prevalence,O
of,O
COVID-19,O
in,O
China,O
",",O
we,O
did,O
not,O
find,O
any,O
significant,O
effects,O
of,O
travel,O
restrictions,O
from,O
China,O
that,O
were,O
enacted,O
on,O
February,O
1,O
(,O
Data,O
S3,O
),O
.,O
The,O
dramatic,O
rises,O
in,O
domestic,O
and,O
international,O
importation,O
risk,O
preceded,O
the,O
state,O
-,O
wide,O
COVID-19,O
outbreak,O
in,O
Connecticut,O
(,O
Figure,O
 ,O
2E,O
),O
",",O
and,O
the,O
recent,O
increase,O
in,O
risk,O
of,O
domestic,O
importation,O
may,O
give,O
rise,O
to,O
new,O
outbreaks,O
in,O
the,O
region,O
.,O
We,O
therefore,O
propose,O
that,O
a,O
unified,O
effort,O
to,O
detect,O
and,O
prevent,O
new,O
COVID-19,O
cases,O
will,O
be,O
essential,O
for,O
mitigating,O
the,O
risk,O
of,O
future,O
domestic,O
outbreaks,O
.,O
If,O
spread,O
between,O
states,O
is,O
now,O
occurring,O
",",O
as,O
our,O
results,O
indicate,O
",",O
then,O
the,O
United,O
States,O
will,O
struggle,O
to,O
control,O
COVID-19,O
in,O
the,O
absence,O
of,O
a,O
unified,O
surveillance,O
strategy,O
.,O
To,O
investigate,O
the,O
origin,O
and,O
diversity,O
of,O
SARS,O
-,O
CoV-2,O
in,O
Connecticut,O
",",O
we,O
compiled,O
a,O
dataset,O
of,O
our,O
nine,O
genomes,O
with,O
another,O
159,O
representative,O
sample,O
of,O
SARS,O
-,O
CoV-2,O
genomes,O
that,O
were,O
available,O
from,O
GenBank,S-Repository
 ,O
(,O
https://www.ncbi.nlm.nih.gov/genbank/sars-cov-2-seqs/,S-URL
),O
and,O
GISAID,S-Dataset
 ,O
(,O
https://www.gisaid.org/,S-URL
),O
.,O
No,O
data,O
that,O
was,O
only,O
released,O
on,O
GISAID,S-Dataset
 ,O
was,O
used,O
without,O
consent,O
from,O
the,O
authors,O
(,O
see,O
Acknowledgments,O
),O
.,O
Root,O
-,O
to,O
-,O
Tip,O
Plot,O
Showing,O
the,O
Evolutionary,O
Rate,O
of,O
the,O
SARS,O
-,O
CoV-2,O
Genomes,O
in,O
Our,O
Dataset,O
",",O
Related,O
to,O
Figure,O
 ,O
1,O
Daily,O
COVID-19,O
cases,O
from,O
international,O
locations,O
were,O
obtained,O
from,O
the,O
European,B-Creator
Centre,I-Creator
for,I-Creator
Disease,I-Creator
Prevention,I-Creator
and,I-Creator
Control,E-Creator
 ,O
via,O
Our,B-Repository
World,I-Repository
in,I-Repository
Data,E-Repository
 ,O
(,O
https://ourworldindata.org/coronavirus-source-data,S-URL
),O
.,O
Daily,O
COVID-19,O
cases,O
from,O
Connecticut,O
and,O
other,O
U.S.,O
locations,O
(,O
Washington,O
",",O
California,O
",",O
Florida,O
",",O
Illinois,O
",",O
and,O
Louisiana,O
),O
were,O
obtained,O
from,O
the,O
repository,O
(,O
https://github.com/CSSEGISandData/COVID-19,S-URL
),O
hosted,O
by,O
the,O
Center,B-Creator
for,I-Creator
Systems,I-Creator
Science,I-Creator
and,I-Creator
Engineering,I-Creator
(CSSE),I-Creator
at,I-Creator
Johns,I-Creator
Hopkins,I-Creator
University,E-Creator
 ,O
(,O
Dong,O
et,O
 ,O
al,O
.,O
",",O
2020,O
),O
.,O
These,O
represent,O
the,O
international,O
and,O
out,O
-,O
of,O
-,O
region,O
domestic,O
(,O
i.e.,O
",",O
excluding,O
New,O
York,O
",",O
Massachusetts,O
",",O
and,O
New,O
Jersey,O
),O
locations,O
with,O
the,O
most,O
reported,O
COVID-19,O
cases,O
.,O
The,O
novel,O
coronavirus,O
SARS,O
-,O
CoV-2,O
was,O
first,O
detected,O
in,O
the,O
Pacific,O
Northwest,O
region,O
of,O
the,O
United,O
States,O
in,O
January,O
2020,O
",",O
with,O
subsequent,O
COVID-19,O
outbreaks,O
detected,O
in,O
all,O
50,O
states,O
by,O
early,O
March,O
.,O
To,O
uncover,O
the,O
sources,O
of,O
SARS,O
-,O
CoV-2,O
introductions,O
and,O
patterns,O
of,O
spread,O
within,O
the,O
United,O
States,O
",",O
we,O
sequenced,O
nine,O
viral,O
genomes,O
from,O
early,O
reported,O
COVID-19,O
patients,O
in,O
Connecticut,O
.,O
Graphical,O
Abstract,O
     ,O
Highlights,O
    ,O
•,O
 ,O
Connecticut,O
’s,O
COVID-19,O
outbreak,O
resulted,O
from,O
multiple,O
domestic,O
virus,O
introductions,O
   ,O
•,O
 ,O
SARS,O
-,O
CoV-2,O
genomic,O
data,O
indicate,O
that,O
coast,O
-,O
to,O
-,O
coast,O
spread,O
occurred,O
in,O
the,O
United,O
States,O
   ,O
•,O
 ,O
Risk,O
of,O
introduction,O
by,O
domestic,O
air,O
travel,O
exceeded,O
international,O
travel,O
in,O
March,O
   ,O
•,O
 ,O
Restrictions,O
on,O
international,O
travel,O
did,O
not,O
significantly,O
alter,O
risk,O
estimates,O
     ,O
Using,O
genomics,O
and,O
air,O
travel,O
information,O
",",O
the,O
spread,O
of,O
SARS,O
-,O
CoV-2,O
in,O
the,O
United,O
States,O
from,O
coast,O
to,O
coast,O
is,O
shown,O
to,O
be,O
more,O
a,O
consequence,O
of,O
domestic,O
introductions,O
than,O
of,O
international,O
travel,O
.,O
The,O
third,O
",",O
SARS,O
-,O
CoV-2,O
",",O
causes,O
the,O
severe,O
respiratory,O
disease,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
(,O
Gorbalenya,O
et,O
 ,O
al,O
.,O
",",O
2020,O
),O
.,O
The,O
June,O
21,O
",",O
2020,O
World,O
Health,O
Organization,O
(,O
WHO,O
),O
Situation,O
Report,O
records,O
over,O
8.7,O
million,O
COVID-19,O
cases,O
and,O
"460,000",O
deaths,O
",",O
numbers,O
that,O
increase,O
daily,O
.,O
Phylogenetic,O
analysis,O
of,O
the,O
global,O
sampling,O
of,O
SARS,O
-,O
CoV-2,O
is,O
being,O
very,O
capably,O
addressed,O
by,O
the,O
Global,B-Dataset
Initiative,I-Dataset
for,I-Dataset
Sharing,I-Dataset
All,I-Dataset
Influenza,I-Dataset
Data,I-Dataset
(GISAID),E-Dataset
 ,O
database,O
(,O
https://www.gisaid.org,S-URL
/,O
;,O
Our,O
analysis,O
pipeline,O
to,O
track,O
SARS,O
-,O
CoV-2,O
mutations,O
in,O
the,O
COVID-19,O
pandemic,O
is,O
based,O
on,O
regular,O
updates,O
from,O
the,O
GISAID,S-Dataset
 ,O
SARS,O
-,O
CoV-2,O
sequence,O
database,O
(,O
GISAID,S-Dataset
 ,O
acknowledgments,O
are,O
in,O
Table,O
S1,O
),O
.,O
GISAID,S-Dataset
 ,O
sequences,O
are,O
generally,O
linked,O
to,O
the,O
location,O
and,O
date,O
of,O
sampling,O
.,O
Hundreds,O
of,O
new,O
SARS,O
-,O
CoV-2,O
sequences,O
are,O
added,O
to,O
GISAID,S-Dataset
 ,O
each,O
day,O
",",O
so,O
we,O
have,O
automated,O
steps,O
to,O
create,O
daily,O
working,O
alignments,O
(,O
Kurtz,O
et,O
 ,O
al,O
.,O
",",O
2004,O
;,O
Figure,O
 ,O
S1,O
),O
.,O
The,O
analysis,O
presented,O
here,O
is,O
based,O
on,O
a,O
May,O
29,O
",",O
2020,O
download,O
of,O
the,O
GISAID,S-Dataset
 ,O
data,O
",",O
when,O
our,O
Spike,O
alignment,O
included,O
"28,576",O
sequences,O
;,O
updated,O
versions,O
of,O
key,O
figures,O
can,O
recreated,O
at,O
our,O
website,O
(,O
https://cov.lanl.gov,O
),O
.,O
This,O
allows,O
daily,O
processing,O
of,O
GISAID,S-Dataset
 ,O
data,O
to,O
enable,O
us,O
to,O
track,O
mutations,O
.,O
These,O
steps,O
are,O
incorporated,O
in,O
a,O
single,O
Perl,O
script,O
",",O
‘,O
align_to_ref.pl,O
’,O
",",O
briefly,O
summarized,O
here,O
:,O
sequences,O
are,O
compressed,O
for,O
identity,O
",",O
then,O
mapped,O
against,O
the,O
given,O
reference,O
sequence,O
using,O
‘,O
nucmer,O
’,O
from,O
the,O
‘,O
MUMmer,O
’,O
package,O
(,O
Kurtz,O
et,O
 ,O
al,O
.,O
",",O
2004,O
),O
.,O
At,O
that,O
time,O
",",O
the,O
G614,O
form,O
was,O
rare,O
globally,O
but,O
gaining,O
prominence,O
in,O
Europe,O
",",O
and,O
GISAID,S-Dataset
 ,O
was,O
also,O
tracking,O
the,O
clade,O
carrying,O
the,O
D614,O
G,O
substitution,O
",",O
designating,O
it,O
the,O
“,O
G,O
clade,O
.,O
”,O
The,O
figures,O
shown,O
here,O
can,O
be,O
recreated,O
with,O
contemporary,O
data,O
from,O
GISAID,S-Dataset
 ,O
at,O
the,O
http://cov.lanl.gov/,O
(,O
A,O
),O
Analysis,O
summaries,O
for,O
all,O
of,O
the,O
level,O
3,O
and,O
4,O
regional,O
subdivisions,O
from,O
GISAID,S-Dataset
 ,O
data,O
(,O
Figure,O
 ,O
1,O
),O
that,O
have,O
at,O
least,O
5,O
each,O
of,O
D614,O
and,O
G614,O
variants,O
and,O
that,O
are,O
sampled,O
on,O
at,O
least,O
14,O
 ,O
days,O
.,O
In,O
the,O
May,O
29,O
",",O
2020,O
dataset,O
used,O
here,O
",",O
Santa,O
Clara,O
county,O
was,O
sampled,O
later,O
in,O
May,O
than,O
any,O
other,O
region,O
in,O
California,O
",",O
so,O
the,O
California,O
G614,O
frequency,O
dips,O
at,O
this,O
last,O
available,O
time,O
point,O
.,O
(,O
Confirmed,O
COVID19,O
case,O
count,O
data,O
from,O
:,O
COVID-19,B-Repository
Data,I-Repository
Repository,E-Repository
 ,O
by,O
the,O
Center,B-Creator
for,I-Creator
Systems,I-Creator
Science,I-Creator
and,I-Creator
Engineering,I-Creator
(CSSE),E-Creator
 ,O
at,O
Johns,O
Hopkins,O
University,O
),O
.,O
Each,O
geographic,O
region,O
that,O
meets,O
these,O
criteria,O
is,O
extracted,O
separately,O
based,O
on,O
the,O
hierarchical,O
geographic,O
/,O
political,O
levels,O
designated,O
in,O
GISAID,S-Dataset
 ,O
(,O
Figure,O
 ,O
1B,O
),O
.,O
Only,O
limited,O
recent,O
sampling,O
from,O
Asia,O
is,O
currently,O
available,O
in,O
GISAID,S-Dataset
;,O
to,O
include,O
more,O
samples,O
on,O
the,O
map,O
the,O
10,O
-,O
day,O
period,O
between,O
March,O
11,O
-,O
20,O
",",O
is,O
shown,O
rather,O
than,O
the,O
period,O
between,O
March,O
21,O
-,O
30,O
;,O
even,O
the,O
limited,O
sampling,O
mid,O
-,O
March,O
the,O
supports,O
the,O
repeated,O
pattern,O
of,O
a,O
shift,O
to,O
G614,O
.,O
In,O
mid,O
-,O
March,O
2020,O
",",O
screening,O
began,O
to,O
include,O
the,O
local,O
population,O
;,O
this,O
coincided,O
with,O
the,O
appearance,O
of,O
the,O
D614,O
variant,O
in,O
the,O
sequence,O
dataset,O
.,O
A,O
June,O
19,O
",",O
2020,O
GISAID,S-Dataset
 ,O
update,O
for,O
several,O
California,O
counties,O
is,O
provided,O
in,O
Figure,O
 ,O
S4C,O
",",O
and,O
the,O
G614,O
form,O
is,O
present,O
in,O
the,O
most,O
recent,O
Santa,O
Clara,O
DPH,O
samples,O
.,O
C.,O
Updated,O
data,O
regarding,O
California,O
from,O
the,O
June,O
19,O
",",O
2020,O
GISAID,S-Dataset
 ,O
sampling,O
.,O
Most,O
of,O
the,O
analysis,O
in,O
this,O
paper,O
was,O
undertaken,O
using,O
the,O
May,O
29,O
",",O
2020,O
GISAID,S-Dataset
 ,O
download,O
",",O
but,O
as,O
California,O
was,O
an,O
interesting,O
outlier,O
",",O
and,O
more,O
recent,O
sampling,O
conducted,O
while,O
the,O
paper,O
was,O
under,O
review,O
was,O
informative,O
",",O
we,O
have,O
included,O
some,O
additional,O
plots,O
from,O
California,O
data,O
that,O
were,O
available,O
at,O
the,O
time,O
of,O
our,O
final,O
response,O
to,O
review,O
",",O
on,O
June,O
19th,O
.,O
Santa,O
Clara,O
DPH,O
",",O
which,O
was,O
essentially,O
all,O
D614,O
in,O
our,O
May,O
29th,O
GISAID,S-Dataset
 ,O
download,O
",",O
had,O
7,O
G614,O
forms,O
sampled,O
in,O
late,O
May,O
that,O
were,O
evident,O
in,O
our,O
June,O
19th,O
GISAID,S-Dataset
 ,O
download,O
.,O
Our,O
second,O
statistical,O
approach,O
to,O
evaluating,O
the,O
significance,O
of,O
the,O
D614,O
-,O
to,O
-,O
G614,O
transition,O
(,O
Figure,O
 ,O
3,O
),O
uses,O
the,O
time,O
series,O
data,O
in,O
GISAID,S-Dataset
 ,O
more,O
fully,O
.,O
Here,O
we,O
extracted,O
all,O
regional,O
data,O
from,O
GISAID,S-Dataset
 ,O
that,O
had,O
a,O
minimum,O
of,O
5,O
sequences,O
representing,O
each,O
of,O
the,O
D614,O
and,O
the,O
G614,O
variants,O
and,O
at,O
least,O
14,O
 ,O
days,O
of,O
sampling,O
.,O
The,O
earliest,O
examples,O
of,O
sequences,O
carrying,O
parts,O
of,O
the,O
4,O
-,O
mutation,O
haplotype,O
that,O
characterizes,O
the,O
D614,O
G,O
GISAID,S-Dataset
 ,O
G,O
clade,O
were,O
found,O
in,O
China,O
and,O
Germany,O
in,O
late,O
January,O
2020,O
",",O
and,O
they,O
carried,O
3,O
of,O
the,O
4,O
mutations,O
that,O
define,O
the,O
clade,O
",",O
lacking,O
only,O
the,O
RdRp,O
P323L,O
substitution,O
(,O
Figure,O
 ,O
S5D,O
),O
.,O
B.,O
The,O
GISAID,S-Dataset
 ,O
G,O
clade,O
is,O
based,O
on,O
a,O
4,O
base,O
haplotype,O
that,O
distinguishes,O
it,O
from,O
the,O
original,O
Wuhan,O
form,O
.,O
The,O
missing,O
RBD,O
residues,O
at,O
the,O
ACE2,O
interface,O
are,O
shown,O
in,O
(,O
D,O
),O
.,O
SARS,O
-,O
CoV-2,O
sequences,O
from,O
999,O
individuals,O
presenting,O
with,O
COVID-19,O
disease,O
at,O
the,O
Sheffield,O
Teaching,O
Hospitals,O
NHS,O
Foundation,O
Trust,O
were,O
available,O
and,O
linked,O
to,O
clinical,O
data,O
.,O
Similar,O
results,O
",",O
reported,O
recently,O
in,O
a,O
preprint,O
that,O
has,O
not,O
yet,O
been,O
peer,O
reviewed,O
",",O
also,O
suggest,O
that,O
G614,O
increases,O
Spike,O
stability,O
and,O
membrane,O
incorporation,O
(,O
Zhang,O
et,O
 ,O
al,O
.,O
",",O
2020,O
),O
.,O
(,O
A,O
),O
A,O
recombinant,O
VSV,O
pseudotyped,O
with,O
the,O
G614,O
Spike,O
grows,O
to,O
a,O
higher,O
titer,O
than,O
D614,O
Spike,O
in,O
Vero,O
",",O
293T,O
-,O
ACE2,O
",",O
and,O
293T,O
-,O
ACE2,O
-,O
TMPRSS2,O
cells,O
",",O
as,O
measured,O
in,O
terms,O
of,O
focus,O
-,O
forming,O
units,O
(,O
ffu,O
),O
.,O
The,O
mutation,O
resulting,O
in,O
the,O
signal,O
peptide,O
L5F,O
change,O
recurs,O
many,O
times,O
in,O
the,O
tree,O
and,O
is,O
stably,O
maintained,O
in,O
about,O
0.6,O
%,O
of,O
the,O
global,O
GISAID,S-Dataset
 ,O
data,O
.,O
The,O
tree,O
is,O
rooted,O
on,O
a,O
reference,O
sequence,O
derived,O
from,O
the,O
original,O
Wuhan,O
isolates,O
(,O
GenBank,S-Repository
 ,O
accession,O
number,O
NC_045512,S-AccessionNumber
),O
",",O
at,O
the,O
3,O
o’clock,O
position,O
.,O
As,O
an,O
example,O
",",O
in,O
this,O
tree,O
",",O
the,O
region,O
from,O
approximately,O
12:30,O
to,O
3,O
o’clock,O
represents,O
GISAID,S-Dataset
’s,O
“,O
GR,O
”,O
clade,O
",",O
defined,O
both,O
by,O
mutations,O
we,O
are,O
tracking,O
in,O
this,O
paper,O
that,O
carry,O
the,O
G614,O
variant,O
(,O
the,O
GISAID,S-Dataset
 ,O
G,O
clade,O
",",O
defined,O
by,O
mutations,O
A23403,O
G,O
",",O
C14408,O
T,O
",",O
C3037,O
T,O
",",O
and,O
a,O
mutation,O
in,O
the,O
5′,O
UTR,O
(,O
C241,O
T,O
",",O
not,O
shown,O
here,O
),O
",",O
and,O
an,O
additional,O
3,O
-,O
position,O
polymorphism,O
:,O
G28881A,O
 ,O
+,O
G28882A,O
 ,O
+,O
G28883C.,O
These,O
base,O
substitutions,O
are,O
contiguous,O
and,O
result,O
two,O
amino,O
acid,O
changes,O
",",O
including,O
N,O
-,O
G204R,O
",",O
hence,O
GISAID,S-Dataset
’s,O
“,O
GR,O
clade,O
”,O
name,O
.,O
Close,O
examination,O
of,O
this,O
triplet,O
in,O
sequences,O
from,O
the,O
Sheffield,O
dataset,O
suggests,O
the,O
mutations,O
are,O
not,O
a,O
sequencing,O
artifact,O
.,O
The,O
GISAID,S-Dataset
 ,O
data,O
",",O
however,O
",",O
provided,O
the,O
opportunity,O
to,O
look,O
into,O
the,O
relationships,O
among,O
the,O
SARS,O
-,O
CoV-2,O
variants,O
in,O
the,O
context,O
of,O
time,O
and,O
geography,O
",",O
enabling,O
us,O
to,O
track,O
the,O
increase,O
in,O
frequency,O
of,O
G614,O
as,O
an,O
early,O
indicator,O
of,O
possible,O
positive,O
selection,O
.,O
The,O
Global,B-Dataset
Initiative,I-Dataset
for,I-Dataset
Sharing,I-Dataset
All,I-Dataset
Influenza,I-Dataset
Data,I-Dataset
(GISAID),E-Dataset
 ,O
(,O
Elbe,B-Creator
and,I-Creator
"Buckland-Merrett,",I-Creator
2017,E-Creator
;,O
Shu,B-Creator
and,I-Creator
"McCauley,",I-Creator
2017),E-Creator
 ,O
has,O
been,O
coordinating,O
SARS,O
-,O
CoV-2,O
genome,O
sequence,O
submissions,O
and,O
making,O
data,O
available,O
for,O
download,O
since,O
early,O
in,O
the,O
pandemic,O
.,O
To,O
assemble,O
a,O
high,O
-,O
quality,O
dataset,O
for,O
mutational,O
analysis,O
",",O
we,O
constructed,O
a,O
data,O
pipeline,O
using,O
some,O
off,O
-,O
the,O
-,O
shelf,O
bioinformatic,O
tools,O
and,O
a,O
small,O
amount,O
of,O
custom,O
code,O
.,O
The,O
MSA,O
was,O
refined,O
using,O
code,O
derived,O
from,O
the,O
Los,B-Repository
Alamos,I-Repository
HIV,E-Repository
 ,O
database,O
“,O
Gene,O
Cutter,O
”,O
tool,O
code,O
base,O
.,O
In,O
our,O
validation,O
set,O
",",O
we,O
see,O
a,O
C,O
present,O
at,O
around,O
50,O
%,O
of,O
called,O
bases,O
at,O
both,O
these,O
positions,O
in,O
raw,O
data,O
but,O
this,O
region,O
is,O
trimmed,O
by,O
the,O
ARTIC,O
pipeline,O
and,O
is,O
therefore,O
not,O
used,O
to,O
call,O
variants,O
and,O
contribute,O
to,O
the,O
final,O
consensus,O
sequence,O
.,O
The,O
resultant,O
coronavirus,O
disease,O
2019,O
(,O
COVID‐19,O
),O
manifests,O
predominantly,O
symptoms,O
in,O
the,O
lower,O
respiratory,O
system,O
",",O
typically,O
presented,O
as,O
viral,O
pneumonia,O
.,O
Suspected,O
COVID‐19,O
patients,O
who,O
had,O
documented,O
history,O
of,O
exposure,O
and,O
exhibited,O
symptoms,O
",",O
but,O
did,O
not,O
have,O
positive,O
polymerase,O
chain,O
reaction,O
(,O
PCR,O
),O
test,O
results,O
",",O
were,O
generally,O
self‐quarantined,O
.,O
Some,O
patients,O
had,O
a,O
contact,O
history,O
with,O
a,O
confirmed,O
COVID‐19,O
patient,O
but,O
did,O
not,O
have,O
typical,O
viral,O
pneumonia,O
symptoms,O
or,O
fever,O
",",O
and,O
so,O
did,O
not,O
get,O
selected,O
for,O
PCR,O
testing,O
.,O
Given,O
the,O
rapidly,O
growing,O
pandemic,O
and,O
the,O
overwhelmed,O
medical,O
system,O
",",O
a,O
number,O
of,O
patients,O
with,O
typical,O
COVID‐19,O
symptoms,O
could,O
not,O
be,O
hospitalized,O
",",O
even,O
if,O
they,O
were,O
tested,O
positive,O
by,O
PCR,O
.,O
The,O
combination,O
of,O
the,O
false,O
negative,O
rate,O
of,O
PCR,O
testing,O
",",O
the,O
biased,O
pre‐screening,O
procedure,O
for,O
patients,O
to,O
get,O
tested,O
",",O
and,O
hospital,O
space,O
limitation,O
results,O
in,O
an,O
increasing,O
number,O
of,O
nonhospitalized,O
COVID‐19,O
patients,O
.,O
Most,O
of,O
the,O
prescribed,O
alternative,O
medicines,O
are,O
",",O
however,O
",",O
neither,O
specific,O
nor,O
highly,O
effective,O
for,O
COVID‐19,O
treatment,O
.,O
The,O
outbreak,O
of,O
COVID‐19,O
in,O
Wuhan,O
",",O
China,O
",",O
in,O
January,O
2020,O
",",O
was,O
the,O
first,O
strike,O
on,O
public,O
health,O
system,O
by,O
SARS‐CoV‐2,O
.,O
Patients,O
infected,O
with,O
COVID‐19,O
had,O
a,O
high,O
chance,O
of,O
developing,O
severe,O
pneumonia,O
and,O
acute,O
respiratory,O
distress,O
syndrome,O
(,O
16%‐17,O
%,O
),O
and,O
the,O
mortality,O
rate,O
was,O
high,O
(,O
4.3%‐11,O
%,O
),O
.,O
",",O
 ,O
",",O
 ,O
",",O
  ,O
Hospitalization,O
became,O
the,O
only,O
possible,O
way,O
for,O
severe,O
COVID‐19,O
patients,O
to,O
receive,O
medical,O
supports,O
and,O
treatment,O
against,O
symptoms,O
.,O
A,O
number,O
of,O
patients,O
in,O
Wuhan,O
had,O
documented,O
contact,O
histories,O
with,O
confirmed,O
COVID‐19,O
patients,O
and,O
also,O
showed,O
respiratory,O
symptoms,O
",",O
however,O
unfortunately,O
",",O
their,O
upper,O
respiratory,O
system,O
did,O
not,O
have,O
viral,O
loads,O
that,O
were,O
high,O
enough,O
to,O
pass,O
the,O
PCR,O
test,O
threshold,O
",",O
and,O
so,O
they,O
did,O
not,O
have,O
a,O
positive,O
PCR,O
test,O
result,O
to,O
qualify,O
for,O
hospitalization,O
in,O
January,O
and,O
early,O
February,O
in,O
Wuhan,O
.,O
Our,O
medical,O
team,O
tracked,O
and,O
helped,O
treat,O
a,O
number,O
of,O
these,O
nonhospitalized,O
COVID‐19,O
patients,O
.,O
On,O
Feb,O
2nd,O
(,O
day,O
22,O
),O
",",O
the,O
patient,O
's,O
fingertip,O
oxygen,O
saturation,O
dropped,O
to,O
93,O
%,O
(,O
comparable,O
to,O
severe,O
COVID‐19,O
patients,O
),O
and,O
routine,O
blood,O
examination,O
showed,O
elevated,O
level,O
of,O
C‐reactive,O
protein,O
(,O
50.02,O
in,O
patient,O
",",O
vs,O
normal,O
ranges,O
at,O
0‐4,O
),O
(,O
Table,O
 ,O
1,O
),O
.,O
Given,O
the,O
patient,O
's,O
history,O
of,O
contact,O
with,O
confirmed,O
COVID‐19,O
patients,O
and,O
her,O
typical,O
COVID‐19,O
symptoms,O
",",O
the,O
most,O
possible,O
infection,O
at,O
the,O
time,O
was,O
SARS‐CoV‐2,O
.,O
During,O
late,O
January,O
and,O
early,O
February,O
",",O
the,O
protocol,O
for,O
COVID‐19,O
clinical,O
diagnosis,O
and,O
patient,O
admission,O
used,O
in,O
China,O
required,O
a,O
confirmation,O
of,O
infection,O
by,O
RT‐PCR,O
positive,O
result,O
",",O
and,O
thus,O
this,O
patient,O
was,O
not,O
eligible,O
for,O
hospitalization,O
at,O
that,O
moment,O
.,O
This,O
patient,O
with,O
suspected,O
COVID‐19,O
was,O
sent,O
home,O
for,O
self‐quarantine,O
.,O
Given,O
that,O
the,O
medicines,O
prescribed,O
in,O
the,O
hospital,O
failed,O
to,O
relieve,O
the,O
patient,O
's,O
symptoms,O
and,O
started,O
to,O
trigger,O
side,O
effects,O
",",O
and,O
that,O
the,O
patient,O
was,O
not,O
eligible,O
for,O
COVID‐19,O
treatment,O
in,O
the,O
hospital,O
",",O
all,O
prescribed,O
medicines,O
were,O
discontinued,O
.,O
Thus,O
far,O
for,O
COVID‐19,O
",",O
there,O
are,O
no,O
pharmacological,O
treatment,O
regimens,O
of,O
proven,O
efficacy,O
.,O
Immunopathology,O
is,O
a,O
leading,O
cause,O
of,O
morbidity,O
and,O
mortality,O
in,O
severe,O
COVID‐19,O
patients,O
.,O
There,O
is,O
an,O
urgent,O
need,O
for,O
treatment,O
regimens,O
that,O
can,O
manage,O
inflammation,O
and,O
tissue,O
damages,O
associated,O
with,O
severe,O
COVID‐19,O
",",O
to,O
reduce,O
mortality,O
and,O
buy,O
time,O
for,O
the,O
immune,O
system,O
to,O
clear,O
the,O
virus,O
from,O
the,O
patients,O
.,O
During,O
the,O
initial,O
COVID‐19,O
outbreak,O
in,O
Wuhan,O
",",O
corticosteroid,O
has,O
been,O
used,O
in,O
hospitals,O
to,O
suppress,O
lung,O
inflammation,O
in,O
COVID‐19,O
patients,O
",",O
 ,O
however,O
",",O
multiple,O
side,O
effects,O
have,O
been,O
observed,O
.,O
Here,O
we,O
report,O
DG,O
",",O
a,O
marketed,O
Chinese,O
traditional,O
medicine,O
with,O
a,O
steroid‐like,O
effect,O
",",O
in,O
combination,O
with,O
VC,O
as,O
a,O
potential,O
anti‐inflammatory,O
treatment,O
to,O
relieve,O
severe,O
symptoms,O
from,O
COVID‐19,O
.,O
Our,O
article,O
here,O
reports,O
a,O
case,O
of,O
nonhospital,O
COVID‐19,O
that,O
showed,O
significantly,O
positive,O
responses,O
to,O
DG,O
treatment,O
.,O
Although,O
the,O
exact,O
functions,O
of,O
DG,O
against,O
SARS‐CoV‐2,O
infection,O
and,O
the,O
associated,O
immunopathology,O
await,O
further,O
investigations,O
",",O
it,O
is,O
possible,O
that,O
the,O
therapeutic,O
effects,O
of,O
DG,O
observed,O
in,O
this,O
severe,O
COVID‐19,O
patient,O
were,O
a,O
combinatory,O
result,O
of,O
the,O
antiviral,O
and,O
anti‐inflammatory,O
effects,O
of,O
DG,O
in,O
the,O
respiratory,O
and,O
neurological,O
systems,O
.,O
Given,O
these,O
encouraging,O
pharmacological,O
effects,O
and,O
the,O
demonstrated,O
safety,O
",",O
as,O
well,O
as,O
the,O
low,O
cost,O
and,O
wide,O
availability,O
of,O
DG,O
and,O
VC,O
",",O
we,O
suggest,O
that,O
a,O
combination,O
of,O
these,O
might,O
be,O
a,O
good,O
candidate,O
for,O
alternative,O
medicine,O
against,O
COVID‐19,O
.,O
Implementation,O
of,O
this,O
treatment,O
regimen,O
might,O
worth,O
more,O
attention,O
",",O
and,O
further,O
investigations,O
in,O
clinical,O
trials,O
can,O
be,O
considered,O
to,O
validate,O
its,O
effects,O
in,O
relieving,O
severe,O
symptoms,O
and,O
reducing,O
mortality,O
of,O
COVID‐19,O
in,O
a,O
larger,O
cohort,O
.,O
For,O
suspected,O
COVID‐19,O
patients,O
who,O
can,O
not,O
be,O
hospitalized,O
and,O
have,O
no,O
venues,O
for,O
COVID‐19,O
specific,O
prescriptions,O
",",O
we,O
suggest,O
that,O
the,O
combination,O
of,O
DG,O
and,O
VC,O
may,O
be,O
a,O
promising,O
candidate,O
as,O
an,O
alternative,O
medicine,O
to,O
help,O
relieve,O
severe,O
symptoms,O
of,O
COVID‐19,O
during,O
self‐quarantine,O
.,O
Abstract,O
 ,O
SARS‐CoV‐2,O
is,O
highly,O
infectious,O
",",O
and,O
infection,O
by,O
this,O
virus,O
results,O
in,O
COVID‐19,O
",",O
manifesting,O
predominantly,O
symptoms,O
in,O
the,O
lower,O
respiratory,O
system,O
.,O
Suspected,O
COVID‐19,O
patients,O
who,O
had,O
a,O
documented,O
history,O
of,O
exposure,O
and,O
exhibited,O
symptoms,O
",",O
but,O
did,O
not,O
have,O
positive,O
PCR,O
test,O
results,O
",",O
were,O
generally,O
self‐quarantined,O
with,O
prescriptions,O
aiming,O
to,O
help,O
attenuate,O
their,O
symptoms,O
.,O
These,O
prescriptions,O
are,O
however,O
neither,O
specific,O
nor,O
highly,O
effective,O
for,O
COVID‐19,O
treatment,O
.,O
We,O
report,O
here,O
a,O
case,O
of,O
severe,O
COVID‐19,O
that,O
never,O
had,O
a,O
positive,O
PCR,O
test,O
result,O
during,O
disease,O
progression,O
but,O
was,O
confirmed,O
with,O
antibody,O
test,O
post,O
recovery,O
.,O
This,O
patient,O
went,O
through,O
severe,O
COVID‐19,O
but,O
eventually,O
recovered,O
upon,O
the,O
implementation,O
of,O
this,O
treatment,O
regimen,O
",",O
suggesting,O
potential,O
therapeutic,O
effects,O
of,O
DG,O
as,O
alternative,O
medicine,O
to,O
help,O
relieve,O
COVID‐19,O
symptoms,O
.,O
We,O
report,O
here,O
a,O
case,O
of,O
severe,O
COVID‐19,O
",",O
in,O
which,O
diammonium,O
glycyrrhizinate,O
and,O
vitamin,O
C,O
were,O
used,O
as,O
alternative,O
medicine,O
to,O
help,O
relieve,O
COVID‐19,O
symptoms,O
.,O
We,O
carried,O
out,O
SARS,O
-,O
CoV-2,O
RNA,O
detection,O
by,O
two,O
first,O
-,O
line,O
real,O
-,O
time,O
reverse,O
transcription,O
(,O
RT)-PCR,O
assays,O
[,O
9,O
],O
",",O
one,O
of,O
which,O
(,O
SpikeP_ps80,O
),O
was,O
developed,O
in,O
-,O
house,O
as,O
soon,O
as,O
the,O
first,O
SARS,O
-,O
CoV-2,O
genome,O
(,O
GenBank,S-Repository
 ,O
Accession,O
no,O
.,O
MN908947,S-AccessionNumber
),O
was,O
released,O
by,O
Chinese,O
teams,O
(,O
on,O
January,O
10,O
",",O
2020,O
),O
.,O
At,O
7:00,O
pm,O
the,O
same,O
day,O
",",O
after,O
a,O
run,O
of,O
4,O
 ,O
h,O
on,O
the,O
GridION,O
X5,O
instrument,O
(,O
Oxford,O
Nanopore,O
Technologies,O
Ltd.,O
",",O
Oxford,O
",",O
UK,O
),O
",",O
we,O
were,O
able,O
to,O
obtain,O
using,O
the,O
CLC,O
Genomics,O
tool,O
(,O
https://digitalinsights.qiagen.com/,O
),O
",",O
by,O
mapping,O
42,O
reads,O
with,O
an,O
average,O
length,O
of,O
1433,O
nucleotides,O
on,O
a,O
set,O
of,O
coronavirus,O
genomes,O
from,O
the,O
Virus,B-Repository
Pathogen,I-Repository
Database,I-Repository
and,I-Repository
Analysis,I-Repository
Resource,E-Repository
 ,O
[,O
11,O
],O
",",O
a,O
"18,611",O
-,O
nucleotide,O
-,O
long,O
consensus,O
sequence,O
corresponding,O
to,O
approximately,O
62,O
%,O
of,O
the,O
viral,O
genome,O
(,O
EMBL,S-Repository
 ,O
Accession,O
no,O
.,O
ERS4366776,S-AccessionNumber
),O
.,O
This,O
sequence,O
",",O
by,O
similarity,O
search,O
using,O
the,O
BLASTn,O
tool,O
[,O
12,O
],O
against,O
the,O
NCBI,S-Repository
 ,O
nucleotide,O
sequence,O
database,O
(,O
GenBank,S-Repository
),O
",",O
found,O
as,O
best,O
hit,O
the,O
genome,O
of,O
a,O
SARS,O
-,O
CoV-2,O
(,O
GenBank,S-Repository
 ,O
Accession,O
no,O
.,O
A,O
total,O
of,O
"18,585",O
reads,O
could,O
be,O
mapped,O
on,O
the,O
SARS,O
-,O
CoV-2,O
genome,O
GenBank,S-Repository
 ,O
Accession,O
no,O
.,O
Over,O
the,O
study,O
period,O
(,O
January,O
6,O
",",O
2020,O
–,O
April,O
14,O
",",O
2020,O
),O
",",O
there,O
were,O
1333,O
laboratory,O
-,O
confirmed,O
cases,O
of,O
COVID-19,O
in,O
Victoria,O
.,O
The,O
majority,O
of,O
cases,O
(,O
827/1333,O
",",O
62.0,O
%,O
),O
were,O
identified,O
in,O
returning,O
travelers,O
",",O
most,O
commonly,O
from,O
north,O
–,O
west,O
Europe,O
and,O
the,O
Americas,O
",",O
and,O
360,O
(,O
27.0,O
%,O
),O
in,O
known,O
COVID-19,O
contacts,O
(,O
Table,O
 ,O
1,O
),O
.,O
Almost,O
all,O
second,O
-,O
level,O
lineages,O
from,O
a,O
recently,O
proposed,O
SARS,O
-,O
CoV-2,O
genomic,O
nomenclature,O
were,O
identified,O
in,O
the,O
dataset,O
(,O
excluding,O
lineage,O
A.4,O
),O
",",O
suggesting,O
that,O
Victorian,O
samples,O
were,O
representative,O
of,O
the,O
global,O
diversity,O
of,O
published,O
SARS,O
-,O
CoV-2,O
sequences,O
",",O
consistent,O
with,O
epidemiological,O
findings,O
(,O
Fig,O
.,O
 ,O
3,O
and,O
Table,O
 ,O
1,O
),O
.,O
In,O
total,O
",",O
737,O
samples,O
belonged,O
to,O
a,O
genomic,O
cluster,O
",",O
representing,O
81.6,O
%,O
of,O
the,O
samples,O
in,O
the,O
final,O
dataset,O
.,O
Among,O
our,O
dataset,O
",",O
4/76,O
(,O
5,O
%,O
),O
genomic,O
clusters,O
had,O
>,O
50,O
%,O
of,O
cases,O
associated,O
with,O
a,O
cruise,O
ship,O
(,O
Fig,O
.,O
 ,O
4,O
),O
.,O
On,O
manual,O
inspection,O
",",O
at,O
least,O
one,O
sequence,O
from,O
each,O
pair,O
was,O
found,O
to,O
have,O
more,O
ambiguous,O
or,O
missing,O
base,O
calls,O
than,O
the,O
rest,O
of,O
the,O
dataset,O
",",O
potentially,O
contributing,O
to,O
the,O
high,O
number,O
of,O
intra,O
-,O
patient,O
SNPs,O
.,O
In,O
addition,O
",",O
recently,O
proposed,O
lineages,O
were,O
also,O
determined,O
for,O
the,O
dataset,O
.,O
Here,O
we,O
report,O
high,O
-,O
throughput,O
genomics,O
for,O
SARS,O
-,O
CoV-2,O
",",O
sequencing,O
80,O
%,O
of,O
cases,O
in,O
Victoria,O
",",O
Australia,O
(,O
population,O
6.24,O
million,O
),O
between,O
6,O
January,O
and,O
14,O
April,O
2020,O
(,O
total,O
"1,333",O
COVID-19,O
cases,O
),O
.,O
Additional,O
sequence,O
data,O
and,O
metadata,O
are,O
available,O
at,O
https://github.com/MDU-PHL/COVID19-paper,S-URL
.,O
The,O
features,O
of,O
the,O
507,O
human,O
samples,O
in,O
our,O
dataset,O
were,O
used,O
to,O
show,O
the,O
patterns,O
with,O
the,O
multidimensional,O
scaling,O
method,O
.,O
Based,O
on,O
the,O
GGAP,O
(,O
g,O
 ,O
=,O
 ,O
3,O
),O
feature,O
",",O
we,O
computed,O
the,O
Euclidean,O
distance,O
of,O
SARS,O
-,O
CoV-2,O
and,O
SARS,O
-,O
CoV,O
from,O
other,O
coronaviruses,O
in,O
the,O
dataset,O
to,O
explore,O
the,O
evolution,O
dynamic,O
",",O
separately,O
.,O
With,O
the,O
improvement,O
of,O
annotation,O
in,O
the,O
database,O
",",O
the,O
false,O
rate,O
could,O
be,O
reduced,O
[,O
19,O
],O
.,O
Moreover,O
",",O
we,O
computed,O
the,O
Euclidean,O
distance,O
of,O
SARS,O
-,O
CoV-2,O
and,O
SARS,O
-,O
CoV,O
from,O
other,O
coronaviruses,O
in,O
the,O
dataset,O
to,O
explore,O
the,O
evolution,O
dynamic,O
.,O
The,O
nomenclature,O
for,O
coronavirus,O
in,O
the,O
dataset,O
is,O
provided,O
as,O
Additional,O
file,O
1,O
.,O
Pangolins,O
have,O
been,O
identified,O
",",O
besides,O
bats,O
",",O
as,O
a,O
possible,O
source,O
of,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
",",O
the,O
cause,O
of,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
(,O
10–14,O
),O
.,O
In,O
silico,O
translation,O
of,O
the,O
pangolin,O
IFIH1,O
pseudogene,O
(,O
GenBank,S-Repository
 ,O
gene,O
ID,O
:,O
108398082,S-AccessionNumber
),O
and,O
alignment,O
of,O
the,O
resulting,O
amino,O
acid,O
sequence,O
to,O
that,O
of,O
human,O
IFIH1,O
showed,O
numerous,O
disruptive,O
mutations,O
(,O
Figure,O
S1A,O
),O
.,O
In,O
silico,O
translation,O
of,O
the,O
pangolin,O
ZBP1,O
pseudogene,O
(,O
GenBank,S-Repository
 ,O
gene,O
ID,O
:,O
108390931,S-AccessionNumber
),O
and,O
alignment,O
of,O
the,O
resulting,O
amino,O
acid,O
sequence,O
to,O
that,O
of,O
human,O
ZBP1,O
showed,O
premature,O
termination,O
of,O
the,O
translation,O
product,O
and,O
lack,O
of,O
the,O
carboxy,O
-,O
terminal,O
half,O
of,O
the,O
protein,O
(,O
Figure,O
S1B,O
),O
.,O
All,O
datasets,O
presented,O
in,O
this,O
study,O
are,O
included,O
in,O
the,O
article,O
/,O
Supplementary,O
Material,O
.,O
Objective,O
 ,O
Although,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
RNA,O
was,O
detected,O
in,O
faeces,O
of,O
patients,O
with,O
COVID-19,O
",",O
the,O
activity,O
and,O
infectivity,O
of,O
the,O
virus,O
in,O
the,O
GI,O
tract,O
during,O
disease,O
course,O
is,O
largely,O
unknown,O
.,O
We,O
investigated,O
temporal,O
transcriptional,O
activity,O
of,O
SARS,O
-,O
CoV-2,O
and,O
its,O
association,O
with,O
longitudinal,O
faecal,O
microbiome,O
alterations,O
in,O
patients,O
with,O
COVID-19,O
.,O
We,O
performed,O
RNA,O
shotgun,O
metagenomics,O
sequencing,O
on,O
serial,O
faecal,O
viral,O
extractions,O
from,O
15,O
hospitalised,O
patients,O
with,O
COVID-19,O
.,O
Results,O
 ,O
Seven,O
(,O
46.7,O
%,O
),O
of,O
15,O
patients,O
with,O
COVID-19,O
had,O
stool,O
positivity,O
for,O
SARS,O
-,O
CoV-2,O
by,O
viral,O
RNA,O
metagenomic,O
sequencing,O
.,O
ExoN,O
increases,O
the,O
fidelity,O
of,O
RNA,O
synthesis,O
by,O
correcting,O
nucleotide,O
incorporation,O
errors,O
made,O
by,O
RdRp,O
[,O
14,O
],O
.,O
GISAID,S-Dataset
 ,O
database,O
(,O
https://www.gisaid.org/,S-URL
),O
filtered,O
from,O
December,O
2019,O
up,O
to,O
March,O
13th,O
",",O
2020,O
was,O
used,O
to,O
collect,O
220,O
SARS,O
-,O
CoV-2,O
complete,O
genomes,O
of,O
different,O
patients,O
all,O
around,O
the,O
world,O
(,O
i.e.,O
China,O
",",O
USA,O
",",O
Canada,O
",",O
Australia,O
",",O
United,O
Kingdom,O
",",O
Germany,O
",",O
France,O
",",O
Japan,O
",",O
Italy,O
",",O
Switzerland,O
",",O
Singapore,O
",",O
Luxembourg,O
",",O
Netherlands,O
",",O
Spain,O
",",O
Portugal,O
",",O
Sweden,O
",",O
Czech,O
Republic,O
",",O
Thailand,O
",",O
India,O
",",O
Cambodia,O
",",O
Hong,O
Kong,O
",",O
Finland,O
",",O
Singapore,O
",",O
and,O
Ireland,O
),O
taking,O
into,O
particular,O
consideration,O
those,O
deposited,O
during,O
the,O
development,O
of,O
European,O
outbreaks,O
.,O
We,O
divided,O
our,O
dataset,O
into,O
4,O
geographic,O
areas,O
:,O
Asia,O
",",O
Oceania,O
",",O
Europe,O
",",O
North,O
America,O
(,O
Fig,O
.,O
 ,O
1,O
),O
.,O
Moreover,O
",",O
we,O
highlighted,O
the,O
presence,O
of,O
additional,O
“,O
conserved,O
mutations,O
”,O
in,O
all,O
the,O
geographic,O
areas,O
",",O
taking,O
into,O
account,O
only,O
those,O
occurring,O
more,O
than,O
10,O
times,O
in,O
our,O
database,O
.,O
In,O
our,O
database,O
",",O
the,O
first,O
appearance,O
of,O
a,O
silent,O
RdRp,O
mutation,O
(,O
nt,O
14804,O
),O
is,O
manifested,O
on,O
February,O
9th,O
",",O
2020,O
in,O
UK,O
(,O
England,O
),O
",",O
while,O
a,O
different,O
RdRp,O
mutation,O
(,O
nt,O
14408,O
",",O
amino,O
acid,O
P,O
to,O
L,O
),O
is,O
observed,O
for,O
the,O
first,O
time,O
in,O
Italy,O
(,O
Lombardy,O
),O
on,O
February,O
20th,O
",",O
2020,O
",",O
when,O
a,O
dramatic,O
increase,O
of,O
the,O
number,O
of,O
European,O
infected,O
patients,O
was,O
reported,O
from,O
the,O
WHO,O
website,O
[,O
27,O
],O
.,O
Background,O
 ,O
SARS,O
-,O
CoV-2,O
is,O
a,O
RNA,O
coronavirus,O
responsible,O
for,O
the,O
pandemic,O
of,O
the,O
Severe,O
Acute,O
Respiratory,O
Syndrome,O
(,O
COVID-19,O
),O
.,O
We,O
analyzed,O
220,O
genomic,O
sequences,O
from,O
the,O
GISAID,S-Dataset
 ,O
database,O
derived,O
from,O
patients,O
infected,O
by,O
SARS,O
-,O
CoV-2,O
worldwide,O
from,O
December,O
2019,O
to,O
mid,O
-,O
March,O
2020,O
.,O
SARS,O
-,O
CoV-2,O
reference,O
genome,O
was,O
obtained,O
from,O
the,O
GenBank,S-Repository
 ,O
database,O
.,O
The,O
datasets,O
analysed,O
during,O
the,O
current,O
study,O
are,O
available,O
in,O
the,O
GISAID,S-Dataset
 ,O
(,O
https://www.gisaid.org/,S-URL
),O
and,O
GenBank,S-Repository
 ,O
(,O
https://www.ncbi.nlm.nih.gov/nuccore/NC_045512,S-URL
),O
repositories,O
.,O
As,O
of,O
August,O
5,O
",",O
2020,O
",",O
"18,566,769",O
persons,O
with,O
COVID-19,O
infection,O
were,O
reported,O
in,O
188,O
countries,O
and,O
territories,O
worldwide,O
and,O
resulting,O
in,O
"701,316",O
death,O
[,O
3,O
],O
.,O
This,O
COVID-19,O
pandemic,O
not,O
just,O
a,O
global,O
health,O
crisis,O
",",O
but,O
also,O
affect,O
the,O
global,O
economy,O
system,O
.,O
Therefore,O
",",O
Taiwan,O
government,O
took,O
very,O
quick,O
reaction,O
to,O
prevent,O
the,O
spread,O
of,O
COVID-19,O
in,O
Taiwan,O
according,O
to,O
the,O
previous,O
experience,O
dealing,O
with,O
SARS,O
.,O
Taiwan,O
still,O
has,O
a,O
low,O
incidence,O
and,O
very,O
low,O
death,O
rate,O
of,O
COVID-19,O
compared,O
with,O
Europe,O
and,O
USA,O
[,O
5,O
],O
.,O
But,O
the,O
situation,O
of,O
COVID-19,O
infection,O
in,O
the,O
United,O
States,O
are,O
still,O
in,O
the,O
peak,O
by,O
mid,O
-,O
April,O
",",O
2020,O
.,O
How,O
to,O
treat,O
and,O
prevent,O
COVID-19,O
infection,O
becomes,O
the,O
most,O
important,O
global,O
health,O
issues,O
.,O
The,O
governments,O
of,O
big,O
countries,O
",",O
the,O
big,O
pharmaceutical,O
companies,O
",",O
the,O
major,O
scientific,O
laboratories,O
all,O
have,O
made,O
big,O
investment,O
for,O
the,O
treatment,O
of,O
COVID-19,O
currently,O
.,O
Since,O
Taiwan,O
has,O
many,O
academic,O
institutes,O
and,O
industries,O
good,O
in,O
the,O
biotechnology,O
and,O
pharmaceutical,O
fields,O
",",O
it,O
is,O
a,O
very,O
good,O
time,O
point,O
for,O
Taiwan,O
to,O
develop,O
quick,O
diagnosis,O
kits,O
",",O
new,O
drugs,O
and,O
vaccines,O
for,O
COVID-19,O
infection,O
.,O
Therefore,O
",",O
after,O
Taiwan,O
start,O
to,O
have,O
COVID-19,O
patients,O
in,O
January,O
",",O
2020,O
",",O
the,O
Minister,O
of,O
Health,O
and,O
Welfare,O
requested,O
National,O
Health,O
Research,O
Institutes,O
(,O
NHRI,O
),O
to,O
take,O
the,O
responsibility,O
in,O
coordinating,O
the,O
research,O
in,O
the,O
treatment,O
and,O
prevention,O
of,O
COVID-19,O
infection,O
in,O
Taiwan,O
.,O
To,O
collect,O
the,O
COVID-19,O
biosamples,O
in,O
accordance,O
with,O
the,O
Human,O
Biobank,O
Management,O
Act,O
[,O
6,O
],O
.,O
The,O
Ethic,O
Committee,O
of,O
NHRI,O
Biobank,O
quickly,O
designed,O
and,O
approved,O
a,O
new,O
non,O
-,O
tumor,O
informed,O
consent,O
form,O
(,O
ICF,O
),O
for,O
COVID-19,O
patients,O
on,O
Feb.,O
13,O
.,O
For,O
recruitment,O
of,O
COVID-19,O
patients,O
and,O
collect,O
specimen,O
from,O
all,O
hospitals,O
in,O
Taiwan,O
",",O
we,O
need,O
to,O
have,O
a,O
connection,O
with,O
all,O
major,O
hospitals,O
",",O
since,O
we,O
did,O
not,O
know,O
COVID-19,O
patients,O
were,O
hospitalized,O
in,O
which,O
hospitals,O
.,O
On,O
Feb.27,O
",",O
The,O
Department,O
of,O
Medical,O
Affairs,O
of,O
MOHW,O
forward,O
the,O
official,O
letter,O
of,O
NBCT,O
to,O
all,O
hospitals,O
at,O
or,O
above,O
the,O
regional,O
level,O
in,O
Taiwan,O
urging,O
all,O
medical,O
institutes,O
to,O
collaborate,O
for,O
collection,O
of,O
biosamples,O
of,O
COVID-19,O
patients,O
and,O
to,O
accelerate,O
the,O
research,O
of,O
COVID-19,O
.,O
On,O
March,O
1,O
",",O
we,O
received,O
the,O
first,O
COVID-19,O
patient,O
blood,O
samples,O
immediately,O
.,O
We,O
also,O
quickly,O
received,O
the,O
first,O
application,O
for,O
COVID-19,O
serum,O
samples,O
on,O
March,O
17,O
and,O
got,O
approved,O
in,O
April,O
.,O
NHRI,O
President,O
Liang,O
rapidly,O
approved,O
the,O
usage,O
of,O
a,O
new,O
laboratory,O
exclusively,O
for,O
NHRI,O
Biobank,O
to,O
store,O
and,O
handling,O
the,O
COVID-19,O
biosamples,O
.,O
In,O
addition,O
",",O
it,O
also,O
needs,O
to,O
have,O
a,O
biosafety,O
cabinet,O
(,O
BSC,O
),O
for,O
handling,O
the,O
COVID-19,O
biosamples,O
.,O
For,O
opening,O
this,O
P2,O
lab,O
",",O
and,O
to,O
handle,O
the,O
COVID-19,O
human,O
biosamples,O
",",O
we,O
need,O
to,O
apply,O
for,O
the,O
permission,O
of,O
NHRI,O
Biosafty,O
Committee,O
.,O
This,O
special,O
P2,O
laboratory,O
was,O
completely,O
set,O
up,O
and,O
got,O
permission,O
to,O
work,O
in,O
2,O
weeks,O
",",O
just,O
before,O
we,O
received,O
the,O
first,O
COVID-19,O
human,O
samples,O
on,O
March,O
1,O
",",O
2020,O
.,O
Since,O
COVID-19,O
patients,O
in,O
Taiwan,O
was,O
few,O
(,O
only,O
32,O
cases,O
reported,O
when,O
the,O
P2,O
laboratory,O
was,O
established,O
),O
",",O
and,O
these,O
patients,O
distributed,O
diversely,O
across,O
Taiwan,O
.,O
This,O
NHRI,O
COVID-19,O
Biobank,O
will,O
also,O
conduct,O
value,O
-,O
added,O
analyses,O
of,O
the,O
collected,O
blood,O
samples,O
",",O
including,O
DNA,O
whole,O
genome,O
sequencing,O
and,O
RNA,O
sequencing,O
.,O
By,O
August,O
5,O
",",O
2020,O
",",O
this,O
COVID-19,O
biobank,O
has,O
collected,O
165,O
blood,O
samples,O
of,O
110,O
patients,O
from,O
more,O
than,O
10,O
 ,O
hospitals,O
across,O
north,O
",",O
middle,O
and,O
south,O
part,O
of,O
Taiwan,O
",",O
including,O
both,O
COVID-19,O
(,O
+,O
),O
and,O
(,O
−,O
),O
pneumonia,O
patients,O
.,O
However,O
",",O
since,O
Taiwan,O
already,O
have,O
reported,O
476,O
COVI-19,O
cases,O
as,O
of,O
August,O
5,O
",",O
2020,O
[,O
5,O
],O
",",O
the,O
current,O
recruitment,O
of,O
COVID-19,O
patients,O
is,O
still,O
not,O
satisfactory,O
.,O
We,O
are,O
very,O
grateful,O
for,O
the,O
doctors,O
and,O
the,O
medical,O
personnel,O
who,O
spent,O
the,O
time,O
and,O
effort,O
to,O
help,O
collect,O
the,O
specimens,O
and,O
all,O
of,O
the,O
patients,O
who,O
are,O
willing,O
to,O
donate,O
their,O
blood,O
samples,O
for,O
COVID-19,O
research,O
.,O
By,O
the,O
request,O
of,O
the,O
Minister,O
of,O
Health,O
and,O
Welfare,O
",",O
NHRI,O
Biobank,O
was,O
assigned,O
to,O
establish,O
a,O
COVID-19,O
biobank,O
in,O
early,O
Feb,O
",",O
2020,O
to,O
collect,O
COVID-19,O
patients,O
’,O
blood,O
samples,O
for,O
Taiwan,O
researchers,O
and,O
industries,O
in,O
an,O
emergent,O
way,O
.,O
By,O
August,O
5,O
",",O
2020,O
",",O
this,O
COVID-19,O
biobank,O
has,O
collected,O
165,O
blood,O
samples,O
of,O
110,O
patients,O
from,O
more,O
than,O
10,O
hospitals,O
across,O
north,O
",",O
middle,O
and,O
south,O
part,O
of,O
Taiwan,O
",",O
including,O
both,O
COVID-19,O
(,O
+,O
),O
and,O
(,O
-,O
),O
pneumonia,O
patients,O
.,O
This,O
biobank,O
can,O
provide,O
applicants,O
with,O
biosamples,O
",",O
such,O
as,O
serum,O
",",O
DNA,O
and,O
RNA,O
",",O
and,O
also,O
the,O
clinical,O
and,O
genomic,O
data,O
",",O
so,O
as,O
to,O
accelerate,O
the,O
COVID-19,O
treatment,O
and,O
prevention,O
research,O
in,O
Taiwan,O
.,O
This,O
COID-19,O
biobank,O
already,O
received,O
15,O
applications,O
.,O
It,O
has,O
become,O
the,O
most,O
important,O
research,O
resource,O
for,O
the,O
COVID-19,O
pandemic,O
in,O
Taiwan,O
",",O
including,O
new,O
screening,O
reagents,O
",",O
disease,O
mechanism,O
",",O
the,O
variable,O
human,O
responses,O
and,O
epidemic,O
preventions,O
.,O
Paired,O
-,O
end,O
reads,O
(,O
2,O
 ,O
×,O
 ,O
150,O
 ,O
bp,O
),O
were,O
assembled,O
into,O
contigs,O
and,O
aligned,O
to,O
viral,O
metagenomic,O
database,O
comprising,O
all,O
viral,O
reference,O
sequences,O
(,O
all,O
viral,O
reference,O
sequences,O
in,O
NCBI,S-Repository
:,O
"12,209",O
strains,O
),O
.,O
In,O
short,O
",",O
plasmid,O
encoding,O
wild,O
-,O
type,O
(,O
reference,O
strain,O
Amsterdam,O
I,O
",",O
accession,O
number,O
:,O
NC_005831.1,S-AccessionNumber
),O
or,O
mutant,O
HCoV,O
-,O
NL63,O
spike,O
protein,O
was,O
transfected,O
into,O
293,O
 ,O
T,O
cells,O
",",O
24,O
 ,O
h,O
later,O
transduced,O
target,O
cells,O
were,O
infected,O
with,O
rVSV,O
-,O
ΔG,O
-,O
luc,O
",",O
viral,O
supernatant,O
was,O
harvested,O
24,O
 ,O
h,O
after,O
transduction,O
.,O
To,O
investigate,O
the,O
biological,O
relevance,O
of,O
I507,O
 ,O
L,O
mutation,O
in,O
spike,O
RBD,O
",",O
pseudotyped,O
HCoV,O
-,O
NL63,O
were,O
generated,O
bearing,O
WT,O
(,O
reference,O
strain,O
Amsterdam,O
I,O
",",O
accession,O
number,O
:,O
NC_005831.1,S-AccessionNumber
),O
and,O
I507,O
 ,O
L,O
mutant,O
S,O
protein,O
.,O
5,O
 ,O
days,O
post,O
transduction,O
",",O
mice,O
were,O
infected,O
via,O
the,O
intranasal,O
route,O
with,O
a,O
50,O
%,O
tissue,O
culture,O
infective,O
dose,O
(,O
TCID50,O
),O
at,O
1.5×105,O
 ,O
TCID50·mL−1,O
of,O
MERS,O
-,O
CoV,O
EMC/2012,O
.,O
50,O
 ,O
mg·kg−1·day−1,O
CsA,O
diluted,O
in,O
DMSO,O
or,O
DMSO,O
alone,O
were,O
mixed,O
with,O
a,O
nut,O
/,O
chocolate,O
cream,O
",",O
and,O
offered,O
to,O
the,O
mice,O
for,O
voluntary,O
uptake,O
.,O
Oral,O
application,O
of,O
CsA,O
significantly,O
reduced,O
viral,O
titres,O
(,O
3.45±0.15,O
versus,O
2.1±0.36,O
TCID50·mL−1,O
in,O
the,O
DMSO,O
versus,O
CsA,O
group,O
),O
at,O
day,O
7,O
post,O
MERS,O
-,O
CoV,O
infection,O
(,O
figure,O
7c,O
),O
.,O
Oral,O
application,O
of,O
CsA,O
(,O
50,O
 ,O
mg·kg−1·day−1,O
),O
or,O
DMSO,O
as,O
solvent,O
control,O
was,O
started,O
at,O
day,O
3,O
post,O
transduction,O
",",O
while,O
mice,O
were,O
infected,O
with,O
1.5×105,O
TCID50·mL−1,O
MERS,O
-,O
CoV,O
via,O
the,O
intranasal,O
route,O
at,O
day,O
5,O
post,O
transduction,O
.,O
Lung,O
homogenate,O
was,O
used,O
to,O
b,O
),O
quantify,O
relative,O
IFNL2/3,O
mRNA,O
and,O
c,O
),O
determine,O
viral,O
load,O
by,O
TCID50,O
.,O
TCID50,O
:,O
50,O
%,O
tissue,O
culture,O
infective,O
dose,O
.,O
To,O
discover,O
BGCs,O
encoding,O
members,O
of,O
the,O
FK506,O
/,O
rapamycin,O
structural,O
class,O
(,O
FK,O
gene,O
clusters,O
),O
",",O
we,O
developed,O
a,O
biosynthetic,O
“,O
search,O
term,O
”,O
to,O
query,O
our,O
microbial,O
sequence,O
database,O
containing,O
partial,O
sequences,O
of,O
pooled,O
DNA,O
samples,O
from,O
"∼135,000",O
Actinomycete,O
species,O
.,O
Pipecolate,O
is,O
incorporated,O
in,O
the,O
final,O
and,O
shared,O
step,O
of,O
FK506,O
and,O
rapamycin,O
assembly,O
-,O
line,O
biosynthesis,O
(,O
19,O
",",O
20,O
),O
and,O
directly,O
binds,O
the,O
FKBP,O
active,O
site,O
.,O
Once,O
we,O
identified,O
genetic,O
matches,O
to,O
the,O
search,O
term,O
in,O
our,O
fragmentary,O
sequence,O
database,O
",",O
we,O
identified,O
the,O
candidate,O
Actinomycete,O
strains,O
harboring,O
putative,O
FK,O
gene,O
clusters,O
.,O
In,O
addition,O
to,O
CEP250,O
",",O
11,O
other,O
targets,O
were,O
identified,O
in,O
the,O
proteomic,O
target,O
-,O
identification,O
(,O
ID,O
),O
screen,O
of,O
FKBP12,O
–,O
WDB002,O
",",O
albeit,O
less,O
reproducibly,O
and,O
with,O
significantly,O
lower,O
spectral,O
counts,O
than,O
CEP250,O
(,O
Fig,O
.,O
2,O
),O
",",O
suggesting,O
that,O
they,O
either,O
bind,O
weakly,O
to,O
FKBP12,O
:,O
WDB002,O
",",O
or,O
they,O
are,O
associated,O
with,O
the,O
complex,O
containing,O
CEP250,O
.,O
We,O
report,O
the,O
structure,O
of,O
CEP25011.4,O
bound,O
to,O
FKBP12,O
in,O
the,O
presence,O
of,O
WDB002,O
(,O
Fig,O
.,O
3,O
",",O
Protein,B-Repository
Data,I-Repository
Bank,I-Repository
[PDB],E-Repository
 ,O
ID,O
6OQA,S-AccessionNumber
),O
.,O
In,O
a,O
recent,O
cellular,O
protein,O
interactome,O
screen,O
for,O
SARS,O
-,O
CoV-2,O
",",O
the,O
causative,O
agent,O
of,O
COVID-19,O
disease,O
",",O
CEP250,O
was,O
identified,O
as,O
a,O
host,O
factor,O
that,O
is,O
engaged,O
by,O
the,O
viral,O
Nsp13,O
protein,O
(,O
42,O
),O
",",O
suggesting,O
the,O
possibility,O
that,O
WDB002,O
may,O
carry,O
inhibitory,O
activity,O
against,O
SARS,O
-,O
CoV-2,O
by,O
binding,O
to,O
CEP250,O
.,O
Finally,O
",",O
since,O
WDB002,O
targets,O
CEP250,O
",",O
it,O
may,O
be,O
a,O
promising,O
starting,O
point,O
for,O
developing,O
a,O
treatment,O
for,O
COVID-19,O
.,O
As,O
CEP250,O
was,O
recently,O
found,O
to,O
be,O
an,O
interaction,O
partner,O
with,O
the,O
Nsp13,O
protein,O
of,O
the,O
SARS,O
-,O
CoV-2,O
virus,O
that,O
causes,O
COVID-19,O
disease,O
",",O
it,O
is,O
possible,O
that,O
WDB002,O
or,O
an,O
analog,O
may,O
exert,O
useful,O
antiviral,O
activity,O
through,O
its,O
ability,O
to,O
form,O
high,O
-,O
affinity,O
ternary,O
complexes,O
containing,O
CEP250,O
and,O
FKBP12,O
.,O
Only,O
a,O
few,O
weeks,O
after,O
the,O
first,O
case,O
of,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
was,O
reported,O
in,O
Wuhan,O
",",O
China,O
",",O
the,O
first,O
case,O
of,O
COVID-19,O
was,O
confirmed,O
in,O
the,O
Republic,O
of,O
Korea,O
on,O
January,O
20,O
",",O
2020,O
.,O
On,O
February,O
18,O
",",O
when,O
a,O
suspicious,O
index,O
case,O
was,O
identified,O
in,O
a,O
religious,O
group,O
",",O
a,O
sharp,O
increase,O
in,O
the,O
number,O
of,O
COVID-19,O
cases,O
was,O
observed,O
",",O
with,O
most,O
infections,O
being,O
reported,O
in,O
specific,O
clusters,O
and,O
geographic,O
regions,O
;,O
the,O
highest,O
number,O
of,O
COVID-19,O
cases,O
was,O
reported,O
in,O
Daegu,O
",",O
followed,O
by,O
Gyeongbuk.1,O
",",O
2,O
",",O
3,O
Until,O
April,O
4,O
",",O
2020,O
",",O
"10,156",O
cumulative,O
cases,O
of,O
COVID-19,O
were,O
reported,O
in,O
Korea,O
.,O
It,O
is,O
well,O
established,O
that,O
most,O
patients,O
with,O
COVID-19,O
have,O
fever,O
along,O
with,O
respiratory,O
symptoms,O
",",O
and,O
human,O
-,O
to,O
-,O
human,O
transmission,O
occurs,O
among,O
close,O
contacts,O
",",O
mainly,O
through,O
respiratory,O
droplets,O
and,O
direct,O
contact,O
.,O
",",O
Hence,O
",",O
the,O
GI,O
symptoms,O
and,O
fecal,O
viral,O
shedding,O
in,O
prolonged,O
respiratory,O
shedders,O
with,O
asymptomatic,O
or,O
mild,O
COVID-19,O
",",O
who,O
were,O
in,O
quarantine,O
for,O
more,O
than,O
a,O
month,O
",",O
must,O
be,O
evaluated,O
.,O
We,O
conducted,O
a,O
prospective,O
cohort,O
study,O
involving,O
the,O
patients,O
diagnosed,O
with,O
asymptomatic,O
or,O
mild,O
COVID-19,O
",",O
quarantined,O
between,O
April,O
4,O
and,O
April,O
24,O
at,O
the,O
Youngdeok,O
Samsung,O
Living,O
and,O
Treatment,O
Center,O
(,O
LTC,O
),O
.,O
Patients,O
were,O
defined,O
as,O
having,O
asymptomatic,O
or,O
mild,O
COVID-19,O
as,O
per,O
the,O
Korea,O
Centers,O
for,O
Disease,O
Control,O
and,O
Prevention,O
severity,O
criteria,O
(,O
http://ncov.mohw.go.kr/en,O
),O
",",O
when,O
the,O
following,O
conditions,O
were,O
met,O
:,O
(,O
1,O
),O
age,O
younger,O
than,O
60,O
years,O
",",O
(,O
2,O
),O
no,O
underlying,O
chronic,O
diseases,O
",",O
(,O
3,O
),O
alert,O
mentality,O
",",O
(,O
4,O
),O
body,O
temperature,O
lower,O
than,O
37.5,O
°,O
C,O
",",O
and,O
(,O
5,O
),O
no,O
radiologic,O
evidence,O
of,O
pneumonia,O
.,O
Originally,O
",",O
Youngdeok,O
Samsung,O
LTC,O
was,O
a,O
human,O
resource,O
training,O
center,O
of,O
Samsung,O
",",O
but,O
on,O
March,O
2,O
",",O
2020,O
",",O
out,O
-,O
of,O
-,O
hospital,O
quarantine,O
and,O
care,O
for,O
patients,O
with,O
asymptomatic,O
or,O
mild,O
COVID-19,O
was,O
mandated,O
by,O
the,O
Korea,O
Centers,O
for,O
Disease,O
Control,O
and,O
Prevention,O
.,O
Therefore,O
",",O
the,O
accommodation,O
facilities,O
including,O
Youngdeok,O
Samsung,O
human,O
resource,O
training,O
centers,O
were,O
transformed,O
to,O
a,O
LTC,O
",",O
and,O
COVID-19,O
patients,O
in,O
Daegu,O
and,O
Gyeongbuk,O
were,O
quarantined,O
there,O
on,O
March,O
4,O
.,O
COVID-19,O
was,O
confirmed,O
by,O
real,O
-,O
time,O
reverse,O
-,O
transcription,O
polymerase,O
-,O
chain,O
reaction,O
(,O
RT,O
-,O
PCR,O
),O
assay,O
for,O
SARS,O
-,O
CoV-2,O
in,O
upper,O
respiratory,O
tract,O
specimens,O
using,O
nasopharyngeal,O
and,O
oropharyngeal,O
swabs,O
and/or,O
lower,O
respiratory,O
tract,O
specimens,O
(,O
ie,O
",",O
sputum,O
),O
.,O
A,O
total,O
of,O
203,O
patients,O
were,O
diagnosed,O
with,O
COVID-19,O
between,O
February,O
18,O
and,O
March,O
1,O
",",O
2020,O
",",O
and,O
quarantined,O
in,O
the,O
Youngdeok,O
Samsung,O
LTC,O
on,O
March,O
4,O
",",O
2020,O
.,O
Another,O
group,O
of,O
169,O
patients,O
was,O
diagnosed,O
with,O
COVID-19,O
between,O
February,O
25,O
and,O
March,O
8,O
",",O
2020,O
",",O
and,O
quarantined,O
in,O
the,O
Gimje,O
Samsung,O
LTC,O
.,O
The,O
clinical,O
characteristics,O
of,O
study,O
participants,O
with,O
asymptomatic,O
and,O
mildly,O
symptomatic,O
COVID-19,O
are,O
described,O
in,O
Table,O
 ,O
1,O
.,O
Fecal,O
specimens,O
were,O
collected,O
from,O
April,O
4,O
to,O
April,O
24,O
",",O
2020,O
(,O
21,O
days,O
),O
",",O
and,O
the,O
median,O
interval,O
between,O
COVID-19,O
diagnosis,O
to,O
the,O
start,O
of,O
fecal,O
sample,O
collection,O
was,O
37,O
days,O
(,O
range,O
",",O
29–41,O
d,O
),O
(,O
Table,O
 ,O
1,O
",",O
Figure,O
 ,O
2,O
),O
.,O
In,O
a,O
meta,O
-,O
analysis,O
of,O
60,O
studies,O
",",O
comprising,O
4243,O
patients,O
",",O
the,O
pooled,O
prevalence,O
rate,O
of,O
all,O
GI,O
symptoms,O
was,O
17.6,O
%,O
",",O
and,O
when,O
compared,O
with,O
the,O
prevalence,O
of,O
GI,O
symptoms,O
according,O
to,O
the,O
severity,O
of,O
COVID-19,O
",",O
pooled,O
prevalence,O
rates,O
of,O
GI,O
symptoms,O
were,O
11.8,O
%,O
and,O
17.1,O
%,O
in,O
patients,O
with,O
nonsevere,O
and,O
severe,O
COVID-19,O
",",O
respectively,O
.,O
Background,O
&,O
Aims,O
 ,O
Although,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
is,O
characterized,O
by,O
fever,O
and,O
respiratory,O
symptoms,O
",",O
some,O
patients,O
have,O
no,O
or,O
mild,O
symptoms,O
.,O
We,O
investigated,O
gastrointestinal,O
symptoms,O
and,O
shedding,O
of,O
virus,O
into,O
feces,O
of,O
patients,O
with,O
asymptomatic,O
or,O
mild,O
COVID-19,O
.,O
We,O
collected,O
data,O
from,O
46,O
patients,O
(,O
median,O
age,O
",",O
26,O
y,O
;,O
46,O
%,O
men,O
),O
with,O
asymptomatic,O
or,O
mild,O
COVID-19,O
(,O
without,O
fever,O
and,O
pneumonia,O
),O
and,O
prolonged,O
respiratory,O
shedding,O
of,O
SARS,O
-,O
CoV-2,O
",",O
quarantined,O
from,O
April,O
4,O
",",O
2020,O
",",O
through,O
April,O
24,O
",",O
2020,O
",",O
in,O
Korea,O
.,O
The,O
median,O
interval,O
between,O
COVID-19,O
diagnosis,O
to,O
the,O
start,O
of,O
fecal,O
sample,O
collection,O
was,O
37,O
days,O
(,O
range,O
",",O
29–41,O
d,O
),O
;,O
213,O
stool,O
specimens,O
were,O
collected,O
from,O
46,O
patients,O
.,O
In,O
an,O
analysis,O
of,O
fecal,O
and,O
respiratory,O
specimens,O
from,O
patients,O
with,O
COVID-19,O
in,O
quarantine,O
in,O
Korea,O
",",O
we,O
found,O
that,O
the,O
gastrointestinal,O
tract,O
could,O
be,O
a,O
route,O
of,O
transmission,O
of,O
SARS,O
-,O
CoV-2,O
even,O
in,O
patients,O
with,O
asymptomatic,O
or,O
mild,O
disease,O
",",O
with,O
no,O
gastrointestinal,O
symptoms,O
.,O
In,O
December,O
2019,O
",",O
a,O
novel,O
coronavirus,O
disease,O
(,O
COVID-19,O
),O
was,O
identified,O
in,O
Wuhan,O
",",O
Hubei,O
Province,O
of,O
China,O
",",O
and,O
a,O
previously,O
unknown,O
Betacoronavirus,O
was,O
subsequently,O
isolated,O
from,O
patients,O
with,O
pneumonia,O
[,O
1,O
],O
.,O
In,O
order,O
to,O
effectively,O
control,O
the,O
COVID-19,O
outbreak,O
",",O
information,O
regarding,O
the,O
period,O
and,O
routes,O
of,O
infectious,O
virus,O
shedding,O
in,O
patients,O
is,O
essential,O
.,O
In,O
general,O
",",O
droplets,O
and,O
close,O
contact,O
with,O
infected,O
respiratory,O
secretions,O
are,O
considered,O
the,O
main,O
transmission,O
routes,O
of,O
the,O
SARS,O
-,O
CoV-2,O
;,O
however,O
",",O
faecal,O
–,O
oral,O
transmission,O
has,O
also,O
been,O
suggested,O
since,O
some,O
COVID-19,O
patients,O
have,O
gastrointestinal,O
symptoms,O
",",O
and,O
viral,O
RNA,O
has,O
been,O
detected,O
in,O
oral,O
and,O
anal,O
swabs,O
from,O
patients,O
[,O
[,O
5,O
],O
",",O
[,O
6,O
],O
",",O
[,O
7,O
],O
",",O
[,O
8,O
],O
",",O
[,O
9,O
],O
],O
.,O
Briefly,O
",",O
viral,O
RNA,O
was,O
extracted,O
from,O
clinical,O
specimens,O
of,O
COVID-19,O
patients,O
using,O
the,O
QIAamp,O
Viral,O
RNA,O
Mini,O
kit,O
(,O
QIAGEN,O
",",O
Hilden,O
",",O
Germany,O
),O
and,O
cDNAs,O
were,O
generated,O
by,O
reverse,O
transcription,O
using,O
QuantiTect,O
Reverse,O
Transcription,O
(,O
QIAGEN,O
",",O
Hilden,O
",",O
Germany,O
),O
according,O
to,O
the,O
manufacturer,O
's,O
instructions,O
.,O
All,O
PCR,O
products,O
regardless,O
of,O
whether,O
ferret,O
or,O
human,O
clinical,O
specimens,O
were,O
sequenced,O
and,O
compared,O
with,O
the,O
SARS,O
-,O
CoV-2,O
reference,O
genome,O
(,O
GISAID,S-Dataset
 ,O
accession,O
ID,O
:,O
EPI_ISL_407193,S-AccessionNumber
),O
.,O
Their,O
underlying,O
diseases,O
",",O
COVID-19,O
severity,O
and,O
treatment,O
courses,O
are,O
summarized,O
in,O
Table,O
 ,O
1,O
.,O
Serum,O
IgG,O
antibody,O
responses,O
of,O
all,O
COVID-19,O
patients,O
are,O
described,O
in,O
Table,O
 ,O
2,O
.,O
These,O
symptom,O
-,O
recovered,O
COVID-19,O
patients,O
(,O
patients,O
1,O
",",O
2,O
",",O
3,O
and,O
5,O
),O
showed,O
positive,O
qPCR,O
results,O
in,O
their,O
urine,O
specimens,O
with,O
viral,O
RNA,O
titres,O
ranging,O
from,O
1.08,O
 ,O
±,O
 ,O
0.16,O
to,O
2.09,O
 ,O
±,O
 ,O
0.85,O
log10,O
copies,O
/,O
mL.,O
Further,O
",",O
in,O
faecal,O
specimens,O
from,O
patients,O
2,O
",",O
4,O
and,O
5,O
(,O
n,O
 ,O
=,O
 ,O
3,O
),O
SARS,O
-,O
CoV-2,O
RNA,O
was,O
detected,O
at,O
1.17,O
 ,O
±,O
 ,O
0.32,O
",",O
2.18,O
 ,O
±,O
 ,O
0.11,O
log10,O
copies,O
/,O
mL,O
and,O
2.01,O
 ,O
±,O
 ,O
0.28,O
log10,O
copies,O
/,O
mL,O
",",O
respectively,O
.,O
In,O
this,O
study,O
",",O
we,O
found,O
that,O
viable,O
SARS,O
-,O
CoV-2,O
can,O
be,O
shed,O
through,O
various,O
clinical,O
specimens,O
",",O
such,O
as,O
saliva,O
",",O
stool,O
and,O
urine,O
",",O
of,O
COVID-19,O
patients,O
even,O
at,O
15,O
 ,O
days,O
after,O
onset,O
of,O
clinical,O
symptoms,O
.,O
In,O
addition,O
",",O
we,O
demonstrated,O
the,O
infectivity,O
of,O
saliva,O
",",O
urine,O
and,O
stool,O
specimens,O
from,O
COVID-19,O
patients,O
using,O
cell,O
culture,O
and,O
an,O
animal,O
model,O
.,O
Given,O
the,O
consistent,O
detection,O
and,O
isolation,O
of,O
SARS,O
-,O
CoV-2,O
RNA,O
from,O
saliva,O
in,O
another,O
study,O
[,O
14,O
],O
",",O
saliva,O
could,O
be,O
an,O
important,O
non,O
-,O
invasive,O
specimen,O
for,O
diagnosis,O
and,O
virus,O
isolation,O
in,O
COVID-19,O
patients,O
.,O
However,O
",",O
despite,O
several,O
attempts,O
[,O
[,O
18,O
],O
",",O
[,O
19,O
],O
",",O
[,O
20,O
],O
],O
",",O
only,O
one,O
study,O
thus,O
far,O
has,O
demonstrated,O
the,O
presence,O
of,O
the,O
infectious,O
virus,O
in,O
faecal,O
specimens,O
from,O
COVID-19,O
patients,O
during,O
the,O
reviewing,O
process,O
for,O
this,O
study,O
[,O
18,O
],O
.,O
The,O
aim,O
was,O
to,O
determine,O
whether,O
various,O
clinical,O
specimens,O
obtained,O
from,O
COVID-19,O
patients,O
contain,O
the,O
infectious,O
virus,O
.,O
To,O
demonstrate,O
whether,O
various,O
clinical,O
specimens,O
contain,O
the,O
viable,O
virus,O
",",O
we,O
collected,O
naso,O
/,O
oropharyngeal,O
swabs,O
and,O
saliva,O
",",O
urine,O
and,O
stool,O
samples,O
from,O
five,O
COVID-19,O
patients,O
and,O
performed,O
a,O
quantitative,O
polymerase,O
chain,O
reaction,O
(,O
qPCR,O
),O
to,O
assess,O
viral,O
load,O
.,O
Further,O
",",O
viable,O
SARS,O
-,O
CoV-2,O
was,O
isolated,O
from,O
naso,O
/,O
oropharyngeal,O
swabs,O
and,O
saliva,O
of,O
COVID-19,O
patients,O
",",O
as,O
well,O
as,O
nasal,O
washes,O
of,O
ferrets,O
inoculated,O
with,O
patient,O
urine,O
or,O
stool,O
.,O
Discussion,O
 ,O
Viable,O
SARS,O
-,O
CoV-2,O
was,O
demonstrated,O
in,O
saliva,O
",",O
urine,O
and,O
stool,O
samples,O
from,O
COVID-19,O
patients,O
up,O
to,O
days,O
11–15,O
of,O
the,O
clinical,O
course,O
.,O
Therefore,O
",",O
boosting,O
the,O
production,O
of,O
MGO,O
into,O
these,O
cells,O
by,O
targeting,O
deamidated,O
HsTIM,O
should,O
deserve,O
further,O
studies,O
as,O
a,O
potential,O
therapy,O
for,O
COVID-19,O
",",O
even,O
more,O
considering,O
that,O
glycolysis,O
sustains,O
the,O
SARS,O
-,O
CoV-2,O
replication,O
and,O
that,O
its,O
proteome,O
is,O
highly,O
labile,O
to,O
MGO,O
.,O
Here,O
",",O
we,O
used,O
the,O
numbering,O
of,O
amino,O
acid,O
residues,O
according,O
to,O
the,O
translated,O
product,O
of,O
the,O
human,O
TIM,O
cDNA,O
(,O
GenBank,S-Repository
 ,O
Accession,O
Number,O
:,O
M10036.1,S-AccessionNumber
),O
.,O
The,O
atomic,O
coordinates,O
of,O
WT,O
and,O
N16D,O
HsTIM,O
(,O
PDB,S-Repository
 ,O
IDs,O
:,O
2JK2,S-AccessionNumber
 ,O
and,O
4UNK,S-AccessionNumber
",",O
respectively,O
),O
were,O
submitted,O
to,O
the,O
PDBsum,O
server,O
(,O
PDBsum,O
-,O
EMBL,O
-,O
EBI,O
),O
to,O
analyze,O
the,O
protein,O
–,O
protein,O
contacts,O
(,O
interface,O
),O
and,O
tunnel,O
formation,O
(,O
MOLEonline,O
2.0,O
),O
.,O
These,O
results,O
indicate,O
that,O
the,O
incorporation,O
of,O
de,O
novo,O
negative,O
charges,O
in,O
N16D,O
HsTIM,O
leads,O
to,O
important,O
structural,O
alterations,O
in,O
the,O
interatomic,O
network,O
of,O
contacts,O
at,O
the,O
interface,O
of,O
the,O
enzyme,O
.,O
The,O
N16D,O
HsTIM,O
incorporated,O
a,O
major,O
number,O
of,O
DTNB,O
molecules,O
",",O
which,O
also,O
docked,O
deeper,O
in,O
the,O
structure,O
than,O
those,O
in,O
the,O
WT,O
HsTIM,O
(,O
Figure,O
3,O
),O
.,O
Thus,O
",",O
an,O
urgent,O
requirement,O
is,O
to,O
search,O
for,O
new,O
treatments,O
for,O
COVID-19,O
.,O
They,O
proposed,O
their,O
findings,O
as,O
evidence,O
of,O
vulnerability,O
of,O
SARS,O
-,O
CoV-2,O
to,O
inactivation,O
by,O
MGO,O
and,O
as,O
a,O
scientific,O
rationale,O
for,O
repurposing,O
these,O
antitumor,O
agents,O
for,O
treatment,O
of,O
COVID-19,O
[,O
54,O
],O
.,O
This,O
study,O
elucidates,O
the,O
properties,O
of,O
deamidated,O
HsTIM,O
regarding,O
its,O
selective,O
inhibition,O
by,O
thiol,O
-,O
reactive,O
drugs,O
and,O
how,O
these,O
drugs,O
can,O
contribute,O
to,O
the,O
development,O
of,O
cell,O
-,O
specific,O
therapeutic,O
strategies,O
for,O
a,O
variety,O
of,O
diseases,O
",",O
such,O
as,O
COVID-19,O
and,O
cancer,O
.,O
To,O
this,O
end,O
",",O
several,O
academic,O
",",O
basic,O
science,O
research,O
laboratories,O
have,O
already,O
contributed,O
to,O
COVID-19,O
testing,O
during,O
the,O
height,O
of,O
the,O
pandemic,O
(,O
Vanuytsel,O
et,O
 ,O
al,O
.,O
",",O
2020,O
",",O
IGI,O
Testing,O
Consortium,O
2020,O
),O
.,O
Please,O
see,O
Table,O
2,O
for,O
US,O
CDC,O
panel,O
recommended,O
interpretations,O
for,O
diagnostic,O
reporting,O
for,O
the,O
one,O
-,O
step,O
multiplex,O
assay,O
adapted,O
from,O
the,O
TaqPath,O
COVID-19,O
Combo,O
Kit,O
manual,O
.,O
When,O
the,O
COVID-19,O
pandemic,O
first,O
emerged,O
at,O
the,O
end,O
of,O
2019,O
",",O
there,O
were,O
many,O
speculations,O
about,O
the,O
potential,O
impact,O
and,O
course,O
of,O
progression,O
",",O
but,O
none,O
would,O
have,O
imagined,O
the,O
speed,O
and,O
the,O
scale,O
of,O
its,O
spread,O
and,O
devastation,O
to,O
people,O
's,O
lives,O
and,O
livelihood,O
across,O
the,O
global,O
[,O
"1,2",O
],O
.,O
Despite,O
the,O
unprecedented,O
efforts,O
and,O
rapid,O
scientific,O
progress,O
in,O
the,O
discovery,O
of,O
the,O
cellular,O
and,O
molecular,O
details,O
for,O
the,O
pathogenesis,O
of,O
COVID-19,O
as,O
a,O
result,O
of,O
SARS,O
-,O
COV2,O
infection,O
",",O
there,O
are,O
still,O
no,O
specific,O
new,O
therapies,O
that,O
have,O
been,O
approved,O
to,O
either,O
prevent,O
or,O
treat,O
COVID19,O
in,O
clinics,O
[,O
"1,2",O
],O
.,O
However,O
",",O
new,O
insights,O
towards,O
the,O
pathogenesis,O
of,O
COVID19,O
have,O
led,O
to,O
many,O
efforts,O
to,O
repurpose,O
existing,O
drugs,O
for,O
the,O
disease,O
.,O
While,O
many,O
of,O
these,O
repurposing,O
attempts,O
are,O
aimed,O
to,O
interrupt,O
the,O
life,O
-,O
cycle,O
of,O
the,O
SARS,O
-,O
COV2,O
virus,O
infection,O
or,O
the,O
ensuing,O
systemic,O
inflammatory,O
injury,O
",",O
it,O
is,O
now,O
clear,O
that,O
the,O
adverse,O
outcome,O
of,O
COVID19,O
can,O
be,O
strongly,O
contributed,O
by,O
a,O
number,O
of,O
pre,O
-,O
existing,O
conditions,O
",",O
in,O
particular,O
hypertension,O
and,O
metabolic,O
disorders,O
.,O
In,O
recent,O
retrospective,O
studies,O
led,O
by,O
a,O
consortium,O
of,O
investigators,O
based,O
on,O
a,O
large,O
clinical,O
cohort,O
of,O
hospitalized,O
COVID-19,O
patients,O
in,O
Hubei,O
",",O
China,O
",",O
one,O
class,O
of,O
medicine,O
originally,O
used,O
for,O
blood,O
pressure,O
management,O
(,O
angiotensin,O
-,O
converting,O
enzyme,O
inhibitor,O
or,O
angiotensin,O
-,O
receptor,O
blockers,O
),O
[,O
7,O
],O
",",O
and,O
another,O
class,O
of,O
medication,O
originally,O
prescribed,O
for,O
hyperlipidemia,O
(,O
statins,O
),O
[,O
8,O
],O
",",O
were,O
analyzed,O
for,O
their,O
association,O
with,O
COVID-19,O
related,O
death,O
and,O
other,O
secondary,O
outcome,O
.,O
After,O
extensive,O
adjustment,O
and,O
matching,O
for,O
major,O
clinical,O
risk,O
profiles,O
",",O
statistical,O
analyses,O
showed,O
both,O
ACEi,O
/,O
ARB,O
and,O
statins,O
were,O
found,O
to,O
be,O
associated,O
with,O
a,O
significant,O
reduction,O
in,O
death,O
and,O
adverse,O
outcome,O
in,O
hospitalized,O
COVID-19,O
patients,O
.,O
Nevertheless,O
",",O
it,O
is,O
emerging,O
that,O
several,O
therapies,O
originally,O
approved,O
to,O
treat,O
pre,O
-,O
existing,O
conditions,O
may,O
bring,O
clinical,O
benefits,O
to,O
reduce,O
death,O
and,O
severe,O
complications,O
in,O
COVID-19,O
patients,O
(,O
Fig,O
.,O
1,O
),O
.,O
The,O
dataset,O
comprised,O
all,O
currently,O
available,O
(,O
n,O
=,O
 ,O
29,O
),O
full,O
genome,O
sequences,O
from,O
the,O
current,O
(,O
2019–2020,O
),O
nCoV,O
epidemic,O
",",O
as,O
well,O
as,O
closely,O
related,O
(,O
n,O
=,O
 ,O
2,O
),O
bat,O
strains,O
(,O
SARS,O
-,O
like,O
CoV,O
),O
retrieved,O
from,O
NCBI,S-Repository
 ,O
(,O
http://www.ncbi.nlm.nih.gov/genbank/,S-URL
),O
and,O
GISAID,S-Dataset
 ,O
(,O
https://www.gisaid.org/,S-URL
),O
databases,O
.,O
The,O
complete,O
dataset,O
was,O
assessed,O
for,O
presence,O
of,O
phylogenetic,O
signal,O
by,O
applying,O
the,O
likelihood,O
mapping,O
analysis,O
implemented,O
in,O
the,O
IQ,O
-,O
TREE,O
1.6.8,O
software,O
(,O
http://www.iqtree.org,O
),O
[,O
8,O
],O
.,O
Both,O
SS,O
and,O
PS,O
estimators,O
indicated,O
the,O
uncorrelated,O
relaxed,O
molecular,O
clock,O
(,O
Bayes,O
Factor,O
 ,O
=,O
 ,O
4.3,O
),O
as,O
the,O
best,O
fitted,O
model,O
to,O
the,O
dataset,O
under,O
analysis,O
.,O
